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A brain tumour is mainly considered intracranial tumour originated from abnormal and 
uncontrolled cell-division, normally either originated in neuron, glial cells(astrocytes, 
oligodendrocytes, ependymal cells, lymphatic tissue, blood vessels), in the cranial 
nerves(myelin-producing Schwann cells), in the brain envelopes (meninnges), skully pituitary 
and pineal gland or spread from cancer primarily located in other organs (metastatic 
tumours).Primary brain tumours are commonly located in the posterior cranial fossa in children 
and in the anterior two-third of the cerebral hemi-sphere in adults. Brain tumours mainly 
include astrocytoma, pliocytic astrocytoma, dysembryoplastic neuroepithelial tumour, 
oligodendrogliomas, ependymoma, glioblastoma multiforme, mixed gliomas, 
oligoastrocytomas, medulloblastoma, retinoblastomas, medulloblastoma, retinoblastoma, 
neuroblastoma, germinoma and teratoma. 
In this thesis, we have studied two kinds of brain tumours, medulloblastoma and astrocytoma. 
Medulloblastoma is an extremly malignant and invasive PNET localizad at the cerebellum 
(Kleihues and Sobon, 2000).It corresponds histologically to WHO grade IV tumour and the 
most commom malignant brain tumour of childhood, representing 20% of all childhood brain 
tumours. 
The annual incidence of medulloblastoma has been estimated at 0.5/100.000 children younger 
than 15 year old. 
The astrocyte,one form of glial cells which comprises much of the background substance of 
the brain and spinal cord, gives rise to large category of primary brain tumours, the diffusing 
and infiltrating astrocytomas.There are the most frequent intracranial neoplast that account for 
more than 60% of all primary brain tumour.These neoplasma can occur in all areas of the brain 
and spinal cord among children and adults.The incidence of astrocytomas is approximately 
7/100.000 cases. 
The Worid Health Organization (WHO) classification recognizes four grades of astrocytoma; 
Grade I- astrocytomas are growing,non-infilrative neoplasm.occurring mainly in children and 
young adults and include juvenile epilocytic astrocytomas and ganglioglioma. 
Grade II- mainly well-differentiated fibrillary astrocytoma 
Grade III- anaplastic astrocytoma is a more aggressive neoplasm. 
Grade IV- Most malignant form of astrocytes named glioblastoma multiforme, it is the most 
common primary malignant brain tumour of adults. 
Brain tumours are highly heterogenous in nature and depicting phenotypically and 
genotypically. Brain is itself a complex system and complete physiology is not very much clear 
and because of this reason, we are still unable to explore clear clues to brain tumour 
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development and its progression. Tumour lieterogeneity varies in several ways.lt changes with 
organ site and cell origin. Heterogeneity shows cellular differences within a single neoplasm. 
Phenotypic heterogeneity shows variation in antigen expressin(Cikes,M and Klein.G 1972; 
Everson et al., 1974),membrane composition(Bosman and Winston, 1970; Pasternak et al; 
1971), response to chemotherapy (Valeriote and Putten; 1975), and metastatic 
proclivity(Suzuki et al., 1978, Weiss, 1980). In case of tumour heterogeneity among tumour 
subpopulations differences are extensive, viz cellular morphology;tumour histology;karyotype 
and other cytogenetic markers; growth rate; cell products; receptors; enzymes; immunological 
characteristics; metastatic ability and sensitivity to therapeutic agents. 
Even phenotypic and genotypic heterogeneity is shown at cellular level in metastatic and 
primary tumours of the brain tumours. In fact, Shapiros' Laboratory (Shapiro et a/., 1981) used 
karyotype heterogeneity as a marker for subpopulation in fresh primary human gliomas and 
then this is used as a criteria for distinctive identification among subpopulation of tumours. 
Even other parameters are also involved including sensitivity to drug (Yung et a/., 1982) and 
genetic stability (Shapiro and Shapiro, 1983). 
Genetic instability is also one of the specific mechanisms for tumour and cause many errors in 
tumour cell DNA replication including point mutation, genomic rearrangement, chromosome 
losses, gene amplification etc. all of which are reflected in increased phenotypic variability. 
Recent investigation showed epigenetic mechanism as the chief source of variability in 
tumours. The most important hurdle of this tumour heterogeneity comes at the time of 
treatment of tumours because this heterogeneity causes failure of therapy. 
In this study we have tried to get answer of some unsolved questions like; what are the genetic 
changes and pathways of oncogenesis and progression that account for the heterogeneity of 
barin tumours? Which genes, genetic changes and genetic pathways are important to the 
initiation, maintenance and progression of brain tumours? 
For this study we have chosen sonic hedgehog signaling pathway in both brain tumours and 
study this pathway heterogeneity in medulloblastoma and astrocytoma. This pathway is well 
known in medulloblastoma development and other tumours including prostate cancer 
(Sanchez et al., 2005;Stecca et al., 2005),oral squamous cell carcinoma(Nishimaki et al., 
2004), colorectal carcinoma(Zhu et al., 2004) however, in astrocytoma it is not well explored 
except for a few reports(Clement et al., 2007). 
The present study is divided into three chapters. 
In the first chapter we have transfected a medulloblastoma cell line Daoy and an astrocytoma 
cell line U87MG with GLI1 sIRNA. After this transfection and sufficient knockdown (>60%) of 
GLI1 in both cell lines, we have checked the other downstream target of GLI1 gene including 
PTCH1, Cyclin D2, Plakoglobin, PAX6, NKX2.2 and Bmi-1 
We have found downregulation of PTCH1 gene in both tumour cell lines, down regulation of 
Cyclin D2 in medulloblastoma cell line and Upregulation in Cyclin D2 in astrocytoma cell line 
U87MG, downregulation of Plakoglobin in medulloblastoma cell line and upregulation of 
plakoglobin in astrocytoma cell line, compared to negative transfected and untransfected cell 
lines. These genes are direct target of GLI1 transcription factor and our results support the 
PTCH1 regulation by GLI1 in both the tumours. However the regulation of Cyclin D2 and 
Plakoglobin varies from the previous report, where the scientists have mentioned the 
upregulation of Cyclin D2 and downregulation of Plakoglobin in GLI1 transfected epithelilal cell 
(Yoon et al., 2002).These differences in regulation of Cyclin D2 and Plakoglobin in these 
tumours further support regional differential gene expression and regulation of sonic hedgehog 
as well in these tumours(Marc Fuccillo, 2007). 
We also checked other putative target genes of GLI1 including PAX6, NKX2.2 and Bmi-1 in 
these tumours cell lines.We found upregulation of PAX6 in medulloblastoma cell line Daoy, 
downregulation in astrocytoma cell line U87MG, compared to negative siRNA and 
untransfected cell lines. PAX6 gene is considered as a tumour suppressor gene in 
glioblastoma(Zhou,YH et al., 2005) and its downregulation by GLI1 indicated the possibility of 
tumourogenesis in astrocytoma by Shh pathway. But the upregulation of PAX6 in 
medulloblastoma cell line showed a differential and multifaced regulation of Shh. 
The NKX2.2 is a homeobox gene and is included among transcription factor II (TF.II). It is also 
putative immediate target gene of GLI1 factor and shows upregulation during early embryonic 
ventral patterning (March Fuccillo, 2006; Yokes SA, 2007; Takahashi, M 2002). After GLI1 
knockdown in medulloblastoma cell line Daoy, PAX6 transcript expression was decreased 
compared to negative siRNA and untransfected cell lines. This decrease in the expression 
suggests that NKX2.2 is upregulated by GLI1 not only during early embryonic development but 
also in medulloblastoma progression. However, GLI1 knockdown astrocytoma did not show 
any changes in expression. 
This Bmi-1 gene considered as an oncogene and assists the stem cell proliferative 
characteristic with sonic hedgehog signaling in medulloblastoma (Liu S et al., 2006). The 
regulation of Bmi-1 by GLI1 is not well defined. After GUI knockdown in medulloblastoma cell 
line Daoy, Bmi-1 expression was decreased, however its expression was increased in GUI 
knockdown astrocytoma cell line U87MG, compared to universal negative siRNA and 
untransfected cell lines. Decreased expression of Bml-1 after GLI1 knockdown In 
medulloblastoma revealed the possibility of upregulatlon of Bml-1 by GLI1. Although, 
upregulatlon of Bmi-1 transcripts after GLI1 knockout in astrocytic cell line indicated that Bml-1 
could be negatively regulated by GUI in astrocytoma. Also few reports mention copy number 
alteration of polycomb gene Bml-1 In glioma tumour (Hayry et al., 2008). 
Remaining five cell lines of medulloblastoma Including PFSK-1, Daoy, TE671c2, D283 and SK-
PN-DW and seven cell lines of astrocytoma including A172, LN405, SW1783, T98G, SW1088 
and GOS-3 showed similarity in expression pattern of the above said genes. 
We further checked the promoter methylation status of PTGH1 and Cyclin D2 in both 
medulloblastoma and astrocytoma cell lines and primary tumour samples. 
The PTCm methylation had been reported in breast cancer cell line MCF-7 and primary 
samples, and this methylation were correlated with low expression of PTCH1 transcript (Idowolf 
et al., 2007). PTCH is also well known tumour suppressor gene and showed epigenetic 
regulation in many human malignancies (Berman DM et al., 2002, Calzada Wack et al., 2002, 
Toyota ef a/., 2001). 
Medulloblastoma cell lines and medulloblastoma samples showed partial/hemi methylation in 
the promoter region of PTCH1 gene. This promoter hypermethylation was also correlated with 
low PTCm transcript expression in one cell line and 2/14 samples (p3 and p11) of 
medulloblastoma. Recently it was reported that proximal promoter of PTCH1 gene (variant 
exon IB) showed methylation In some cases of medulloblastoma (Pritchard JI and Olson 
JM, 2008). 
All of these studies support the possibility of methylation in PTCH1 promoter region and it 
could be one of the reasons for silencing of this gene in many cell tumours including 
medulloblastoma. 
In glioblastoma, only one cell line and 3/44(7%) glioma samples showed partial/hemi 
methylation in the promoter region of PTCH1 gene. Moreover, their methylation showed 
correlation with low transcript expression in glioma cell lines and samples. 
This PTCH1 methylation in few cell lines and samples of all these major brain tumours 
comprise medulloblastoma, and glioblastoma further support the previous investigation which 
had assumed two way of sonic hedgehog pathway activation i.e. one is ligand dependent and 
the other one ligand independent in which PTCH1 shows inactivation(Cohen et al., 2005). 
Cyclin D2 is a member of the D-type Cyclins, implicated in cell-cycle regulation, differentiation 
and malignant transformation.Many cases of Cyclin D2 promoter methylation had been 
reported in pancreatic cancer (Matsubayashi, et al 2003), breast cancer (Evron, et al., 2001, 
Evron et al., 2001, Lehmann et al., 2002, Sharma, et al., 2007) and Human epithelial Ovarian 
Cancer (Sakuma, et al., 2007). 
Our studies establisti ttiat thie promoter hypermethylation of Cyclin D2 gene plays a major role 
in brain tumours of medulloblastoma and glioblastoma tumours cell lines and primary tumour 
samples. 
In cell lines A172, SW1783, T98G, CCF-STTG-1 and GOS-3, some showed low or no 
expression of Cyclin D2 and Cell lines U87MG, A172 and SW1783 showed low or no 
expression of PTCH1. The 5-aza-2'-deoxycytosine and TSA treatment showed increase in 
expression of these silent cell lines showing additional control at an epigenetic level 
(p=0.0014). 
Promoter methylation of two CpG rich sites of Cyclin D2 in cell lines is that associated with low 
expression. In some conditions, these two sites showed hypermethylation and that was by 
5-aza-2'-dC and TSA showing role of epigenetic control. 
In second chapter, we have checked the expression and epigenetic regulation of other 
associated genes with sonic hedgehog including SMO, HHIP, SUFU, SFRP1 and GLI3 in 
medulloblastoma and astrocytoma cell lines and primary tumour samples. 
This high expression of SMO itself is an indication of the oncogenic in nature of SMO and sonic 
hedgehog pathway activation. In medulloblastoma, sonic hedgehog pathway is well studied 
though this sonic hedgehog pathway activation is not very much explored in the astrocytomas. 
In this study, we have checked the role and activation of Shh signal activation in the 
astrocytoma. This high expression of SMO in astrocytoma cell lines could suggest the 
possibility of sonic hedgehog pathway activation in astrocytoma. However, few cell lines and 
samples showed promoter methylation in SMO which has not been discussed in thesis thesis. 
HHIP acts as an antagonist of Shh pathway, the upregulation of Shh pathway leads to 
downregulation in the HHIP1 expression. In this study, low expression of HHIP transcript in 
medulloblastoma and astrocytoma cell lines was compared with normal brain tissue. It was 
highly significant (p<0.0001). This low expression of HHIP1 in these tumours cell lines indicate 
the possibility of sonic hedgehog pathway activation, because high expression of HHIP inhibits 
the Shh pathway in similar way as PTCH Inhibition (McMahon et al 1999a and McMahon et. al. 
1999b). It was also reported that HHIP showed epigenetic regulation in many cancers including 
Pancreatic cancer cell lines (Beachy et al., 2002) (McMahon et al., 1999). It also further 
establishes the possibility of epigenetic regulation of this HHIP gene in medulloblastoma, 
astrocytic cell lines and primary tumour samples. 
SUFU acts as one of the tumour suppressor genes (TSGs) of sonic hedgehog pathway and 
blocks the nuclear accumulation of GLI1 and GLI2 (Barnfield et al., 2005) by felicitating 
phosphorylation in them. It was found to show overall low expression of SUFU in 
medulloblastoma and astrocytoma cell lines (p=0.0090). High SUFU expression showed 
negative effect on Shh signaling by inhibiting GLI1 and GLI2 transcriptional activation. Most of 
the tumours cell lines and samples showed low expression of SUFU. This low expression 
indicated that there could be possibility of inactivated SUFU in medulloblastoma and 
astrocytoma cell lines. This did not inhibit the transcriptional activator GLI1, consequently GLI1 
is accumulated in the nucleus without any hindrance, and gets activated by other downstream 
target genes of this pathway. 
SFRP1 protein is an antagonist of canonical pathway of WNT. This WNT pathway is also 
responsible for many cellular processes, organ development and malignant transformation 
(Bejsovec A, 2005; Brembeck et al, 2006; Kikuchi et al., 2006 and Lee ef a/., 2006). In another 
finding, it was reported that GLI1 also binds with the promoter region of SFRP1 and down 
regulates its expression (Katoh and Katoh, 2005). 
This low expression indicates that SFRP1 is acting as a tumour suppressor gene and down 
regulates the activation of Shh signaling in medulloblastoma and astrocytoma. However, our 
results were contrary to previous reports, which explained the process of upregulation of 
SFRP1 in medulloblastoma development (Lee ef al., 2003) 
The Drosophila Shh pathway is mediated by downstream transcriptional molecule cubitus 
interruptus (Ci), having both activator and repression domain and their functions are according 
to the signal activation. The homologue of Vertebrate Ci has three GLI1, GLI2 and GLI3 
transcriptional factors. Thus GLI1 and GLI2 are activators, and GLI3 has both activator and 
repressor domains. 
It has been reported that GLI3 has two forms, one is full length (190kDa) and acts as 
activator(GLI3A) of Shh and another one is truncated and acts as a repressor(GLI3R) (89kDa) 
of Shh (Ping Dai, 1999). This activator showed high expression due to activation of Shh 
signaling and increased the expression of GLI1 by binding at 5'promoter region of GLI1. 
In this study, it was determined that all six medulloblastoma cell lines showed high expression 
of GLI3 transcript as compared to normal adult brain tissue (p=0.0554). All eight astrocytoma 
cell lines also showed high fold expression of GLI3 transcripts compared to normal brain tissue. 
Astrocytic cell lines also showed full-length expression of GLI3 protein (190kD). High 
expression of GLI3 in medulloblastoma and astrocytoma cell lines support the expression of 
full-length GLI3 transcript, which acts as an activator for sonic hedgehog pathway. 
The HHIP is also regulated epigenetlcally and was reported to show promoter methylation in 
pancreatic neoplasm (Martin etal., 2005) and gastrointestinal cancer (Taniguchi et al., 2007). 
It was found that both medulloblastoma and astrocytoma tumour cell lines and primary samples 
showed methylation and their methylation correlated with low or no expression of HHIP 
Moreover, HHIP acts as a negative regulator of Shh signaling and its methylation in these 
tumours, besides other tumours, suggested the possibility of two kinds of regulatory 
mechanisms controlling the expression of HHIP. Henceforth, HHIP is under two levels of 
regulation; one is epigenetic and another is under influence of Shh signaling activation. 
The candidate SUFU is a newly identified tumour suppressor gene, which is predisposed in 
individual to develop medulloblastoma tumour (Taylor et al., 2002). Hence it is critical for 
embryonic development and tumour suppression. 
It was found that only 2/44 glioma samples showed partial/hemi methylation in the promoter 
region of SUFU. This gene did not show any methylation in the 6 medulloblastoma, 8 
astrocytoma cell lines, 14 medulloblastoma and remaining 42 glioma primary tumours samples. 
Moreover, there was no report, which has mentioned SUFU promoter methylation in any 
tumour so far. Henceforth, SUFU may not be under epigenetic control in these major brain 
tumours. 
The SFRP1 encodes a Wnt/U-catenin signaling antagonist and showed frequent promoter 
methylation in many tumours.SFRP1 is also one of the target molecules of Shh signaling and is 
repressed by Shh activation (Ingram, etai, 2002). 
In this study, we have determined the methylation of SFRP1 in medulloblastoma and 
glioblastoma cell lines and primary tumour samples. In medulloblastoma, one cell line TE671 
and 5/14(36%) samples showed partial/hemi methylation in the promoter region of SFRP1. 
However, this medulloblastoma methylation result is contrary to previous investigation, which 
showed no methylation in the promoter region of SFRP1 gene in medulloblastoma (Chang et 
al., 2005). Moreover, this hypermethylation results were in correspondence to no expression of 
SFRP1 transcripts in respective cell line and primary tumour samples. 
In astrocytoma, 5/8 cell lines (A172, T98G, SW1088, CCF-STTG-1 and GOS-3) and 14/44 of 
glioma samples showed partial/hemi methylation in the promoter region of SFRP1 gene; 
however this methylation was supported by low or no expression of SFRP1 transcript. 
Moreover, it was reported that GUI binds to the promoter region of the SFRP1 gene and 
down-regulates its activity (Katoh, Y and Katoh, M, 2006). From this result, it is found that 
SFRP1 shows promoter hypermethylation in both brain tumours, medulloblastoma and 
astrocytoma, and this methylation is correlated with low expression of SFRP1 in these tumours. 
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Taken together, it has revealed two levels of controls, which regulates SFRP1 expression 
gene, one is regulated by sonic hedgehog signaling and the other is under epigenetic 
regulation. 
In the third chapter, we have checked the effect of specific inhibitor of Shh signaling pathway 
cyclopamine in medulloblastoma cell line Daoy and astrocytoma cell line U87MG.The effect of 
cyclopamine was measured with MTT assay, cell cycle analysis and apoptosis analysis. In this 
study, cyclopamine showed inhibitory effects on sonic hedgehog signaling in these cell lines, 
which is manifested as toxic in nature, anti-proliferative effect and increased apoptosis in these 
two cell lines. These results further support the sonic hedgehog activation in glioblastoma 
besides medulloblastoma. 
Our study confirmed the possible role of sonic hedgehog signaling in the development of 
astrocytoma tumour besides medulloblastoma. Sonic hedgehog shows differential expression 
and multi-facet action, not only in the early embryonic development but also in the progression 
of brain tumours. 
Many sonic hedgehog signaling downstream targets genes showed two level of regulation: one 
at transcriptional level and another one at epigenetic level. And signaling pathway of sonic 
hedgehog shows heterogeneity between medulloblastoma and glioblastoma tumours even at 
molecular level. 
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Introduction 
Introduction 
Brain tumours are highly heterogeneous, both phenotypically and genotypically. Still there are 
existing gaps in our knowledge and understanding of the involved genes, genetic changes and 
pathways in the genesis, progression, biology and clinical behavior of brain tumour. Because of 
the complex environment of the brain, we are still unable to fully understand the complete 
biology of brain tumours; namely, 
We need to overcome many challenges and answer many questions for the complete 
elimination of brain tumours: What are the genetic changes and pathways of oncogenesis and 
progression that account for the heterogeneity of brain tumours and how well can these be 
studied? Which genes, genetic changes and pathways are important for the initiation, 
maintenance and progression of brain tumours? 
Are the genetic changes and pathways that are required for initiation, the same as those 
required for maintenance of the neoplastic phenotype and its biological behaviours? 
How does the spatial-anatomical site of the tumour against its specific genetic background 
determine the gene expression pattern and contribute to tumours heterogeneity, biological and 
clinical behaviours and therapeutic outcome? 
Are there genetic changes and pathways that are common to different brain tumour subtypes? 
What pathways, such as signaling, cell cycle, apoptosis are involved in the response of brain 
tumours to intra and extracellular stimuli such as growth factors or redox changes? 
What are the stem cells and progenitor cells of the different brain tumour subtypes? 
For getting rid off these challenges and problems, we need to think in combinational approach 
like: 
Define the multigenetic changes and pathways involved in oncogenesis, progression, and 
maintenance of brain tumours, with particular attention to their heterogeneity. 
Identify the genes and pathways that are differently involved in tumour initiation and 
maintenance (Source: Brain Tumour Progress Review, www.ninds.nih.gov). 
The similarity between stem cells and cancer cells of self-renewal led to new concept of cancer 
progression. There has been reported, cancer stem cells in Leukemia, multiple myeloma and 
breast cancer which show the self-renewal cells for the progression of these tumour and are 
very much similar in characteristic to stem cells. So they are named as cancer stem cells. 
Brain tumours have also been reported to possess a subpopulation of cancer stem like 
cells that have ability to proliferate, self-renew and be multipotent. Brain tumours are 
phenotypically heterogeneous because they are composed of cells expressing both the 
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markers of differentiation and non-differentiation. Populations of proliferating tumour stem cells 
differentiates into more mature cell types that characterize the tumuor. 
Singh et al 1994 for the first time isolated stem cells from brain tumours and showed the 
characteristic of self-renewable, proliferation and differentiation. They were able to differentiate 
these cells from others cells with the marker CD133+, a five transmembrane protein used as a 
stem cell marker which have capacity to grow in vitro and showed resemblance to patients of 
tumour cells (Tunici et al., 2006). 
The cellular heterogeneity of brain tumour suggested that only a small fraction of cancer cells 
are able to regenerate tumours and that targeting these cells could be an innovative approach 
to eliminating the tumour. 
In these studies, we have chosen two major brain tumours comprising medulloblastoma and 
astrocytoma. We have checked possible role of sonic hedgehog signaling pathway in these 
tumours. However, people have investigated and shown significant contribution of Shh pathway 
in medulloblastoma development though this Shh signaling pathway is not well studied in 
astrocytoma. Since sonic hedgehog pathway is responsible for stem cell renewable, state it can 
cause cancer. We have checked genetic heterogeneity of Shh pathway and tried to understand 
the difference at molecular level in the mechanism of downstream Shh pathway downstream 
action in these tumours. 
Aims ^ OSjectives 
Aim & Objectives 
This thesis has been divided into three chapters; 
I. In the first chapter, we transfected medulioblastoma and astrocytoma cell lines with GLI1 
siRNA and in turn after efficient GLI1 knockdown (70-80%) we checked comparative 
expression of other downstream target genes including PTCH1, Cyclin D2, Plakoglobin, 
PAX6, NKX.2.2 and Bmi-1 and then also checked epigenetic regulation of PTCH1 and 
Cyclin D2 in these major brain tumours of cell lines and samples. 
II. We further checked the expression of other involved genes of the Shh pathways 
including SMO, HHIP, SUFU, SFRP1 and GLI3 and thereafter determined the promoter 
hypermethylation of putative TSGs (tumour suppressor genes) namely HHIP, SUFU and 
SFRP1 in medulioblastoma and astrocytoma cell lines and primary tumuor samples. 
III. In third chapter, we have treated the medulioblastoma and astrocytoma cell lines with 
different concentration of Shh signaling specific inhibitor Gyclopamine and did MTT 
assay, Cell Cycle and Apoptosis analysis to estimate the cytotoxic and antiproliferative 
effects of this inhibitor on the treated cell lines. 
^K^view of Literature 
Review of Literature 
1.1 The Nervous System 
Origin of the Nervous System 
Almost all the elements of the nervous tissue are derived from a specialized region of ectoderm 
along the dorsal midline of the embryo. Under the influence of the notochord and the adjoining 
mesoderm, the cells of this region of ectoderm elongate and are determined to form the neural 
tissue. The differentiation in the human embryo starts in the third week of gestation with the 
formation of the neural plate from which the entire CNS is derived (Weiss, L 1983). The PNS 
arises from cells of the neural crest that undergo extensive migrations. At the end of the third 
week of gestation, the neural tube is formed by the fusion of the edges of the neural groove in 
the upper cervical region that extends rostrally and caudally in a process called neurulation. 
Initially, the neural tube is open in the two extremes (anterior and posterior neuropores), but 
during the fourth week of gestation, it becomes closed. The epithelium of the neural tube, from 
which derive the neuronal and supporting elements of CNS, is named variously as germinal 
epithelium, neuroepithelium, and matrix or ventricular layer (Weiss,L 1983). Proliferation in the 
neural tube forms a layer known as mantle or intermediate zone that expands and leads to the 
walls of the brain and the spinal cord. The cells of the mantle zone are called neuroblasts, if 
they give rise to mature neurons, and glioblasts if they give rise to neuroglial cells 
(Weiss L 1983). Glial cell proliferation continues after formation of all the neurons and most of 
the glial cells retain the capacity of division throughout the life of the organism. Cells in the 
nervous system migrate from the region where they are generated to their definitive location. 
Some neuroepithelial cells persist in the mature nervous system as ependymal cells. In the 
rostral part of the neural tube, three vesicular swellings appear: prosencephalic, mesencephalic 
and rohmbencephalic vesicles. These vesicles will give rise to the forebrain, midbrain and 
hindbrain, respectively, while the caudal unexpanded portion of the neural tube forms the spinal 
cord (Weiss L, 1983). 
The cerebellum develops from two germinal matrix regions: the subventricular matrix and the 
EGL. The cells from the subventricular matrix give rise to neurons of the deep nuclei, Purkinje 
cells, glial cells and Golgi neurons, EGL proliferation and cerebellar size is regulated by the 
Hedgehog pathway. Purkinje cells secrete ligand Sonic Hedgehog that binds to PTCH, and 
promotes the proliferation of granular cell precursors of the EGL (Weiss, L1983). 
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Division of tlie Nervous System 
The nervous system is divided into two: CNS and PNS. 
Peripheral Nervous System 
Tlie PNS is a prolongation of the neurons of the CNS along the entire organism. The function 
of the PNS is to pick up the signals and transmit the responses. The PNS consists of sensory 
neurons that inform the CNS and the motor neurons coming out from the CNS to the muscles 
and the glands to take the action. The PNS is subdivided into two: the sensory-somatic nervous 
system and the autonomic nervous system. 
Sensory-somatic nervous system 
The sensory-somatic nervous system is responsible for the consciousness of the external 
environment and of all of our motor activities. It consists of 12 pairs of cranial nerves and 31 
pairs of spinal nerves. 
Autonomic nervous system 
The autonomic nervous system controls the contraction of the smooth muscle and the cardiac 
muscle. It is responsible for involuntary actions, in contrast with the sensory-somatic nervous 
system, and of bringing about appropriate changes in the internal environment. Another 
difference with the sensory-somatic nervous system is that the autonomic nervous system 
presents two groups of motor neurons to stimulate the effectors instead of one (pre-ganglionic 
and postganglionic neurons). The autonomic nervous system is subdivided into: 
• Sympathetic nervous system: Pre-ganglionic motor neurons arise in the spinal cord, and pass 
into the sympathetic ganglia. Pre-ganglionic sympathetic neurons stimulate postganglionic 
neurons through a neurotransmitter called acetylcholine, while postganglionic neurons release 
noradrenaline that acts in a particular gland or muscle. A preganglionic sympathetic neuron 
synapses, usually, with many postganglionic neurons. The release of adrenaline could 
stimulate all the cells of body independently of whether postganglionic neurons reach them or 
not. 
• Parasympathetic nervous system: the main nerves of the parasympathetic system are the 
vagus nerves whose origin is in the medulla oblongata. Differently to the sympathetic nervous 
system, each parasympathetic pre-ganglionic neuron synapses with few postganglionic 
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neurons, and the neurotransmitter released by the pre-ganglionic and the postganglionic 
neurons is acetylcholine. However, some postganglionic neurons release nitric oxide instead of 
acetylcholine. The parasympathetic nervous system is in charge of reversing the changes 
produced by the sympathetic nervous system. 
Central Nervous System 
CNS controls and coordinates the reception and response to many conscious or unconscious 
stimuli. It is constituted by nervous cells or neurons, and the glial cells and is made up mainly 
by the brain and the spinal cord. 
Spinal cord 
The spinal cord is composed of 31 pairs of mixed spinal nerves that conduct the sensory 
information from the PNS to the brain and the motor information from the brain to the effectors 
(skeletal, cardiac and smooth muscles, and glands). Spinal cord also serves as a minor reflex 
center responsible of some simple reflex. The brain receives the sensory information from the 
spinal cord, as well as from 12 pairs of cranial nerves, and initiates an appropriate and 
coordinated response. 
Brain 
Three different parts can be distinguished in the brain, which are derived from three swellings 
at the anterior end of the neural canal of the embryo: 
• Prosencephalon or forebrain: the major structures of the prosencephalon are: 
Cerebellum: it represents 10% of the brain weigh, but it contains as many neurons as the 
whole brain. It consists of two deeply convoluted hemispheres. Cerebellum is the part of the 
brain that controls coordination, body movement balance and posture, and is the center for 
learning of motor skills. 
Medulla oblongata: is the place where some nerve impulses arise. Medulla oblongata makes 
breathing possible; it regulates the heartbeat, and adjusts the blood flow. 
Pons: it participates in reflexes that regulate breathing and it seems a relay station carrying 
signals from the cerebral cortex to the cerebellum. 
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• Mesencephalon or midbrain: it occupies a very small region in humans. It originates from the 
cerebral peduncles, the nuclei of the fourth cranial pair, and the epiphysis. 
• Rhombencephalon or hindbrain: It is made up of: 
Diencephalon: Which is a group of structures located deep within the cerebrum: thalamus, 
hypothalamus, lateral geniculate nucleus and posterior lobe of the pituitary. Hypothalamus is 
the seat of the autonomic nervous system and is the source of some important hormones. 
Cerebrum or telencephalon: is composed of two cerebral hemispheres, each of them 
subdivided into four lobes: frontal, parietal, occipital and temporal. Olfactory bulbs, striatum, 
nucleus accumbens, and limbic system are hidden beneath these regions of the cerebral 
cortex. The cerebrum controls the senses (hearing, smell, sight, taste, and touch), memory and 
learning, and emotion. 
The CNS is covered by the meninges that are three contiguous sheets of connective tissue 
(durameter, arachnoid and piameter). The space between the arachnoid and the piameter is 
filled with the CSF. The brain occupies almost the entire skull cavity and is surrounded by a 
cushioning layer of CSF. Most of the CSF, about 500 ml per day, is secreted by the choroid 
plexus of the ventricles and flows throughout the CNS (cerebrospinal canal of spinal cord and 
system of four ventricles in the brain) and returns to the blood through the veins that drain the 
brain. The CSF circulates continuously and contains many substances that are necessary for 
normal function and nourishment of the nervous system. The CSF provides a protection within 
and around the brain. Before entering the sub-arachnoid space, the CSF flows through the 
ventricles and out of three small openings of the fourth ventricle. The sub-arachnoid space 
surrounds the brain and the spinal cord. Eventually, the CSF is absorbed into the blood stream 
in a delicate balance. If the CSF cannot flow through the ventricles and the sub-arachnoid 
space, or, if it is not absorbed into the blood, the patients develop hydrocephalus. 
Hydrocephalus could also be developed if there is an overproduction of CSF related to an 
abnormal process such as choroid plexus papilloma. 
1.2 Malignant Brain Tumours of Childliood 
Introduction 
All cancers, including malignant brain tumours, display features of the normal cells from which 
they arise. However, neoplastic transformation causes a failure in the regulation of cell 
differentiation, so the cells are in a less differentiated state. Some brain tumours arise from 
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multipotential stem cells, and lead to tumours composed of primitive cells, or show mixed 
phienotypes (neurons and astrocytes), or, more rarely, contain tissues not normally present in 
the brain. Although cancer is rare in the children, primary brain tumours constitute the most 
frequent location of solid tumours in childhood. The occurrence of brain tumours occurrence is 
2.5 to 4 cases per 100,000 children. The cause of the most of childhood brain tumours is 
unknown. 
Childhood brain tumours are a heterogeneous group of diseases characterized by an abnormal 
growth of the tissue contained within the skull. They are classified according to their 
histopathological features and tumour location. For example, undifferentiated primitive 
neuroectodermal tumours that arise in the cerebellum are classified as medulloblastoma, while 
histologically identical tumours located in the pineal region are diagnosed as pineoblastoma. 
The phenomena of tumour extension and also tumour location are important factors that affect 
both treatment and prognosis. Nowadays, immuno-histochemical analyses, cytogenetic and 
molecular genetic analyses, and other measures such as analysis of the mitotic activity, are 
playing a great role in the diagnosis and classification of brain tumours. 
According to location, brain tumours of childhood can be subdivided into: 
• Infratentorial: infratentorial tumours are those that arise in the lower part of the brain. 
Approximately, half of the brain tumours in children are infratentorial, usually located in the 
cerebellum or the fourth ventricle (75% of them). This category includes: 
Medulloblastoma 
Cerebellar astrocytoma 
Infratentorial ependymoma 
Brain stem glioma 
• Supratentorial: Supratentorial tumours are those that occur in the sellar or suprasellar region 
and/or other areas of the cerebrum, the upper part of the brain. This category includes: 
Cerebral astrocytoma 
Supratentorial ependymoma 
Supratentorial primitive neuroectodermal and pineal tumours 
Craniopharyngioma 
CNS germ cell tumour 
Visual pathway and hypothalamic gliomas 
• Spinal cord tumours: they are rare benign tumours located in the spinal cord. 
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The general effects of brain tumours are due to an increase in tlie intracranial pressure caused 
by a mass of tumour growing in the brain, hydrocephalus due to obstruction of the CSF flux, or 
by cerebral edema. Rapidly growing tumours have a high vascularity that can cause cerebral 
edema. Hydrocephalus is a common sign observed in posterior fossa tumours (Di Rocco and 
lannelli, 1996). 
Diagnosis of human brain tumours is based on their microscopic, immunohistochemical and 
ultrastructural features, and also on an assessment of their neuroimaging, clinical behavior, or 
grading. The grading is performed by attending to cellularity, nuclear atypia, proliferation rate, 
necrosis, calcification and other features. To assess the proliferative index, mitoses could be 
counted or antibodies such as Ki-67 could be used. Cytogenetic and molecular genetic studies 
also play an important role in the diagnosis and treatment of brain tumours (Shiminski-Maher 
and Shields 1995). 
Factors involved in brain tumour development 
There are several factors involved in the development of brain tumours such as: 
• Age: embryonal tumours occur predominantly in children. Neurogenesis and neuronal 
migration in the cerebrum are completed by mid-gestation, but in the cerebellum it continues 
during the first year of life. In childhood, the production rate of glial cells is very high, so that the 
risk for new gene defects is also high. 
Cerebellum is the part of the CNS with a higher cellular content and, is also the part that takes 
more time to develop, so it is not a coincidence that the cerebellum is by far the most frequent 
location of brain tumours in children. 
• Hereditary factors: there are several syndromes such as Li-Fraumeni or Gorlin syndromes 
that are associated with an increased incidence of some brain tumour types. 
• Genetic factors: allelic losses, mutations, gene amplifications and other alterations that affect 
the structure or function of tumour suppressor genes and oncogenes are directly related to 
carcinogenesis, but also with tumour progression, angiogenesis, and metastasis. There are 
also epigenetic changes that affect the regulation of gene expression and also contribute to 
brain tumour development. 
• Viruses: the tumourigenic capacity of some viruses lil^ e polyomavirus has been described in 
some studies (Khalili et al., 2003) they postulate that the interaction between the IGF and the 
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T-antigen of human polyomavirus JC contributes to malignant transformation in 
medulloblastomas. 
• Radiation: ionizing radiation induces mesencliymal tumours in animals. Also some rare brain 
tumours have been reported in humans after radiotherapy. 
• Chemical carcinogens: some substances, such as nitroso compounds, are potent 
neurocarcinogens in animals. The authors have a ubiquitous nature, and it is considered that 
they are involved in human brain tumour development (McBride, ML 1998). 
• Immunosuppression: cerebral lymphoma is frequent in the immunosuppressed patients. 
WHO Classification of Nervous System Tumours 
The WHO made a classification of tumours of the nervous system in 2000 (Kleihues and Sobin, 
2000). The present study is focused in the groups of embryonal tumours and neuroblastic 
tumours of the WHO classification, which are described in detail in the next section. 
Embryonal Tumours of Childhood 
Embryonal tumours are undifferentiated round-cell tumours that show divergent patterns of 
differentiation. They are composed of small cells with scanty cytoplasm and with a high 
nuclear-to-cytoplasm ratio. They represent a heterogeneous group of tumours whose origin 
and histopathological classification of embryonal tumours remains unclear. Their diagnosis is 
based mainly on their morphological appearance. Their clinical symptoms are related with an 
increased intracranial pressure and hydrocephalus, comprising headache, nausea, and 
vomiting. 
There are embryonal tumours of the CNS as well as of the PNS. Embryonal tumours can be 
divided according to the WHO classification (Kleihues and Sobin 2000), into the following 
histological entities: 
• Embryonal tumours of the CNS: 
Ependymoblastoma 
Medulloepithelioma 
Atypical teratoid/rhabdoid tumour (AT/RT) 
Pineoblastoma 
Medulloblastoma (MB) 
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Supratentorial primitive neuroectodermal tumours (sPNET) 
• Embryonal tumours of the PNS: 
Peripheral PNET (pPNET) have been observed in different locations as ovary, urinary 
bladder, cauda equina, kidney and in the chest wall (Askin's tumour). 
Neuroblastic tumours: 
Olfactory neuroblastoma or esthesioneuroblastoma 
Neuroblastomas (NB) of the adrenal gland and the Sympathetic nervous system pPNET, not 
from the PNS, have also been described. They usually arise either in bone or the soft tissue 
and are rare in children, occurring more frequently in the adolescence than in childhood. 
Ev\/ing's sarcoma is a family of small, round cell tumours that arise in the bone and/or soft 
tissues frequently referred as pPNET. It can spread in to lungs, bone and bone marrow. 
PPNET differs from Ewing's sarcoma in that pPNET shows more developed features of cells 
associated with the nervous system. Genetic analyses have shown that pPNET and Ewing's 
sarcoma have a common genetic alteration that consists in a translocation between 
chromosomes 11 and 22 (FLI-EWS), in contrast with central PNET (Sorensen, PH 1993). 
Embryonal tumours of the CNS 
Ependymoblastoma 
Ependymoblastoma is a rare, rapidly growing, and highly malignant embryonal tumour that 
correspond histologically to WHO grade IV (Cruz-Sanchez et ai, 1991), with preferential 
occurrence in neonates and the young children lesser than 5 years of age[10] (Dohrmann, GJ 
1976). This tumour is usually located in the supratentorial compartment, generally related to the 
ventricles. Patients with ependymoblastoma have a poor outcome with survivals ranging from 6 
months to one year after diagnosis. 
Medulloepithelioma 
Medulloepithelioma is defined as a rare, highly malignant embryonal brain tumour that 
corresponds histologically to WHO grade IV with typically occurrence in children between 6 
months and 5 years old. It can be located at the supratentorial compartment, as well as in the 
infratentorlal (Molloy, PT 1996). Most commonly, it appears periventricular, within the cerebral 
hemispheres, but it has also been described in the eye, usually occurring intraorbitally and in 
the optic nerve. 
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Atypical teratoid/rhabdoid tumour 
AT/RT tumour is a malignant embryonal tumour of the CNS with a poor clinical outcome that 
corresponds to WHO grade IV. It occurs predominantly in children less than 5 years of age at 
diagnosis, but also in adults from 21 to 41 years of age in 6% of the cases. Most frequently, 
AT/RT are located in the posterior fossa (52%), followed by a supratentorial localization in 39% 
of the cases. In adults, these tumours are predominantly located at the cerebrum. 
Biological characteristics and clinical features are similar to those of the MRTK (Weeks, DA 
1989).The name of "atypical teratoid/rhabdoid tumour" was applied by Rorke et al., 1996 
because of the observation of the combination of rhabdoid, primitive neuroepithelial, epithelial, 
and mesenchymal components.The FISH studies have been done in AT/RT and 90% of the 
tumours show monosomy or deletion of chromosome 22 (Biegel, et al., 1999).The gene 
involved in AT/RT (hSNF5/INI1) is located at 22q11.2. 
Pineoblastoma 
Pineoblastoma is defined by the WHO [6] as a rare intracranial, poorly differentiated, and highly 
malignant (WHO grade IV) primitive embryonal tumour of the pineal gland. It occurs 
predominantly in children and adolescent in the first two decades of life (Cheng, et al., 1995; 
Hoffman, et al., 1994).There is a genetic predisposition to pineoblastoma in patients with 
familial retinoblastoma. The occurrence of pineoblastoma together with a bilateral 
retinoblastoma is termed as "trilateral retinoblastoma" (De Potter, P 1994; Lueder, GT 1991). 
Embryonal tumours of the PNS 
Esthesioneuroblastoma 
Esthesioneuroblastoma or olfactory neuroblastoma is a very rare and slow growing malignant 
neuroectodermal tumour of the PNS that is thought to arise from olfactory receptor cells in the 
nasal cavity (Kleihues and Sobin, 2000). It is not typically pediatric and presents a bimodal age 
distribution, with peaks around 20 and 50 years of age. Usually, esthesioneuroblastoma is 
located in the cribiform plate that is destroyed by the slow growth and local invasion of the 
tumour. It can spread to cervical lymph nodes, lungs and bone, and also to the brain by 
leptomeningeal dissemination. 
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Olfactory neuroblastoma is genetically different from classic NB and it does not show 1p 
deletion, MYCN amplification, expression of tyrosine hydroxylase and neurotrophin receptor 
TrkA. It has been observed that esthesioneuroblastoma shows translocations involving EWS 
and FLU genes as Ewing's sarcomas (Kleihues and Sobin, 2000). 
Central PNET 
Introduction 
PNET constitute a group of histologically similar tumours with quite different locations. They are 
defined as small-cell malignant embryonal tumours showing divergent differentiation of variable 
degree along neuronal, glial, or, rarely, mesenchymal lines. PNET of the CMS can be divided 
into infratentorial (MB or iPNET) and supratentorial (sPNET) tumours. The most common 
tumour of the PNET group is MB. Supratentorial tumours are very rare, but in the young adults 
(21-40 years old) they are more frequent than MB. Some studies have suggested that MB and 
sPNET present different molecular genetic aberrations (Nicholson., ef a/., 1999; Russo., et ai, 
1999) Initially, it was though that all PNET have a common origin from primitive. 
neuroectodermal cells and that they differ only in the localization and degree of differentiation. 
In the last WHO classification (Kleihues and Sobin, 2000), some of those tumours are classified 
as separate entities in the basis that these embryonal tumours could also arise from cells 
already committed to differentiation. Primitive cells grow in sheets or cords of dense cellularity. 
They have an increased mitotic index and the nucleus-cytoplasm ratio is very high. Very often, 
Homer-Wright rosettes can be observed indicating a high mitotic activity and a marked 
pleomorphism. There are unusual variants such as rhabdomyoblastic differentiation, melanin 
deposition, ordesmoplastic features. 
Supratentorial PNET 
General Information 
sPNET is defined by the WHO as an embryonal tumour in the cerebrum or supraeellar region 
composed of undifferentiated or poorly differentiated neuroepithelial cells of WHO grade IV 
(very malignant) with the capacity of displaying divergent differentiation patterns (Kleihues and 
Sobin 2000). These tumours have been designated by several terms including cerebral MB, 
cerebral neuroblastoma, cerebral ganglioneuroblastoma, the "blue tumour", and PNET 
(Kleihues and Sobin, 2000). 
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The sPNET can present different differentiation patterns along neuronal, astrocytic, ependymal, 
muscular or melanotic lines. The sPNET with neuronal differentiation located at the cerebrum 
are termed as cerebral neuroblastoma. If there are ganglion cells in a cerebral neuroblastoma, 
it is termed cerebral ganglioneuroblastoma (Kleihues and Sobin, 2000).Though, the sPNET are 
not very common, it is difficult to estimate their incidence because of the different criteria 
regarding their classification. The sPNET are used for preferentially childhood brain tumours 
with an age ranging from 4 weeks to 10 years (mean 5.5 years). They are more frequent in 
boys than in girls (2:1). 
Histopathology 
Histologically, sPNET and MB are very similar with varying proportion of features that suggest 
neuronal, astrocytic or ependymal differentiation. sPNET are composed of undifferentiated or 
poorly differentiated neuroepithelial cells, with commonly small, round and deeply basophilic 
nucleus. They are rich chromatin tumours and have scant cytoplasm (Kleihues and Sobin, 
2000). The sPNET can vary in their morphological features. In some tumours, cells are larger 
with more pleomorphic nuclei. Necrosis and hemorrhagic areas are present. Melanin-bearing 
cells are rarely observed, in contrast to Homer-Wright and Flexner-Wintersteiner rosettes 
and/or ependymal canals (Kleihues and Sobin, 2000). 
Cerebral PNET has a variable desmoplastic component, typically of fibrocollagenous nature 
(Kleihues and Sobin, 2000). 
Immunohistochemistry 
There is an evidence of divergent differentiation. The most useful markers are GFAP, NFP, and 
desmin. Other markers such as synaptophysin, vimentin, and keratin can be used, but they are 
not essential and they do not provide additional information (Kleihues and Sobin, 2000). The 
mitotic activity of sPNET at any location is very variable. While Ki-67-positive cells are in high 
proportion, but the Ki-67 index varies from 0% to 85% (Kleihues and Sobin, 2000). 
Cytogenetics 
sPNET have not been deeply studied. Isochromosome 17q [1(17q)], the most frequent 
abnormality in MB, has been rarely found in sPNET (Pruchon, E 1994, Burnett et al., 
1997;Biegel,JA 1999 and Bigner, etal., 1988). 
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Although little studies have been performed in sPNET, it is hypothesized that sPNET are 
genetically different from PNET that arise at cerebellum or MB (Rousso e^  a/., 1999). 
Medulloblastoma 
General Information 
MB is an extremely malignant and invasive PNET localized at the cerebellum (Kleihues and 
Sobin, 2000). They correspond histologically to WHO grade IV tumours and are the most 
common malignant brain tumour of childhood, representing 20% of all childhood brain tumours. 
Their pathogenesis and their relationship to other embryonal CNS tumours remain unclear. 
Originally, MB was classified as gliomas, but now they are referred as central PNET. The 
annual incidence of MB has been estimated at 0.5 per 100.000 children younger than 15 years 
old. MB is most common in children from 3 to 8 years old. The peak incidence is at 7 years old. 
Seventy percent of MB occurs in individuals younger than 16, and 50% in the first decade of 
life. MB can also occur in adults, but they are extremely rare (1%) and most of them occur 
between 21 and 40 years old. Their origin remains unknown. They are slightly more frequent in 
males than in females (Kleihues and Sobin, 2000). MB can metastasize to the spinal cord via 
the CFS and can cause subarachnoid disease, but rarely spreads to other organs of the body. 
Extracranial metastases have been observed in bone, liver, and lymph nodes. CFS 
dissemination at diagnosis has been observed in 10-30% of the patients, while extracranial 
metastases account only for 5% of the cases (Kleihues and Sobin, 2000). 
Histopathology 
Histologically, MB is a high dense cellular tumour composed of hyperchromatic round cells, 
with scant cytoplasm. Prominent mitotic activity and necrosis are very commonly observed[ 
(Kleihues and Sobin, 2000). 
Neuronal differentiation is more common than glial differentiation, but both are observed In MB. 
Neuronal differentiation is manifested by rosette formation, consisting of a group of tumour cells 
disposed in a circle around a fibrillary center. Mature neurons are infrequently observed in MB. 
Glial differentiation is evidenced by the presence of GFAP-positive cells. There are other 
differentiation patterns along oligodendroglial and mesenchymal lines, but they are more rare 
(Kleihues and Sobin, 2000). 
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Classic MB 
Classic IVIB is a dense cellular tumour composed of packed cells with round to oval or carrot-
shaped nuclei. Cells present hyperchromatic nuclei and scant cytoplasms. Neuroblastic 
rosettes composed of tumour cells disposed in a circular fashion are typical, but not a constant 
characteristic. Neuroblastic rosettes are frequently associated with high mitotic activity. 
Multinucleated giant cells, nuclear gigantism, vascular proliferation, calcification, and massive 
hemorrhages are occasionally observed (Kleihues and Sobin, 2000). 
Desmoplastic MB 
Desmoplastic MB is a type of neuroblastic MB that contains lobules in which the tumour cells 
have more rounded and vesicular nuclei that create a "pale-island" (reticulin-free zones) 
appearance with deposition of reticulin among the pale island nodules. The cells surrounding 
the nodules are more irregular and hyperchromatic. It also includes Homer-Wright rosettes, 
mature ganglion cells and immunoreactivity for neuronal markers such as synaptophysin and 
NFP, indicating neuronal differentiation (Kleihues and Sobin, 2000). Some authors have 
suggested that desmoplastic MB have better prognosis than classic MB (Maire, JP 1992). If 
there is not nodular pattern, but there is an increased amount of reticulin and collagenous 
fibers, it is also considered as a desmoplastic MB variant. Tumour extension into the arachnoid 
membrane elicits a fibroblastic reaction that gives to this kind of MB a particular appearance. 
This MB variant is more frequent in the cerebellar hemispheres and in older patients. 
Cerebellar neuroblastoma 
In children younger than 3 years old, there is a variant of MB called "cerebellar neuroblastoma" 
(Kleihues and Sobin, 2000) that is characterized by an extensive nodularity and advanced 
neuronal differentiation. Mature ganglion cells can be observed and there are intranodular cells 
that resemble the neurocytes of central neurocytoma. It has been suggested that they 
constitute a different tumour entity. 
Large cell MB 
Large cell MB is an infrequent variant of MB (4% of the cases) composed of cells with large, 
round and/or pleomorphic nuclei. The cells have a more abundant cytoplasm and the nucleoli 
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are more prominent. There are large areas of necrosis, high mitotic activity and high apoptotic 
rate. Large cell IVIB is histologically similar to AT/RT tumour (Kleiuhues and Sobin, 2000). 
Lipomatous MB 
Lipomatous MB presents immunohistochemical and architectural features of neuronal 
differentiation combined to adipocytic features. This variant arises more often in adults and is 
correlated with favorable prognosis (Kleihues and Sobin, 2000). 
Immunohistochemistry 
A subset of MB with neuronal differentiation expresses synaptophysin. This marker of neuronal 
lineage is not present in tumours of glial or mesenchymal origin. Neuronal differentiation is 
frequent in desmoplasic MB. 
The expression of different IFP is a molecular marker of the development of cells from the CNS 
(Kleihues and Sobin, 2000). Different lineages of MB could be identified with those IFP. Nestin 
is a class IV IFP expressed in neuroephitelial progenitor cells of the human CNS in 
development and is a marker of CNS precursor cells. At the end of gestation, expression of 
nestin is overcome. This molecular marker has been detected in many types of brain tumours, 
such as MB, astrocytomas, GEM and ependymomas. Vimentin is a class III IFP whose 
expression is closely parallel to nestin expression and is strongly expressed in classic MB. 
Glial differentiation is reflected by positivity to GFAP marker. GFAP is another class of III IFP 
marker restricted to developing and mature astrocytes in CNS. Almost all MB contain stellate 
GFAP-positive cells. Although many MB (about 50%) show GFAP immuno positivity, glial 
differentiation is less common. It is not clear whether the immuno reactivity is due to trapped 
astrocytes or to differentiated neoplastic astrocytes. However, GFAP immunoreactivity has 
been observed In MB metastases. There are many MB that show neuronal and glial 
differentiation. 
There are three groups of neuron-specific IFP used to identify neuronal lineage in MB: triplet 
NF (low, middle and high), alpha internexin, and peripherin. Phosphorylated high and middle 
NF proteins are expressed in more advanced stages of neuronal development than the less 
phosphorylated NF. 
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MB expresses rhodopsin and retinal S-antigen that are photoreceptor proteins. The expression 
is typical of MB, but it is not a regular feature. The level of differentiation is also reflected by the 
expression of N-CAMs. N-CAMs appear to be important for cell migration in the developing 
nervous system. Mesenchymal differentiation is very rare. In medullomyoblastoma, for 
example, tumour cells show cross striations and immune reactivity for muscle markers. 
Apoptotic nuclei are detected by ISEL in classic and desmoplastic MB in 1.3 ± 0.5% of nuclei. 
Apoptotic nuclei are more common in areas with higher mitotic rate and higher number of Ki-
67-positive cells. The proliferation rate is significantly higher in MB than in malignant glioma 
(Hoshino et al, 1985). The growth fraction, estimated by Ki-67 index, is often >20%. Positive 
cells for Ki-67 are more regularly distributed in classic MB, and are infrequent in pale islands of 
the desmoplastic variants. 
Genetic susceptibility 
Although most of the MB is sporadic, MBs are associated with other brain tumours and 
extraneural malignancies, including Wilm's tumour. There have been reported cases of MB in 
monozygotic twins, siblings and dizygotic twins (Scheurlen et al., 1996). 
MB can also occur in association with some syndromes: 
• Gorlin syndrome or NBCCS: is caused by the mutation of genes below the Sonic Hedgehog 
pathway. Mutations in these genes have been observed in approximately 25% of sporadic MB 
(Reifenberger et al., 1998;Smyth et al., 1999). In addition, mutations on the PTCH gene in 
mice cause MB-like tumours in 10-15% of the cases (Goodrich et al., 1997). 
• Turcot syndrome results from germline mutations in the APC gene, a member of the Wnt 
signaling pathway. The Wnt pathway acts promoting the degradation of the proteosoma. 
Mutations in genes of this signaling pathway have been identified in 25% of sporadic MB 
(Huang etal., 2000; Zurawel etal., 1998; Zurawel etal., 2000). 
• Li-Fraumeni syndrome is characterized by inherited mutations of TP53. Affected individuals 
develop a large spectrum of CNS and extra-CNS tumours, including MB. Mutations in TP53, on 
the contrary, are rarely observed in sporadic MB (Raffel et al., 1993; Badiali et al., 1993). 
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Cytogenetics 
The most common specific abnormality in IVIB is the presence of isochromosome 17q, [i(17q)]. 
It is present in approximately 30-50% of the cases (Biegel, et ai, 1989; Michiels et ai, 2002; 
Vagner-capodano et al., 1994). The breakpoint in most MB is in the proximal portion of 17p, 
between D17S689 and D17S95 at 17p11.2 (Scheurlen et ai, 1999). In a small number of MB, 
loss of partial or complete 17p occurs through interstitial deletion, unbalanced translocation, or 
monosomy (Biegel et a!., 1992). Rearrangements of chromosome 1 resulting in 1q trisomy 
without loss of 1p are also frequently observed in MB (Bigner et ai., 1988; Micheils et a!., 2002, 
Avet-Loiseauefa/., 1999). 
Other non-random changes have been found by CGH studies (Avet-Loiseau et a!., 1999; 
Gilhuis eta!., 2000; Nicholson etal., 2000). Losses of chromosomes lOq (40%), 11 (45%), and 
gain of chromosome 7 (45%) are also frequent. Deletions of 6q, 9q, and 16q and gains on 4p, 
5p, 8q, and 9p have also been observed (Kleihues and Sobin, 2000). 
Molecular genetics 
Two thirds of MB cell lines and xenografts present DM, in contrast to biopsy samples in which 
DM are observed in less than 5% of the cases. DM usually contains amplification of MYC 
(Badiali et ai., 1991; Batra et ai., 1994; Bigner et ai, 1990) and less frequently MYCN[45] 
(Troost et ai., 1990). (Scheurlen et ai., 1998) reported MYC amplification in 20% of MB in a 
CGH study. 
LOH at chromosome arm 17p has been found in 30-45% of the cases by RFLP and 
microsatellite analysis (Cogen et ai., 1996), though, a MB-related tumour suppressor gene on 
17p has not been found yet. Even, most of the cases present deletions of the short arm of 
chromosome 17. The smallest overlapping region of deletion is located at 17p13.3 (Biegel et 
ai., 1992; Koch et ai., 1996; McDonald et ai., 1994). The TP53 tumour suppressor gene is 
located at 17p13 and is mutated in a variety of human tumour types and initially, it was thought 
to be a candidate gene in MB. Mutations at the TP53 locus have been demonstrated in a small 
subset of MB (5-10%) (Adesina et ai., 1994; Ohgaki et ai., 1993). Other putative tumour 
suppressor genes mapping the region 17p13.3 have been proposed: ROX/MNT (Sommer et 
ai., 1999), HIC1 (Wales etai., 1995 and BCR-related (ABR) (Cogen etai., 1996). 
Other chromosomal regions that present frequent losses of genetic material are 1q and lOq, in 
20-40% of the cases (Scheurlen etai., 1998; Rasheed et ai., 1997; Kraus et al., 1996; Blaeker 
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et ai, 1996). Target genes in those regions have not been identified yet. The lost region in 1q 
corresponds to a locus deleted in breast cancer (1q31-q32) (Benitez et ai, 1997). On 
chromosome lOq, there are tv\/o candidate genes: PTEN at 10q23 and DMBT1 at 10q25.3-
q26.1. Intragenic homozygous deletions of the DMBT1 gene have been detected in a small 
subset of MB (Mollenhauer et at, 1997), suggesting that they might play a role in the 
pathogenesis of some MB. Mutation or deregulation of several developmental pathways has 
been described in MB (Weiss et al., 2000). There are germline mutations in hereditary 
syndromes that increase the risk of developing MB (Taylor et at., 2000). Mutations in the APC 
and PTCH genes have been observed in patients with Turcot's and Gorlin's syndromes, 
respectively, as well as in a smaller frequency in the sporadic MB (Huang et ai, 2000; Hamilton 
eta!., 1995; Vortmeyerefa/., 1999). 
The APC gene encodes a protein that functions as a downstream transcriptional activator of 
the Wnt signaling pathway (Barth ef al., 1997). Somatic mutations have been frequently found 
in sporadic colon cancer, resulting in p-catenin accumulation, which also activates the Wnt 
pathway (Cottrell etal., 1992; Munemitsu etal., 1995). The Wnt pathway is involved in sporadic 
MB. Mutations in P-catenin and APC genes are observed in 13% of sporadic MB (Huang ef a/., 
2000), although they are mutually exclusive. The locus for NBCCS has been mapped to 9q. 
Losses at this region have been observed in 10-18% of MB (Scheurlen et al., 1998; Schofield 
et al., 1995). Patients with NBCCS are predisposed to develop basal cell carcinoma and 
desmoplastic MB. Germline mutations of the human homologue of the PTCH gene {Drosophila 
segment polarity gene patched) are present in patients with NBCCS. PTCH gene encodes a 
cell surface receptor present in cerebellar granule cell progenitors. PTCH is inhibited by the 
hedgehog ligand binding resulting in an increased transcription of genes as GLI1, WNTs and 
TGPp-related genes, as well as PTCH (Dean M, 1996). It is believed that PTCH is a tumour 
suppressor gene. Inactivating mutations of PTCH have been found in a small subset of 
sporadic MB (Raffel et ai, 1997; Xie et ai, 1997; Dong et ai, 2000). Pietsch et ai suggested 
that mutation of this gene occurs predominantly in desmoplastic MB[70] (Pietsch et ai, 1997). 
Other genes of the PTCH pathway, such as GLI3, SHH and SMOH (Zurawel et ai, 1998; Erez 
et ai, 2002) are rarely mutated in sporadic MB. 
Histogenesis 
MB was recognized as a distinct clinico-pathological entity by Bailey and Gushing in 1925 
(Bailey ef ai, 1925). They proposed that MB derives from proliferating embryonal and 
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undifferentiated cells that could differentiate into spongioblasts and neuroblasts called 
medulloblasts. Nowadays, there are three hypotheses of the histogenesis of MB (Figure i). The 
first hypothesis suggests that MB originates from the EGL of the cerebellum, which is formed 
during the embryogenesis by migration of undifferentiated cells from the roof of the fourth 
ventricle to the surface of the fetal cerebellar cortex. This structure is present during 
development, but it is not found in the adult brain. Later, those cells give rise to neurons as well 
as glial cells in the mature vertebrate brain. It is believed that MB arises from an early precursor 
to cerebellar granule cell located in the roof of the fourth ventricle through the activation of the 
Shh pathway (Pomeroy et ai, 2002). This is the most supported view, as mutations of the 
PTCH gene have been detected (Raffel et ai, 1997; Xie et ai, 1997; Dong et ai, 2000). If this 
view is true, it is expected that MB have neuronal differentiation, because there is no evidence 
of the glial or mesenchymal differentiation capacity of the cells from the EGL (Swarz and Del 
Cerro 1977). 
The second hypothesis assumes that MB is derived from subependymal matrix cells that are 
present there throughout the embryonal CNS. These cells could give rise to neuronal and glial 
cells. The basis of this hypothesis lies in the PNET concept, so that sPNET and MB would 
derive from a common precursor. 
The last hypothesis proposes that MB have more than one cell of origin based on studies that 
show differential immuno-reactivity to calbindin-D28k and class III (3-tubulin isotype. Calbindin-
D28k is a ventricular matrix-associated neuronal calcium-binding protein that is not expressed 
in the EGL, neither in its progeny, while class III p-tubulin isotype is expressed in neuronal cells 
of the ventricular matrix and the EGL (Katsetos et al., 1993; Katsetos et ai, 1995; Katsetos ef 
a/., 1998). 
Prognostic factors 
From 1960 until now and due to the improvement in MB treatment, the period of 5-year survival 
has increased from 30% to 50-70%. There are many predictive factors to be considered in MB 
patients. Age, of the patient tumour location and the extent of surgical resection remains 
controversial as predictive factors. Some authors suggest that desmoplastic MB has better 
outcome than classic MB (Maire et al., 1992) while other authors suggest that desmoplastic MB 
is associated with poor prognosis (Giordana ef a/,, 1995; Hubbard ef ai, 1989). These 
differences could be explained due to the different classification of desmoplastic MB. MB with 
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extensive nodularity presents a very favorable outcome despite almost all the patients are 
classified as poor risk. In contrast, large cell variant of MB appears to be very malignant with 
frequent CSF dissemination. Some authors suggest that GFAP expression conferred a bad 
prognosis to MB (Goldberg et al., 1991; Janss et al., 1996) while expression of the S-antigen 
and rhodopsin appear to be associated with good prognosis (Czerwionka et al., 1989; 
Maraziotis ef a/., 1992). 
Tumour cell proliferation has a limited prognostic value. Tumours with a BrdU labeling index 
higher than 20% appear to have worse prognosis (Ito et al., 1992). Aneuploid tumours are 
associated with good prognosis (Tomita et al., 1988 Yasue et al., 1989). Patients with a high 
apoptotic index had a better outcome than other patients, independently of the risk group of 
diagnosis (Haslam et al., 1988).The LOH at 17p remains a controversial prognostic factor. 
While some authors suggest that LOH on 17p is associated with poor prognosis (Cogen et al., 
1996; Cogen et al., 1991) and reduced survival (Batra e^  al., 1995), other authors failed to 
demonstrate any correlation between 17p loss and survival. Presence of i(17q) has been 
suggested to indicate unfavorable outcome. Tumours with MYC amplification are resistant to 
therapy (Scheurlen et al., 1998) which confers a bad prognosis. 
1.3 Astrocytomas 
Introduction 
The astrocyte, one form of glial cell which comprises much of the background substance of the 
brain and spinal cord, gives rise to a large category of primary brain tumours, the diffusely 
infiltrating astrocytomas. These are the most frequent intracranial neoplasms and account for 
more that 60% of all primary brain tumours. These neoplasms can occur in all areas of the 
brain and spinal cord in children and adults. The incidence of astrocytomas is approximately 7 
per 100.000 inhabitants. The World Health Organization (WHO) classification recognizes four 
grades of astrocytoma: Grade I atrocytomas are slow growing, non-infiltrative neoplasms, 
occurring mainly in children and young adults and include juvenile epilocytic astrocytomas and 
gangliogliomas. Grade II astrocytomas are mainly well- differentiated fibrillary astrocytomas, 
while grade III astrocytoma, the anaplastic astrocytoma, is a more aggressive neoplasm. The 
most malignant form of astrocytoma, the grade IV tumour, is glioblastoma multiforme, which is 
the most common primary malignant brain tumour of adults. In addition to these four tumour 
grades, astrocytomas may combine with oligodendrocytes to produce oligoastrocytoma. 
22 
Review of Literature 
Although astrocytomas most commonly occur in the cerebral hemispheres of older individuals, 
they can be seen throughout the brain and spinal cord of patients of all ages. 
In almost half of the cases, the first symptom of an astrocytoma is the onset of a focal or 
generalized seizure. Between 60 to 75% of patients, they will have recurrent seizures in the 
course of their illness. Signs of increased intracranial pressure (headache, vomiting) usually 
present late in the disease course. In children, the tumour is usually located in the cerebellum 
and will present with some combination of gait instability, unilateral ataxia, and signs of 
increased intracranial pressure (headache, vomiting). In rare cases (0.8% - 0.05% of all cases) 
the tumour produces metastasis growths into other parts of the brain slowly causing a lack of 
blood and nutrient supply, and causing the brain to work harder and produce a higher 
percentage of the brain to be used to keep up with the workload, this can cause flashes of light 
in vision and increased cognitive skills and extremely higher knowledge recall and problem 
solving skills. A Computed Tomography or Magnetic Resonance Imaging scan is necessary to 
characterize the anatomy of this tumour (size, location, consistency). Computer Tomography 
will usually show distortion of the third and lateral ventricles with displacement of anterior and 
middle cerebral arteries. Histologic diagnosis with tissue biopsy will normally reveal an 
infiltrative character suggestive of the slow growing nature of the tumour. The tumour may be 
cavitating, pseudocyst-forming, or noncavitating. Appearance is usually white-gray, firm, and 
almost indistinguishable from normal white matter. These tumours contain the glial fibrillary 
acidic protein (GFAP), which is a useful diagnostic marker in a tissue biopsy. Resection of the 
tumour will generally allow functional survival for many years. These tumours will eventually 
undergo malignant transformation, and addition of radiation therapy or chemotherapy will be 
necessary. Astrocytomas often recur even after treatment and are usually treated similarly as 
the initial tumour, with sometimes more aggressive chemotherapy or radiation therapy. In some 
rare cases the tumour creates two or more cell types making a treatment kill one type of cell 
but allowing the other to become more aggressive and immune to future treatments. 
Astrocytoma Progression 
Glioblastoma tumours may develop from low-grade astrocytomas (WHO grade II) or anaplastic 
astrocytomas (WHO grade III) {secondary glioblastoma), but, more frequently, they manifest de 
novo, without any evidence of a less malignant precursor lesion (primary glioblastoma). The 
Primary GBMs account for the vast majority of cases (60%) in adults older than 50 years. 
When these tumours manifest de novo (i.e, without clinical or histopathologic evidence of a 
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preexisting, less-malignant precursor lesion), they present again after a short clinical history, 
usually less than 3 months. 
Secondary GBMs (40%) typically develop in younger patients (under 45 years) through 
malignant progression from a low-grade astrocytoma (WHO grade II) or anaplastic astrocytoma 
(WHO grade III). When patients with diffuse astrocytoma WHO grade II develop a recurrent 
lesion, the second surgical biopsy often shows histopathological evidence of increased nuclear 
atypia, hyperchromasia, mitotic activity (anaplasic astrocytoma) and, eventually, microvascular 
proliferation and/or necrosis i.e. features of the glioblastoma. The acquisition of anaplastic 
features, though an inherent property of diffusely infiltrating astrocytomas, is largely 
unpredictable clinically and histopathologically, in particular, as regards the time over which 
these changes take place. While some astrocytomas show no change in histological grade 
over more than 10 years following the first operation, others show a rapid transition to 
malignancy within 1-2 years, the mean interval being 4-5 years. Progression from anaplastic 
astrocytoma to glioblastoma is more rapid, within approximately 2 years. 
Primary and secondary glioblastomas constitute distinct disease entities that evolve through 
different genetic pathways, affect patients at different ages, and differ in response to some of 
the present therapies. Of all the astrocytic neoplasms, glioblastomas contain the greatest 
number of genetic changes, which, in most cases, result from the accumulation of multiple 
mutations (Figure ii). 
1.4 Chromosomal and Genetic Alterations in Astrocytomas 
The formation of human tumours is a complex process involving the accumulation of genetic 
lesions in genes that normally regulate pathways of cell proliferation, differentiation and death 
required for organ development. As with tumours that occur at other sites, two types of genes 
have been identified which are targets for this disregulation. Dominantly acting oncogenes 
whose protein products serve to accelerate cell growth are typically altered by increased gene 
dosage (amplification) or by activating mutations, while tumour suppressor genes whose 
proteins products serve as brakes on cell growth are typically altered by deletion, 
hypermethylation or by inactivating mutations. 
1.5 Chromosomal alterations in astrocytomas 
The most consistent chromosomal changes in astrocytomas are; 
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LOH analyses of astrocytomas revealed that approximately one third of these tumours have 
loss of all or part of 17p. LOH for 17p occurs in astrocytomas of all grades. Point mutations of 
the TP53 gene can be demonstrated in the majority of the astrocytomas with 17p loss (Orellana 
et al., 1998). Loss of hetrozygosity of chromosome 22q occurs in 20-30% of glioma of all 
grades, suggesting the presence of a tumour suppressor gene that plays a role in the early 
stages of gliomagenesis (James ef al., 1988).Other common chromosomal alterations can be 
found mainly in high grade astrocytoma (glioblastoma multiforme) (Signer et al., 1988; Bigner 
etai, 1990; Bogleref a/., 1995;Von Deimling etal., 1994;Von Deimling et ai, 1993): Gains of 
chromosome 7, seen in about 80% of tumours. Losses of chromosome 9p, seen in about third 
of the cases (Bigner et a/.,1988). Losses of chromosome 10, seen in 60% of tumours. Loss of 
one copy of chromosome 10 is a frequent event is glioblastoma, occurring in the great majority, 
while being rare in lower grades of astrocytic tumours. Loss of heterozygosity on large regions 
at the lOp, 10q23 and 10q25-26 loci or loss of an entire copy of chromosome 10 is the most 
frequent genetic alterations in glioblastomas. Losses of 19q, occurring in 40% of high-grade 
astrocytic tumours (Ito ef al., 1992). The presence of double minute chromosomes (D mins) 
reported in up to 50% of the cases. 
1.6 Sonic hedgehog Pathway: 
Hedgehog signaling pathway is very important developmental pathway, and is conserved from 
flies to humans. Its name was derived from the polypeptide "hedgehog". It was first discovered 
in fruit fly Drosophila, in which this pathway is involved in regulating the body plane and is later 
involved in the process of embryogenesis and metamorphosis. Mammals have three 
homologues of hedgehog, Desert, Indian and Sonic hedgehog, All are important in the 
development process. Among these, sonic hedgehog is well- studied. It was reported that sonic 
hedgehog pathway components in knockout mice showed failure in the proper development of 
the brain, skeleton, musculature, gastrointestinal tract and lungs. It was also recently reported 
that this pathway is also responsible for renewable adult stem cells and Cancer. Because of 
these, many pharmaceutical companies are involved in the designing of different target 
molecules and drugs. 
Discovery: 
In 1995 Edward B. Lewis, Chritiane Niissslein-Volhard and Eric F. Wieschaus were awarded 
the Noble Prize for studying the genetic mutation in Drosophila embryogenesis. They 
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discovered that body segmentation process is a multiple gene process and hedgehog is one of 
them. Hedgehog mutant embryo manifests itself into abnormal short and stubby shaped 
embryos and has "solid lawn" of denticles (Figure.iii).This appearance of stubby and hairy. 
Mechanism: 
Sonic hedgehog (Shh) is well known ligand in vertebrates.This Shh precursor is ~45kDa 
prepeptide which has autocatalytic activity and further cleavage into ~20kDa N terminal 
Shh(Shh-N) and ~25kDa C-terminal with no known signaling role. This ~20kDa N- terminal 
carboxyl group undergoes cholesterol modification for trafficking, secretion and receptor 
interaction of the ligand (Figure iv). Shh acts both autocrine and paracrine. For paracrine it 
needs participation of Dispatched protein. (Nusslein-Volhard et ai, 1980). 
When Shh reaches its target cell, it binds to twelve transmembrane receptor Patchi. Before the 
binding of Shh, Patch 1 inhibits the action of the another seven transmembrane (7T) receptor 
smoothened (SMO) (Taipale et ai, 2002).This^ inhibition is controlled by two proposed 
mechanism, patchi has sterol sensing domain (SSD) which is helping in inhibition of SMO and 
removal of oxysterol, and SMO remain inactive.Patchi acts like a sterol pump and remove 
oxysterol that have been created by the 7-dehydrocholesterol reductase (Figure v). (Corcoran 
RB, 2006). 
The accumulation of sterols allows SMO to remain active. This activated SMO then further 
activates the zinc finger transcription factors Glil and Gli2 activators and Gli3 as a repressor; 
however the exact mechanism of SMO and Glis genes is not very much clear (Figure vi). This 
activated GUI move to nucleus and influence the downstream gene of this pathway. 
In another independent study, it was found that this activation of Patch is independent of 
Smoothened (Rahnama etai, 2006). 
Unlike Drosophila (invertebrate) vertebrates posses, another kind of Shh regulation through 
hedgehog interacting protein (HHIPI).Unlike Patchi HHIP acts directly to SMO. 
Role: 
Members of hedgehog family play important role in the variety of developmental role. The 
concept of morphogen came during developmental study of chick digit by Saunders and 
Gassely in 1968.They have determined the role of Shh In chick digit development and it 
depends upon concentration and exposure time of Shh. This follows for all developmental 
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process.The current model was proposed by Hafe et al in 2000.In this model, they have 
proposed both concentration and time of exposure of Shh which are determinant of digit 
development in mice embryo (Figure vii). 
In the digit development, Shh showed autocrine function without DISC which is required for 
extra cellular diffusion of Shh. Among digits, the concentration and time of exposure of Shh 
varies, digit V needs higher concentration and longer time exposure, digit IV needs lesser and 
shorter, III needs much lesser and shorters till, II needs least concentration and Shh exposure 
and digit I develops by default. 
Sonic hedgehog pathway also proliferates adult stem cells in many tissue like hematopoietic 
cells (Bhardwaj G et al 2001), mammary (Liu S et al 2006), neural (Rowitch et al., 1999) and 
stem cells. 
Human disease: 
Disruption of this pathway either by deleterious mutation or due to consumption of teratogens 
leads to severe embryonic abnormalities. Holoprosencephaly is abnormal embryonic condition 
in which pros encephalon is not properly developed into cerebral hemisphere and it is with the 
frequency of 1/16,000 live birth. It is reported that 1/200 spontaneous abortion is also due to 
mutation in SHH and PTCH. Consumption of specific inhibitor of this pathway "cyclopamine" by 
gestating mammals causes Cyclopia which is a severe defect of Holoprosencephaly (Keeler 
RF, 1978). 
Activation of sonic hedgehog pathway causes cancer in such tissue like brain, lung, and 
mammary gland, prostate and skin. Basal cell carcinoma (BCC) is one of the most common 
malignant cancer and shows close association with sonic hedgehog signaling. Loss-of-function 
mutation in patch and activating mutation in SMO leads to disease in patients (Xie, J et al 
1998). Abnormal activation of the this signaling transforms adult stem cells into cancer stem 
cells and develops the tumours. Specific inhibitor of these signaling targets is useful for efficient 
therapy for wide range of malignancy (Chen et al., 2002). 
Targeting the hedgehog pathway: 
Modulating SMO and its antagonist and agonist are good agents as therapeutics.PTCH 1 
(Nakamura etal., 2007) antibody also regulate the pathway. Targeting the main transcriptional 
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activator of this pathway Gli1 with siRNA is also an effective way to understand the molecular 
nnechanism of downstream target of this pathway (Stecca et al., 2005). 
Involvement in cancer progression: 
This pathway promotes the metastasis in cancer by increasing the concentration of snail 
protein expression and inhibiting E-cadherin and tight junction expression[111]( Li ef al., 
2006).This pathway increases the angiogenic factor angiopoietin-1, decreases angiopoietin-2 
(Lee SW et al 2007), increases Cyclins (D1 and B1) (Kenney et al., 2006), also decreasing 
antiapoptotic genes and increase apoptotic genes (Fas) (Athar et al, 2004). 
1.7 Sonic hedgehog 
It is well studied protein known to be important in the development. Its other homologues are 
Desert hedgehog (DHH) and Indian hedgehog (IHH). For the first time, Lewis Wolpert reported 
that sonic hedgehog acts as a morphogen, the French flag model. This is acting in a 
concentration gradient manner. It is also responsible for cell division in adult stem cell and this 
activation of stem cells changes this stem cell to cancer stem cells. 
Function: 
Because of morphogenic characteristic, this Shh is responsible for patterning of many systems 
including limb (Currie and Ingham 1996), midline structure in the brain (Machold and Fishell 
2002) and spinal cord (Lewis et al 2001) and the thalamus by the Zone limitation 
intrathalamica. Mutation in the human Shh gene leads to holoprosencephaly type 3(HPE3) as a 
result of loss of the ventral midline. Shh is secreted by the zone of polarizing activity (ZPA), 
which is located on the posterior side of a limb bud in an embryo. Shh is also involved in axonal 
cue. 
Processing. 
Firstly it is translated in 45kD preproprotein and then it is cleaved into two fragment of 20Kd N-
terminal and 25Kd C-terminal (Figure Iv). The C-terminal has auto-processing activity of 
cleavage. This N-terminal undergoes for cholesterol modification which is necessary for 
trafficking, secretion and interaction with receptor (Porter ef al., 1996). This modification 
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increases the signaling efficiency 30 fold over the non-palmityl form (Pepinsky etal., 1998).C-
terminal does not have any known signal activity. 
1.8 Smoothened (SMO) (Chromosome 7:128.62-128.64 mb) 
SMO is a G protein-coupled receptor (Molnar et ai, 2007) protein encoded by the SMO gene of 
the hedgehog pathway. It is conserved from flies to human. Its function is inhibited by teratogen 
cyclopamine (Taipale J, 2000). Before the activation of Shh signaling, the smoothened is 
inhibited by PTCH, another transmembare of Shh signaling. When Shh signal is activated, the 
binding to patch receptor leads to relive of Smoothened (SMO). This relived SMO is now 
activated and translocated in side the cell and binds with costal-2 which further activates the 
zing finger transcription factor Glis family protein (Corbit et al., 2005).SMO can function as an 
oncogene and its unregulated activation leads to cancer development (Xie etal., 1998). 
1.9 HHIP 
HHIP is a glycoprotein located on chromosome 4q31.21-31.3. It is the secreted type of 
hedgehog-interacting protein and shows an endogenous antagonist for the SHH, IHH and DHH 
(Chuang and McMahon 1999). It has eleven binding sites for bHLA transcription factor in the 
promoter region. HHIP is upregulated by down regulation of Notch-CSL-HES/HEY signaling 
which further represses bHLA transcription factor and finally leads to decrease in the hedgehog 
VEGF-Notch signaling Cascade. In a similar way, HHIP shows downregulation due to up 
regulation of Notch signaling in vascular endothelial cells during angiogenesis, which 
consequently leads to upregulation of the hedgehog-VEGF-Notch signaling. It is the target of 
pharmacogenomics because of involvement in vascular modeling. It has low expression in 
variety of tumours like gastric, pancreatic, colorectal, esophageal and lung cancer (Olsen et al., 
2004, Martin et al., 2005) however it shows low expression in human aortic endothelial cells 
(Olsen et al., 2004) It is considered anti-cancer agent because of inhibiting hedgehog pathway. 
HHIP shows negative regulation of Shh like PTCH (Chunag et al., 1999,). Low expression of 
HHIP is also associated with epigenetic regulation, which was reported in pancreatic cancer 
cell lines and pancreatic cancer xenografts. However this silencing reversal after the 
demethylating drug 5-aza-2'-deoxycytidine shows low expression of Gli and Shh expression 
(Martin et al., 2005). HHIP chromosomal locus 4q31.21-31.3 shows frequent loss of 
hetrozygosity (LOH) in pancreatic cancer (Chuang and McMahon 1999). 
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In a similar pattern to PTCH1, HHIP is transcriptionally activated in response to Shh signaling, 
overlapping the expression domain of PTCH1 (Goodrich et ai, 1996; Chuang and McMahon 
1999).Gain-of-function experiments showed HHIP binding to Shh ligand weakened Shh 
signaling (Chuang and McMahon 1999). Loss-of-function mutant in HHIP result in an 
upregulation of Hh signaling in mouse embryo, dismpting cell interaction essential for the 
normal morphogenesis of the lung and skeleton (Chuang etal., 2003). 
HHIP expressing cells are located next to Shh express cells [123](Chuang and McMahon 
1999). Ectopic expression of Shh leads to ectopic HHIP expression indicating that HHIP is a 
transcriptional target of Hh signaling (Chuang et ai, 2003).HHIP also forms negative feed back 
loop with Hh lignad (Chunag and McMahon, 1999). 
1.10 Suppressor of Fused (SUFU): 
SUFU acts as a negative regulator of Shh signaling (Ding et ai., 1995) and inhibits Gli transport 
from cytoplasm to nucleus. SUFU remains as a tetra-complex in cytoplasm with 
serine/threonine kinase-fused, the kinestin-like costal-2 and Ci (Robbins et ai, 1997, Monnier 
et ai, 1998, Stegman et ai, 2000). It is physically interacting with Gli protein (Pearse et ai, 
1999, Kogerman et ai, 1999, Ding et ai, 1999, Simon et ai, 2000).Mutation in human SUFU 
gene predisposes the patients to medulloblastoma (Taylor et ai, 2002). 
Human SUFU gene encodes three different protein products of 433,481 and 484 amino acids 
(Stone et ai, 1999).Two another spliced variants encoding 359 and 388 amino acids were also 
reported from human SUFU (Grimm et ai, 2001).AII these proteins were found among humans 
and share a common N-terminal region of 340 residues, corresponding to the first eight exons 
and variable C-terminal regions. SUFU showed expression in developing embryo which is 
patterned by Shh signaling (Ding etai, 1999). 
SUFU is located at 10q24.3 locus of chromosome, a region which showed loss of hetrozygosity 
(LOH) in many cancer including prostate cancer, lung cancer, breast cancer and 
medulloblastoma (Latini etai, 2001 and Leube etai, 2002). 
SUFU inactivates the function of Gli molecules which subsequently leads to inactivation of Shh 
signaling. (Ding et ai, 1999, Kogerman et ai, 1999 and Stone et ai, 1999). SUFU retains the 
GUI protein in the cytoplasm and masking nuclear localization for the activation of Shh target 
gene (Priit Kogerman, 1999). SUFU sequesters GUI in the cytoplasm mostly through a 
mechanism that depends on the activity of the nuclear export protein CRM1, The N-terminal of 
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SUFU is also capable to inhibit GLI protein even in the absence of cytoplasmic sequestration. 
The SUFU also functions as a negative regulator of Wnt/b-cantenin signaling (Taylor et al., 
2004). Over expression of mouse and human SUFU inhibits GLI1 dependent transcription and 
promotes cytoplasmic localization of GLI1 (Ding et al., 1999; Kogerman et al., 1999 and Stone 
et al., 1999). Nuclear export signal (NES) in SUFU implicates that SUFU may function as 
nucleocytoplasmic shuttling molecules (Paces-Fessy et al., 2004) C-terminal of SUFU is 
required for binding, transcriptional inactivation and cytoplasmic sequestration of GUI 
(Kogerman et a/.,1999; Grimm et al, 2001; Taylor et al., 2002; Dunaeva et al., 2003). Loss of 
suppressor of the fused (SUFU) function, promotes tumourigenesis (Lee etai, 2007). 
1.11 Bmi-1 
Bmi-1 is a member of the polycom group family of transcriptional regulators that was originally 
identified as an oncogenic partner of c-Myc in murine lymphomagenes (Alkema e^  al, 1993). 
Both Bmi-1 and Shh are important for the self-renewal of normal and tumourigenesis of human 
mammary stem cells. Lack in expression of Bmi-1 also causes defects in hematopoicsim and 
development of the central and peripheral nervous system.(Molofsky et al., 2005, Van der Lugt 
efa/., 1994). 
High expression of Bmi-1 in primary melanomas and melanoma metastases (Mihic-Probst, et 
al, 2007) causes brain, spinal cord, kidney, lung and gonad tumours (Kopper et al., 2004,Smith 
and Chepko 2001). Bmi-1 Knockout through shRNA showed involvement in P21-Rb pathway 
of NSC self renewal process during development (Fasano et al, 2007).Poly comb group (PcG) 
genes like Bmi-1 are epigenetic gene silencers that preserve transcription pattern to maintain 
cell identity (Lund and Van Lohuizen, 2004 Buszczak and Spradling 2006). There are thus Bmi-
1 upregulated brain tumours (Hemmati et al, 2003, Leung et al, 2004). High expression of 
Bmi-1 caused tumourigenesis in neuroblastoma cell lines and tumours (Cui, etal, 2007).Bmi-1 
acts as a transcriptional repressor of the INK4a/Arf locus 6, which encodes 2 separate tumour 
suppressor genes, namely p16ink4a and p14Arf(p19 Arf in mouse),which are read in 
alternating reading frames. This locus (INK4a/Arf locus) shows either deletion or silencing in 
tumours. 
Bmi-1 overexpression has been found in various cancers including colorectal cancer (Kim et 
al, 2004), non-small cell lung cancer (Singh et al, 2003), hepatocellular carcinoma (Wang et 
al, 2008), prostate (Kenney etal, 2000) and neuroblastoma (Cui etal, 2007). 
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Overexpression of Bmi-1 in stem cells leads to uncontrolled growth and cancer development, 
(Molofsky et ai, 2005). It is also essential for cerebellar development and is overexpressed in 
human medulloblastoma (Leung, C 2004). High expression of PTCH1 and Bmi-1 show 
connecting links to Shh in medulloblastoma (Leung, C 2004). 
1.12 Glioma-associated oncogene homolog 1 (GLI1) 
Location at Chromosome 12, main effector molecules of Shh signaling, involved in cell-fate 
determination, proliferation and patterning (Ruiz i Altaba A, 1999). It shows initiation of some 
gene transcription and suppression in another (Sasaki et ai, 1997). Gli proteins have an 
18-amino acids region, highly similar to the 16-activation domain of alpha-helical herpes 
simplex viral protein 16 activation domain. This domain has a consensus recognition element 
for the human TFIID TATA box-binding protein associated factors TAFII31 (Li et ai, 1998). 
Another protein such as missing in metastasis (MIM/BEG4) influence the transcriptional 
efficiency of GLI1 on target gene. Both GLI1 and MIM act as synergistically to induce the 
epidermal growth. It was showed that both Glil+MIM over expressing graft show similar growth 
pattern to Shh grafts (Callahan et a/., 2004). The Gli family proteins are of three types viz GLI1, 
GLI2 and GLI3, all the three are transcriptional factors. They have conserved zinc finger motif 
C2-H2, which is linked to sequences histidine/cystidine between zinc fingers. 
This Gli motif is very much similar to Kruppel which is a Drosophila segmentation gene of the 
gap class (Kim et al., 1998). Mutation in to the zinc finger motif leads to non-functional Gli 
protein which eventually leads inactivation of Shh target genes (Figure viii) (Park et ai, 2000). 
The conserved stretch of 9 amino acids connects C-terminal histidine of one finger to the 
N-terminal cystein of the next. The GLI consensus finger amino acid sequence is [Y/F] 
JXCX3GCX3 [FA'] X5LX2HX4H [T/S] GEK (Kim et al., 1998). Many sonic hedgehog target 
genes have GLI1 binding consequences sequence GACCACCCA (Kinzler and Vogelstein 
1990). GLI1 protein transcriptional factor protein showed many cases of tissue specific 
regulation. For example GLI1 in primary kertatinocytes upregulate F0XM1 (Teh et al., 2000) 
whereas in mesenchymal C3H10T1/2 cells, it has been shown to upregulate platelet-derived 
growth factor receptor PDGFRalpha (Xie J etal., 2001). 
Human GLI1 acts as an oncogene (Nilsson,M 2000), It was reported that N-terminal region of 
GLI1 recruits histone deacetylase complexes via SUFU, which helps in DNA folding in 
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chromosome (Cheng and Bishop, 2002). This complex leads to inhibition of the transcription 
activity by GLI1. This indicated GLI1 acts activator as well as inhibitor. 
The human GLI1 promoter is regulated by a 1.4kb 5' region including a 5' flanking sequences, 
an untranslated exon and 425 bp of the first intron. The GLI1 promoter region is influenced by 
these protein including SP1, USF1, USF2, and Twist (Villavicencio et al., 2002, Gitelman, 
I 1997). GLI1 expression has been seen in gut mesoderm, ventral neural tube, ependymal 
layer of spinal cord, forebrain, midbrain, cerebellum, and its site of endochondral bone 
formation (Walterhouse ef al., 1993 and Wallace, 1999).The Cyclin D2 and Plakoglobin 
(Y catenin), which are involved in the regulation of cell cycle and apoptosis respectively are also 
regulated by GLI1 (Figure ix) (Yoon etal., 2002a). GLI1 also upregulates F0XM1 in BCC (Teh 
ef al., 2002). Its expression also mimics the Shh expression in some cells (Dahman ef al., 
1997b). 
GLI1 was for the first time, isolated from glioma tumour and its high expression has been seen 
in many tumours like brain, muscle and Skin tumours such as basal cell carcinoma (BCC) 
(Dahmane, ef al.,1997). Shh and GUI genes are normally expressed in hair-follicles. In skin 
tumour, GLI1 arises from hair follicles. T variation in expression of GLI1 showed correlation 
with tumour grades in bone and soft tissue sarcomas (Dahmane ef al., 1997). 
Over expression of GUI in transgenic mice and frog develop BCC and hair-follicle derived 
neoplasia like- trichoepitheliomas (Dahmane ef al., 1997; Nilsson ef al., 2000). It was reported 
that high expression of GUI developes into tumours in many transgenic mice (Nilsson ef al., 
2000) and it also showed that high expressing GLI1 mutation induces BCC tumour (Dahmane 
ef a/., 1997a). 
1.13 Cyclin D2(CCND2): 
Cyclin D2 is located at 12p13 locus of the chromosome. It is a member of Cyclin D family and 
has three closely related types Cyclins D1, D2 and DS.They showed overlapping reductant 
expression in all proliferating cell types and collectively control the progression of cell cycle. 
The protein encoded by this gene belongs to the highly conserved Cyclin family, whose 
member is characterized by a dramatic periodicity in protein abundance through the cell cycle 
(Figure x). They are significant for cell-division and also showed involvement in cancer 
progression. It regulates the CDK kinases. Each Cyclin has a different expression and 
degradation pattern, which contributes to temporal coordination of each mitotic event. Cyclin 
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D2 forms a complex with CDK4 or CDK6, and acts as regulating subunit of CDK4 or CDK6 
during cell cycle G1/S transition. This Cyclin D2 shows involvement in the phosphorylation of 
tumour suppressor protein Rb. 
Knockout studies of this gene in mouse suggest the essential role of this gene in ovarian 
granulose and germ cell proliferation. High level expression of this gene was observed in 
ovarian and testicular tumours (Bartova et al., 2000). It shows also high level in many tissues 
including brain. It was also reported that this gene is upregulated by sonic hedgehog signaling 
transcription factors in transformed epithelial cells because this gene 5'prime promoter region 
has consensus sequence 5'CACCACCA 3' for the binding of GLI1 transcription factor (Yoon et 
al., 2002). 
1.14 Plakoglobin (y catenin) 
Plakoglobin is located at 17q21 locus of the chromosome. Plakoglobin gene has 13 exons 
covering 17 Kb long DNA regions (Whittock et al., 2000). It was first identified as a component 
of desmosomes, where it can bind to the cadherin family member called desmogelin-1. 
Plakoglobin also shows association with classical cadherin, E-cadherin because of this reason 
it is called y-catenin. It shows 0-glycosylation near its N-terminal destruction box. It shows the 
cell adhesive role and its functional loss leads to tumour invasion and metastasis. It has 
conserved central 12 armadillo repeats which facilitate binding to many protein including 
E-cadherin, a-catenin and adenomatous protein polyposis coli tumour suppressor (McCrea et 
al., 1991). It maintains the cellular polarity and acts a binding molecule of cell to cell attachment 
with the direct involvement of E-cadherin cytoplasmic domain (Tselepis et al., 1998, and Butz 
et al., 1992). Plakoglobin lost shows worse biological consequences in tumour progression 
(Syrigos etal., 1998, Shimazui etal., 1996). 
Plakoglobin shows tumours suppressor activity (Gastaldi et al., 2006) and high expression 
suppresses tumourigenicity in various transformed cells (Simcha et al., 1996). It is the only 
cytoplasmic protein which shows common action to both junctional complexes mediating cell to 
cell adhesion, junction and desmosomes. In these complexes, it more or less looks like a linker 
between transmembrane protein of cadherins superfamily to the actin cytoskeleton and 
intermediate filament system respectively. Disruption of intercellular adhesion filament is a 
common lesion in skin and carcinomas promoting tumour progression and metastasis. This 
Plakoglobin gene was downregulated in human rhabdomyosarcoma cells compared to normal 
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one and it was mentioned ttiat this downregulation was due to binding of GLI1 transcription 
factor of sonic liedgeliog signaling. This GLI1 transcription factors binds to many genes having 
consensus sequences in the 5' region of the promoter, and, thus some are upregulated and 
some are downregulated. (Yoon et al., 2002). 
1.15 PAX6: 
Paired box gene (PAX) was originally identified in Drosophila as a segmentation gene such as 
paired (prd), gooseberry-distal (gsb-d) and gooseberry-proximal (gsb-p) (Bopp et al., 
1996).This PAX6 gene is located at 11p13 locus of the chromosome. This family of genes is 
very much conserved, and encodes transcriptional factors which are involved during 
embryogenesis (Stuart et al., 1993). Paired pox genes are tissue specific transcriptional 
factors, containing paired domain and have partial or complete homeodomain. It plays very 
important role during early embryonic development for specification of tissue and also 
regenerate epimorphic limb in animal. 
Within the mammal family, there are four well defined groups of PAX genes. 
PAXgroup1(PAX1and9) 
PAXgroup2(PAX2,5and8) 
PAX group 3(PAX 3 and 7) and 
PAX group 4(PAX4 and 6) 
These orthologous gene exits throughout the metazoan kingdom. 
PAX6 is a well studied gene and is called the master control gene for the development of eyes 
and sensory organs, certain neural and epidermal tissue as well as other homologues 
structure, usually derived from ectodermal tissue. Their involvement in cell differentiation, cell 
polarity and cell proliferation is there because it specifically binds to DNA sequences of many 
genes which regulate this developmental process. 
PAX6 encodes a highly conserved DNA-binding domain motif of 128 amino-acids, called the 
paired box domain, located at the amino terminus of the protein. PAX6 shows involvement in 
the development of normal eye, nose, pancreas and brain (Grindley et al., 1995; Sander et al., 
1997; Li et al., 1994). PAX6 actions are controlled by sonic hedgehog in grading 
pattern and have control over progenitor cell identity and neuronal fate[188] (Figure xi) 
(Briscoe ef a/., 1999). 
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It also shows suppressive role during glioma invasiveness (Mayes et al., 2006), and because 
of this reason, it is considered as tumour suppressor gene(TSGs) in GBIVI cells (Zhou et al., 
2005) and shows low expression in GBM (Zhou et al., 2003).It has an involvement in controlling 
migration in cortex (Chapouton etai, 1999). 
1.16 NKX2.2 (NK2 homeobox2) 
This gene encodes protein and contains homeobox domain which may be involved in the 
morphogenesis of the central nervous system. This gene is found on chromosome 20 near 
NKX2-4, and these two genes appear to be duplicated on chromosome 14 in the form of TITF1 
and NKX2-8.The encoded protein is likely to be nuclear transcription factor. 
It is the homeodomain transcription factor II and induced by sonic hedgehog. It shows 
involvement in subdividing ventral neural progenitor into five cardinal progenitors (Briscoe, J et 
al., 2000). This NKX2.2 repress the Class I homeobox gene PAX6 and thus indirectly specifies 
the p3 neuronal progenitor domain (Briscoe et al., 2000). Gene NKX2.2 Knockout mice showed 
lack of differentiated \/3 neurons and motor neuron are ventrally expanded (Figure xi) (Briscoe 
efa/., 1999). 
NKX2.2 and Olig 2 shows co-expression in neuroepithelial cells which is induced by Shh. Shh 
signal is also important for dorsal extension of NKX2.2 (Agius et al., 2004). 
This homeodomain gene encodes transcriptional factors which are important for morphogenetic 
events and cellular differentiation during embryonic development (Pabst et al., 2000). Shh 
signaling inducing NKX2.2 for originating oligodentrocytes progenitor (Soula et al., 2001). 
NKX2.2 has its role in early axon pathway and development of the Zona limitaus intrathalamica 
(Pabst ef a/., 1998). 
1.17 SFRP1 (the secreted frizzled-related protein) 
It was for the first time reported in 1987 by several groups and is found to have cystein-rich 
domain (CRD). It is considered as tumour suppressor gene (TSG) and shows down regulation 
in human hepatocellular carcinoma, mapped on to chromosome 8p12-p11.1 (Finch et al., 
1997). It has frequent loss of hetrozygosity in hepatocellular carcinoma, encodes a wingless 
type (WNT) signaling type antagonist and also showed promoter hypermethylation in many 
human cancers. 
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It has involvement in vascular cell proliferation, postnatal skeletal muscles, growth and 
hypertrophy and the growth of retinal ganglion cell axons (Ezan et al., 2004, Steelman et al., 
2006). SFRP1 shows genetic alteration in breast cancer (Joesting et al., 2005), colorectal 
carcinomas (Suzuki et al., 2002) and HCC (Shih et al., 2006). It shows low expression in many 
cancers including breast cancer, ovarian cancer, bladder cancer, mesothelioma, prostate 
cancer (Lodygin et al., 2005, Joesting et al., 2005), colorectal cancer (Caldwell et al., 2004 and 
Suzuki et al, 2002) and non-small cell lung cancer (Fukui et al, 2005). SFRP1 is a family of 5 
secreted glycoprotein acts as an extracellular signaling molecule that antagonizes the Wnt 
signaling pathway (Finch etal, 1997). Phosphorylation status of GSK-3 (Serin-threonin kinase) 
shows strong interrelationship between SHH and WNT signaling. (Kalderon et al, 2002). 
SFRP1 is the target of Shh and downregulated by Shh (Ingram et al, 2002). 
Reduced expression of SFRP1 promotes non-canonical signal, which contributes to tumour 
progression (Caldwell et al, 2004) SFRP1 is the hedgehog target to continue canonical WNT 
signaling within stem or progenitor cell e.g. differentiated epithelial cells of mesenchymal cells 
(Katoh et al, 2006).' Both Hedgehog and WNT signaling pathway networks together during 
embryonic development and cancer progression (Katoh and Katoh 2005). 
1.18 GLI3 (GLI-Kruppel family member GLI3): 
It is located at 7p13 locus of the chromosome. This gene encodes a protein and belongs to 
C2H2-type zinc finger protein subclass of the Gli family. It binds to DNA and mediated by sonic 
hedgehog signaling. This gene has involvement in embryonic development. Gli3 is considered 
as transcriptional repressor, but also shows positive transcriptional function. (Taipale and 
Beachy, 2001, Jacob etal, 2003).GliS depresses dHand and Germalin. Which are involved in 
developing digits (te Welscher et al, 2002). 
Shh cleaves Gli3 according to functional requirement in a similar way to CI (Jacob et al, 
2002).Gli3 mutant mice have many abnormalities in development, including CNS and lung and 
limb Polydactyly (Grove et al, 1998, Hui and Joyner, 1993 and Bose et al, 2002). Mutation in 
this gene has been associated with several disease including Greig cephalopolysyndactyly 
syndrome, Pallister-Hall syndrome, preaxial polydactyl type IV and postaxial polydactyl type Al 
and B (1). Greig cephalopolysyndactyly syndrome (GCPS) is autosomal dominant disease 
affects limb and craniofacial development in human due to translocation with the GLI3 gene 
(Bose ef a/., 2002). 
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Interaction with Gli1 and Gli2: 
Co-overexpression of Gli1 with Gli2 and Gli2 with Gli3 leads to transgenic mice malformation 
and death respectively but not the formation of BCC (Dahmane et ai, 1997). This suggests that 
overexpression of more than one Gli protein is not necessary for BCC formation. 
1.20 Transfection: 
It is the method by which foreign material is introduced into eukaryotic cells using a virus vector 
or other means of transferring agents. Transfection processes involve uptake of any genetic 
material through transient pores or holes in the cell plasma membrane. Genetic material such 
as supercoiled plasmid DNA or siRNA constructs or even antibodies may be transfected. 
Beside electroporation, transfection can be carried out by mixing a cationion lipid with the 
material to produce liposome, which fuses with the cell plasma membrane and delivers their 
cargo inside the cell. 
IVIethod: 
There are various methods of introducing foreign DNA into a eukaryotic cell. Many materials 
have been used as carriers for transfection, which can be divided into three kinds: (cationic) 
polymers, liposomes and nanoparticles. 
One of the cheapest (and least reliable) methods is transfection by calcium phosphate, 
originally discovered by F. L. Graham and A. J. van der Eb in 1973. The HEPES-buffered 
saline solution (HeBS) containing phosphate ions are combined with a calcium chloride solution 
containing the DNA to be transfected. When the two are combined, a fine precipitate of the 
positively charged calcium and the negatively charged phosphate will form, binding the DNA to 
be transfected on its surface. The suspension of the precipitate is then added to the cells to be 
transfected (usually a cell culture grown in a monolayer). By a process not entirely understood, 
the cells take up some of the precipitate, and with it, the DNA. 
Other methods use highly branched organic compounds, so-called dendrimers, to bind the 
DNA and get it into the cell. A very efficient method is the inclusion of the DNA to be 
transfected in liposomes, i.e. small, membrane-bounded bodies that are in some ways similar 
to the structure of a cell and can actually fuse with the cell membrane, releasing the DNA into 
the cell. For eukaryotic cells, lipid-cation based transfection is more typically used, because the 
cells are more sensitive. 
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Another method is the use of cationic polymers such as DEAE-dextran or polyethylenimine. 
The negatively charged DNA binds to the polycation and the complex is taken up by the cell via 
endocytosis.A direct approach to transfection is the gene gun, where the DNA is coupled to a 
nanoparticle of an inert solid (commonly gold) which is then "shot" directly into the target cell's 
nucleus. DNA can also be introduced into cells using viruses as a carrier. In such cases, the 
technique is called viral transduction, and, the cells are said to be transduced. Other methods 
of transfection include nucleofection, electroporation, heat shock, magnetofection and 
proprietary transfection reagents such as Lipofectamine, Dojindo Hilymax, Fugene, jetPEI, 
Effectene or DreamFect. 
Stable and transient transfection: 
For most applications of transfection, it is sufficient if the transfected gene is only transiently 
expressed. Since the DNA introduced in the transfection process is usually not inserted into the 
nuclear genome, the foreign DNA is lost at the later stage when the cells undergo mitosis. If it 
is desired that the transfected gene actually remain in the genome of the cell and its daughter 
cells, a stable transfection must occur. To accomplish this, another gene is co-transfected, 
which gives the cell some selection advantage, such as resistance towards a certain toxin. 
Some (very few) of the transfected cells will, by chance, have inserted the foreign genetic 
material into their genome. If the toxin, towards which the co-transfected gene offers 
resistance, is then added to the cell culture, only those few cells with the foreign genes inserted 
into their genome will be able to proliferate, while other cells will die. After applying this 
selection pressure for some time, only the cells with a stable transfection remain and can be 
cultivated further. A common agent for stable transfection is Geneticin, also known as G418, 
which is a toxin that can be neutralized by the product of the neomycin resistant gene. 
1.21 RNAI Introduction: 
Antisense RNA experiments lead to the discovery of Interference RNA [RNAI]. The antisense 
approach to gene silencing involves injecting an organism with RNA sequence complementary 
to mRNA transcribed from a target gene. The antisense RNA and sense mRNA hybridizes and 
blocks translation and the production of an encoded protein. The presence of dsRNA duplex 
led to what we now recognize as an RNA interference effect. 
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Using genetically altered strains of the roundworm C. elegans (round worms), scientists in fall 
of 2000, discovered genes responsible for a process called RNA interference (RNAI) in which 
double-stranded RNA triggers the natural degradation of a homologous mRNA. RNA 
interference (RNAI) is a process in which double-stranded RNA triggers the degradation of a 
homologous messenger RNA (sharing sequence-specific homology to particular "target" 
mRNAs). Some of the same genes that are responsible for RNA interference appear also to be 
involved in nonsense-mediated decay, a protective mechanism that may be used by cells to 
proofread newly created messenger RNA (mRNA) and to prevent the production of defective 
protein molecules. 
In an article published in the September issue of the journal Science, Howard Hughes Medical 
Institute investigator Brenda L. Bass and geneticist Susan Mango and their colleagues at the 
University of Utah reported that three of seven genes of a gene family called smg were 
involved in RNAI. 
Since Bass's discovery molecular biologists have used double-stranded RNAi as a tool to 
degrade mRNA in cells to shut down the effects of specific genes in C. elegans, Drosophila and 
many other cell-types. In an experimental test of the role of smg genes they obtained C. 
elegans strains containing mutations in the various smg genes. They next injected these strains 
and a wild-type strain with double-stranded RNA designed to interfere with production of 
myosin, a protein that is critical to muscle development. Thus, they could quantify the 
effectiveness of RNAi by measuring paralysis in the worms using a crawl assay—a test of the 
worms' ability to move across a laboratory dish. In the wild-type worms, they found that the 
progeny treated with RNAi were paralyzed from day one and remained paralyzed. Therefore 
the RNAi technique completely interfered with normal muscle development by stopping the 
action of myosin mRNA. 
Today RNA Interference (RNAi) is a technique in which exogenous, double-stranded RNAs 
(dsRNAs) that are complimentary to known mRNA are introduced into a cell to specifically 
destroy that particular mRNA, thereby diminishing or abolishing gene expression. The 
technique has proven effective in Drosophila, Caenorhabditis elegans, plants, and recently, in 
mammalian cell cultures. To make the technique work in cultured mammalian cells for research 
purposed, scientists must deliver small interfering RNAs (siRNAs), which are dsRNAs and of 
some 21-25 nucleotides (called siRNAs), into the cell. This is done with transfection reagents, 
which are solutions optimized for allowing DNA and RNA to be absorbed by cultured cells. 
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Thus, RNA interference (RNAi) is a gene-silencing teciinique used in studying the absence of 
normal gene action (by disrupting its activity in vivo, i.e., turning it off) in fruit flies, nematodes, 
and mammalian cells. 
During the 1990's, scientists realized the power of the RNAi technique to determine gene 
function by blocking the expression of a specific mRNAs. Sort of a "REVERSE of GENETICS". 
The introduction of dsRNA mimics a gene knockout of almost any known gene by an effect of 
deletion of the mRNA of the gene. The application of RNAi to mammalian cells has the 
potential to revolutionize the field of functional genomics. The ability to simply, effectively, and 
specifically down-regulate the expression of genes in mammalian cells holds enormous 
scientific, commercial, and therapeutic potential. 
Artificial siRNAs can be made in the lab by a phage enzyme referred to as DICER. The 
mechanism involves complexing siRNA into a multi-protein siRNA complex termed RISC for 
RNA Induced Silencing Complex. Typically, 3-5 double-stranded siRNA molecules are 
designed per gene in order to find a siRNA that has a strong effect. This means synthesizing 
and purifying 6-10 RNA oligonucleotides of 20+ nucleotide pairs, at a minimum cost of $1500 
per gene. (Adapted from http://wvw.si-ran.com). 
1.22 RNAi Pathway: 
RNAi describes the phenomenon by which dsRNA induces potent and specific inhibition of 
eukaryotic gene expression via the degradation of complementary messenger RNA (mRNA), 
and is functionally similar to the processes of posttranscriptional gene silencing (PTGS) or co-
suppression in plants (Cogoni et al., 1994; Napoli et al., 1990) and quelling in fungi (Cogoni & 
Macino, 1997; Cogoni & Macino, 1999; Romano & Macino, 1992). In plants, the PTGS 
response is thought to occur as a natural defense against viral infection or transposon insertion 
(Anandalakshmi etal., 1998; Jones etal., 2004; Voinnet etal., 1999). 
In eukaryotic organisms, dsRNA produced in vivo or introduced by pathogens is processed into 
21-23 nucleotide double-stranded short interfering RNA duplexes (siRNA) by an enzyme called 
Dicer, a member of the RNase III family of double stranded RNA-specific endonucleases 
(Bernstein et al., 2001; Ketting et al., 2001).The siRNA is then incorporated into an RNA-
induced silencing complex (RISC), an enzyme complex that serves to target cellular transcripts 
complementary to the siRNA for specific cleavage and degradation (Figure xii) (Hammond et 
al., 2000; Nykanen et al, 2001). In addition to dsRNA, other endogenous RNA molecules 
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including short temporal RNA (stRNA) and micro RNA (mlRNA) (Ambros, 2001; Carrington & 
Ambros, 2003) have been identified and shown to be capable of triggering gene silencing. 
1.23 Stealth™ RNAi 
Stealth™ RNAi is chemically modified, and blunt end dsRNA are developed to overcome the 
limitations of traditional siRNA. The two strands of Stealth™ RNAi are modified in a manner 
that prevents sense strand activity, eliminating sense strand mediated-off-target activity. The 
Stealth™ RNAi interacts with the RNAi machinery to elicit gene silencing, similar to traditional 
siRNA, Using Stealth™ RNAi for RNAi analysis offers the following advantages: 
• Obtain effective target gene knockdown at levels that are equivalent to or greater than those 
achieved with traditional siRNA 
• Reduces non-specific effects caused by induction of cellular stress response pathways 
• Exhibits enhanced stability for greater flexibility in RNAi analysis 
A large varietyjjHggdy-tn-nrder, pre-designed Stealth™ RNAi products are available from 
Invitrogen to facilitate RNAi analysis or may design and order custom Stealth™^RNAiloi^lny" 
target gene of interest using the BLOCKiT ™ RNAi Designer from Invitrogen 
(www.invitrogen.com/rnaidesiqner). 
1.24 Lipofectamine: Lipofectamine or Lipofectamine 2000 is a common transfection 
reagent, produced and sold by Invitrogen, used in molecular and cellular biology. It is used to 
introduce, that is transfect, siRNA or plasmid DNA into in vitro cell cultures by lipofection. 
Lipofectamine treatment alters the cellular plasma membrane, allowing nucleic acids to cross 
into the cytoplasm. It was invented by Dr. Yong Hang Chu at Life Technologies, Inc 
(Figure xiii). 
1.25 DNA Methylation Review 
DNA involvement in cancer pathology has become one of the hottest topics in cancer research. 
It is now apparent that not only genetic, but also epigenetic changes may be responsible for 
cancer initiation and progression. Epigenetic events lead to a change in gene expression 
without altering the genetic code, through the methylation of cytosine residues in DNA and 
different DNA covalent modifications of histone proteins, followed by remodeling of chromatin 
structure. DNA cytosine methylation occurs in the context of CpG dinucleotides. Almost all CpG 
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dinucleotides randomly located throughout the whole genome are methylated; these are 
densely grouped in CpG islands, and are fragments of DNA where the proportion of CpG 
dinuleotides is much higher than in other DNA sequences. CpG islands constitute about 1% of 
the genome and are protected from methylation. A CpG rich region of the genome is defined as 
a CpG island when the C+G proportion is 55% at minimum level, its size is around 0.5 and 4 
Kb and the frequency of observed CpG dinucleotides/expected CpG is al least 60-65%. CpG 
islands are found in the promoter regions of many genes and their aberrant methylation in 
cancer cells lead to the functional silencing of those genes due to chromatin compactation 
(Jones and Takai, 2001) (Figure xiv). Silenced chromatin is rich in deacetylated and 
methylated histones. Covalent modifications of histones occur on aminoacid residues, thus, 
forming specific histone code (Jenuwein and Allis 2001). 
Aberrant epigenetic changes occur in the early stages of carcinogenesis. In cancer cells a 
general decline on the methylated cytosine level (genomic hypomethylation) is accompanied by 
local CpG island hypermethylation (Baylin et al., 2001, Laird e^ al., 2005) Both DNA hypo- and 
hypermethylation may promote cancer development. Genomic hypomethylation may lead to 
both genome instability and hypomethylation of proto-oncogenes, which lead to their stronger 
expression (Ehrlich, M 2002). On the other hand, local promoter CpG island hypermethylation 
induces functional silencing of tumour suppressor genes, mimicking their genetic mutations. 
The clinical benefit of such a way of losing gene expression is the fact that, in contrast to 
genetic mutation, it is reversible under pharmacological intervention with demethylating agents 
(Esteller, M 2005). However, the potential side-effects of such an intervention as a result of 
induced hypomethylation (leading to e.g. genome instability) need to be carefully considered. 
One of the most important features of cancer DNA methylation changes, making them useful 
for cancer detection and classification, is that they are tissue and tumour type specific (Esteller 
M et al., 2001).Hypermethylation of most genes is rarely found in healthy individuals, although 
minor changes may occur with age or due to endogenous and environmental stress (Ahuja et 
al., 1998; Jaenisch, and Bird, 2003).Tumours derived from different tissues show unique 
patterns of DNA methylation changes, but still there is evident of variation between tumour 
samples of the same origin, depending on environmental exposures, genetic predisposition and 
other factors influencing epigenetic control. Moreover, histopathological subtypes of many 
human cancers show differing patterns of methylation changes, thus facilitating further 
classifications. Tumour derived DNA can be obtained from biopsy material, but also from body 
fluids such as saliva, sputum, semen, gastrointestinal fluids, urine, faeces, etc depending on 
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tumour localization. Cancer patients show an abnormally high level of plasma free circulating 
DNA, which is considered to be, derived from apoptotic and necrotic cancer cells (Jahr, et al., 
2001). This DNA may be used for aberrant methylation detection. Besides hypermethylation, 
the assessment of the global decrease of DNA methylation and certain repetitive sequences' 
hypomethylation, which might lead to chromosome rearrangements, may provide 
complimentary information for tumour characteristics. DNA methylation is essential for the 
normal development and functioning of organisms. 
Epigenetic regulation of genes is also playing very much significant role in many malignancies 
to human beings. It was reported many tumour suppressor genes are epigenetically regulated 
and their promoter hypermethylation and histone deacetylation cause silencing in 
expression.(Widschwendter and Jones, 2002, Szyf et al., 2004).DNA methylation is mediated 
by DNA-Cytosine methyltransferase (DNMTs) and is found in CpG island at the promoter 
region of many genes. Histone deacetylation is mediated by histone deacetylases (HDACs). 
DNA promoter methylation is inhibited by demethylating agent or DNMTs inhibitor such as 5-
aza-2'-dexoycytidine (5-aza-dC), and histone deacetylation can be inhibited by HDAC inhibitor 
trichostatin A (TSA). 
Methylated DNA is associated with transcriptionally repressive chromatin, have deacetylated 
histone, either of drug, viz the DNMTs inhibitor or HDAC inhibitor upregulate epigenetically 
silenced gene (Cameron et al., 1999; Suzuki, et al., 2002), however, when these inhibitor are 
used together, synergistic effect is observed and a large number of epigenetically silenced 
genes can be identified, thus providing a sensitive tool for the identification of methylated 
tumour suppressor gene. This method has been applied to unmasked TSGs in many cancers 
including gastrointestinal, head, and neck, prostate and endometrial Cancer (Yamashita et al., 
2002, Tokumaru efa/., 2004; Lodygin efa/., 2005; Takai etal., 2005). 
Sonic hedgehog signaling protein binds to twelve transmembrane receptor PTCH1 and this 
binding of Shh protein to PTCH causes some conformational changes in PTCH, which further 
relieves SMO, another seven transmembrane receptor from PTCH inhibition, and then this 
SMO further activates the down stream zinc finger GLI1 transcription factor of this pathway. 
Smoothened acts as an oncogene of this pathway, however few reports have showed promoter 
methylation in the Smoothened gene in colorectal carcinoma cell lines (Zhu et al., 2004). We 
have also checked the Smoothened methylation in all two brain tumours; medulloblastoma and 
glioblastoma. Some recent data have reported epigenetic regulation of PTCH in malignant 
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disease. Heterozygote mice for PTCH gene sliowed higli incidence of rhabdomyosarcoma and 
medulioblastoma which is associated with epigenetic silencing of the unmutated PTCH allele 
(Calzada et al., 2002, Uhmann et al, 2005), and, in the human cells, PTCH silencing through 
DNA promoter methylation has been found in medulioblastoma and acute myeloid Leukemia 
(Bermanefa/., 2002). 
The hedgehog pathway overactivity has been observed in the development of a variety of 
human cancers. The human hedgehog interacting protein (HHIP), a negative regulation of 
hedgehog signaling, has been shown to be under expressed in pancreatic cancers (Martin et 
al, 2005). The human hedgehog Interacting protein gene (HHIP) is expressed as a membrane 
glycoprotein which binds to all the three human hedgehog proteins with the same affinity as 
PTCH transmembrane protein and negatively regulates hedgehog signaling pathway (Kayed, 
et al., 2004, Chuang, et al., 2003). HHIP expression has previously been reported to be low or 
of reduced expression in many human cancer cell lines (Chuang and McMahon, 1999), 
including pancreatic cancer (Berman etal., 2002). 
Suppressor of fused (SUFU) protein is a Gli/Ci-interacting protein, which acts as a negative 
regulator of the Hh signaling in Drosophila and vertebrates (Barnfield, et al., 2005). Loss of 
SUFU result in activation of the hedgehog pathway (Sheng, et al., 2004).SUFU is localized at 
chromosome 10q24 region with frequent loss of heterozygosity (LOH) in several cancers 
including prostate cancer, lung cancer, breast cancer and medulioblastoma (Latini et al., 2001 
Leube et al., 2002). The SUFU inhibits the function of GLI molecules, leading to inactivation of 
Shh pathway (Ding etal., 1999, Kogerman etal., 1999 , Stone etal., 1999).SUFU retains the 
GLI1 isoform, which is more pronounced for GLIFL(full-length GLI1) as this contains an 
N-terminal SUFU binding site (Shimokawa et al., 2008). So, far there is no report of promoter 
methylation of SUFU in any type of malignancies. 
The Shh signaling main transcription factor GLI1 has downstream targets as PTCH, Wnt and 
many other kind of genes like cell cycle genes, cell adhesion genes, signal transduction genes 
and genes regulating apoptosis. These genes have a consensus sequence for the GLI1 
binding in the 5' upstream region. Some are upregulated by GUI like cell cycle gene e.g., 
Cyclin D2 and some are downregulated like cell adhesion and apoptosis gene e.g., plakoglobin 
(Yoonefa/.,2002). 
Cyclin D2 is one of the D-type Cyclin and it plays a crucial role for the cell transition 
fromGO/GI to S phase with help of Cyclin dependent Kinase 4 (CDK4)and Cyclin dependent 
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kinase 6 (CDK6) leading to the phosphorylation of retinoblastoma (Matsubayshi et ai, 2003) 
Despite the growth proliferative function of Cyclin D2, it also shows growth inhibitory effects 
and blocks the cell cycle progression, thereby promoting exit from cell cycle and maintaining 
the non-proliferative state of many normal human tissues like brain and breast (Meyyapan et 
ai, 1998). 
Some previous studies have reported promoter methylation of Cyclin D2 in breast cancer 
(Buckley et ai, 1993, Tam et ai, 1994, Lukas et ai, 1995, Sweeny et ai, 1997). Ectopic over 
expression of Cyclin D2 effectively blocks cell cycle progression suggesting alternative role of 
Cyclin D2 in promoting exit from cell cycle and maintaining a non-proliferative state (Evron, E 
2001). Absence of Cyclin D2 expression is associated with promoter hypermethylation in 
gastric cancer (Yu et a/., 2003; Oshimo et al., 2003), prostate cancer (Padar et a!., 2003, 
Henrique etal., 2006), ovarian cancer (Sakuma et al., 2007). 
The Hedgehog, BMP/TGF beta, FGF, WNT and Notch signaling pathways constitute the stem 
cell signaling network, which play a key role in a variety of processes, such as embryonic, 
maintenance of adult tissue homeostasis, tissue repair during chronic persistent inflammation 
and carcinogenesis.SFRPI acts as a antagonistic gene in WNT signaling pathway and target 
gene of Shh signaling pathway transcription factor GLI1. 
This SFRP1 has been reported to show under regulation of epigenetic control and showed 
frequent promoter methylation in human colorectal cancer (Suzuki et al., 2002) renal cell 
carcinoma (Dahl et ai, 2007), ovarian cancer (Takada et a/.,2004), esophageal adenoma 
carcinoma (Zou et ai, 2005),Gastric cancer (Zhao ef ai, 2007,Cheng et ai, 2007).Human 
hepatocellular Carcinoma (Huang et ai, 2007), colorectal cancer (Zhang et ai, 2007), breast 
cancer (Suzuki et ai, 2008).There is not any report of methylation in brain tumours including 
medulloblastoma and glioblastoma. 
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Materials & Methods 
Cell lines: One cell line from the medulloblastoma Daoy and astrocytoma U87MG had been 
taken. Medulloblastoma cell line was grown in RPMI L-Glutamax medium, supplemented with 
2% fetal bovine serum (FBS), 4% non-essential amino acids (NEA) at 37°C with 5% CO2. 
Astrocytoma cell line was cultured in RPMI L-Glutamax medium, supplemented with 2% fetal 
bovine serum (FBS) at 37°C with 5% CO2. 
Stealth™ Select RNAI 
The Stealth™ Select RNAi are highly effective pre-designed Stealth™ RNAi molecules 
available individually or as a set of three non-overlapping sequences to thousands of human, 
mouse, or rat genes. For each set of three Stealth™ Select RNAi, 2 out of 3 RNAi sequences 
are guaranteed to knockdown transcript levels by at least 70%. 
Table.1 GLI1 siRNA Sequences (Invitrogen Life technologies, GB) 
Cat No/Lot No. 
10620312/116833/D04 
10620312/116833/D05 
10620312/116833/D08 
10620312/116833/D09 
GUI Stealth siRNA Sequenecs 
GCAGAUACCUGCUUCGGGCAAGAUAU 
(GLI-HSS104170) 
AUAUCUUGCCCGAAGCAGGUAGUGC 
(GLI-HSS104170) 
CAAGCCGUGCUAAAGCUCCAGUGAA 
(GLI1-HSS104172) 
UUCACUGGAGGUUUAGCACGGCUUG 
(GLI1-HSS104172) 
Amount 
lOOnM 
lOOnM 
LIpofectamine™ 2000 Reagent 
LipofectamJne™ 2000 Reagent is a proprietary formulation for the delivery of the BLOCK-iT™ 
Fluorescent Oligo and Stealth™ RNAi or standard siRNA oligomers to mammalian cells for 
RNAi analysis (Gitlin et al., 2002;). 
• Highest transfection efficiency in many cell types and formats (e.g. 96-well). Refer to the Cell 
Lines database at www.invitrogen.com for a list of cell types successfully transfected. 
• Nucleic acid-Lipofectamine™ 2000 complexes can be added directly to cells in culture 
medium, in the presence or absence of serum. 
47 
Materials & Methods 
• It Is not necessary to remove complexes or change/add medium after transfection, but 
complexes may be removed after 4-6 hours. 
Stealth™ RNAi Negative Control Duplex 
Stealth™ RNAi Negative Control Duplex (Medium GC) is ideal for use in RNA interference 
(RNAi) experiments as a control for sequence independent effects following Stealth™ RNAi 
delivery in any vertebrate cell line. The Stealth™ RNAi Negative Control Duplex is designed to 
minimize sequence homology to any known vertebrate transcript, does not induce the 
interferon mediated stress response pathways as measured by real-time quantitative RT-PCR, 
and demonstrates minimal knockdown of vertebrate target genes. The Stealth™ RNAi 
Negative Control Duplex (Medium GC) contains 48% GC content and is suitable for use with 
Stealth™ RNAi duplexes containing 45-55% GC. The Stealth™ RNAi Negative Control Duplex 
is supplied in a ready-to-use Format 
BLOCK-IT™ Fluorescent Ollgo 
The BLOCK-IT™ Fluorescent Oligo is a fluorescein-labeled dsRNA oligomer designed for use 
in RNAi analysis to facilitate assessment and optimization of cationic lipid-mediated delivery or 
electroporation of dsRNA oligonucleotides into mammalian cells. 
Using the BLOCK-iT™ Fluorescent Oligo in RNAi studies offers the following advantages: 
• Provides a good indication of the transfection efficiency with Invitrogen's Stealth™ RNAi, 
standard unmodified siRNA, or purified Dicer-generated siRNA. 
• Allows strong, easy fluorescence-based indication of transfection efficiency in every RNAi 
experiment. 
Optl-MEM® I Reduced Serum Medium 
Optl-MEM® I Reduced Serum Medium is a versatile, chemically-defined medium used for 
diluting the lipid and nucleic acid during transfection. The Opti-MEM® I Reduced Serum 
Medium is a multi-purpose medium proven to be useful in reducing serum requirements for a 
wide variety of cell lines and applications and has been effective in the growth and 
maintenance of adherent and non-adherent cell lines. When supplemented with 2-4% fetal 
bovine serum or alternative sera, Opti-MEM® I Reduced Serum Medium supports proliferative 
rates and maximal cell densities comparable to, and in some cases superior to, conventional 
media supplemented with 10% fetal bovine serum. Relatively nonfastidious cell lines may be 
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maintained in long-term culture with even more substantial serum reduction. If using adherent 
cell lines and less than 2% serum supplementation or in an agitated system such as in roller 
bottles, the medium should be further supplemented with 100 mg/l CaCI2. The versatility of 
Opti-MEM® I Reduced Serum Medium in the propagation of various cell types makes this 
medium the optimal choice for many cell culture requirements. For details on using the medium 
to reduce serum requirements for various cell lines, one can download the Opti-MEM® I 
Reduced Serum Medium manual from www.invitroqen.com. 
1X RNA Annealing/Dilution Buffer 
1X RNA Annealing/Dilution Buffer is supplied with the kit for use in diluting RNAi molecules, if 
necessary. For an RNAi molecule, the concentration of reagent required to induce effective 
target gene knockdown (if the RNAi molecule is active) can vary with each mammalian cell line 
and requires optimization. When optimizing your transfection conditions, use the 1X RNA 
Annealing/Dilution Buffer to dilute the RNAi reagent stock solution, if needed. 
Table.2 Kit Cotents: The componenets included with BiomoduleTM Transfection and control 
unit with BLOCK-IT™ Technologies are described below. 
Item 
Lipofectamine™ 2000 
Reagent 
BLOCK-IT™ Fluorescent 
Oligo 
Stealth™ RNAi Negative 
Control Duplex (Medium GC) 
1X RNA Annealing/Dilution 
Buffer 
Opti-MEM® 1 Reduced 
Serum Medium 
Compostion 
Proprietary formulation 
20 pM stock of fluorescein-labeled double 
Stranded RNA (dsRNA) oligomer in: 
100 mM potassium acetate 
30 mM HEPES-KOH, pH 7.4 
2 mM Magnesium acetate 
20 pM in IX RNA Annealing/Dilution Buffer 
10 mM Tris-HCI, pH 8.0,20 mM NaCI, 1 mM 
EDTA, pH 8.0 
See below for formulation 
Amount 
0.75 ml 
2x125 pi 
250 pi 
1 ml 
500ml 
Formulation of Opti-MEM® I Reduced Serum Medium 
Opti-MEM® I Reduced Serum Medium is a modification of Eagle's Minimal Essential Medium, 
buffered with HEPES and sodium bicarbonate, and supplemented with hypoxanthine, 
thymidine, sodium pyruvate, L-glutamine or GLUTAMAX™, trace elements, and growth factors. 
The protein level is minimal (15 pg/ml); insulin and Iransferin are the only protein supplements. 
Phenol red is included at a reduced concentration as a pH indicator. 
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Cells were transfected in 6-well Plate: 
1. One day before transfection, plated cells in 2ml of growth medium/well, are taken without 
antibiotics such that they will be 30-50% confluent at the time of transfection. We take 
duplicate of GLI1 siRNA; negative siRNA and mock cell line (Untreated with any siRNA) in 
each well, so that the total wells for experiment were six. 
2. For each transfection well, prepare the following: 
A. Diluted lOOpmole (5|J1 of 20 |JM solution) Stealth TM RNAi in 250|jl Opti-MEM® I Reduced 
serum Medium without serum (resulting concentration of RNAi was 40nM).Mix gently. 
B. Diluted 180pmole (9|jl of 20(JM solution) BLOCK-iT™ Fluorescent oligo in 150|jl Opti-
MEM®! Reduced serum medium without serum (resulting concentration of the Fluorescent 
oligo is lOOnM).Mix gently. 
C. Mix Lipofectamin™ 2000 gently before use, then diluted 5[jl in 250 Opti-MEM® I Reduced 
Serum Medium. Mix gently and incubated for 5 minutes at room temperature. 
D. After the 5-minutes incubation, combine the diluted oligomer with diluted Lipofectamine™ 
2000.Mix gently and incubate for 20 minutes at room temperature (solution may appear 
cloudy). 
3. Add the oligomer-Lipofectamin™ 2000 complexes to each well containing cells and 
medium. Mix gently by rocking the plate back and forth. 
4. Incubate the cells at 37°C in a 002 incubator for 24-96 hours until ready to assay for 
gene knockdown. Medium was changed after 4-6 hours. 
Standard RT-PCR and quantitative RT-PCR 
RNA was extracted from two transfected cell lines Daoy (medulloblastoma) and U87MG 
(glioblastoma) after 72 hours using the Quick Prep Total RNA Extraction Kit (Amersham 
Biosciences, UK). Normal adult brain RNA (Stratagene, Cedar Creek, TX) and lung RNA 
(Chemicon International Inc., Temecula, CA), were used as positive controls of 
expression. 1pg RNA was converted to cDNA by the Superscript II RNase H Reverse 
Transcriptase kit (Invitrogen Life Technologies, Carlsbad, CA). The cDNAs were finally 
amplified by standard PCR using the oligonucleotides of following genes GLI1 and PTCH1 
(Table 3) .The conditions and program for PCR were standardized in the laboratory mention in 
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Table 4 and Table 5 We also checked GLI1, PTCH1, HHIP, Bmi-1, CyclinD2, Plakoglobin, 
PAX6, NKX2.2 and SFRP1 genes expression levels in two transfected cell lines by qRT-PCR 
and all reactions were normalized to the housekeeping gene GAPDH expression. The 
oligonucleotides were designed using Primer 3 software and their list is mentioned in Table 6. 
Cell lines 
Six medulloblastoma cell lines (TE671, PFSK-1, Daoy, TE671c2, D283 and SK-PN-DW) and 
eight high grade astrocytoma cell lines (U87MG, A172, LN405, SW1783, T98G, SW1088, 
CCF-STTG1, and GOS-3) were used in this study. The CCF-STTG1, SW1088 and SW1783 
cell-lines were provided by the American Type Culture Collection (ATCC), Manassas (VA), and 
USA. Cell lines A172, T98G, U87MG, and GOS-3 were purchased from the European 
Collection of Cell Culture, ECACC, Salisbury, and Wiltshire, United Kingdom. LN-405, GOS-3, 
were available at the Deutsche Sammlung von Mikroorganismen und Zellkulturen, 
Braunschweig, Germany. All medulloblastoma cell lines were grown in RPMI L-Glutamax 
medium, supplemented with 10% fetal bovine serum(FBS), 4% non-essential amino 
acids(NEA), 1% penicillin/streptomycin, and 0.1% amphotericin B at 37°C with 5% CO2. 
All astrocytoma cell lines were cultured in RPMI L-Glutamax medium, supplemented with 10% 
fetal bovine serum (FBS), 1% penicillin/streptomycin and 0.1% amphotericin B, at 37°C with 
5% C02.When cells on the flasks were almost confluent, they were trypsinized with 
trypsin/EDTA 1x and split into new sterile flasks. 
Primary Tumour Samples 
We got fourteen medulloblastoma samples of RNA and corresponding DNA as a generous gift 
by Dr. Charles and Dr. Xing from Johns Hopkins Medical Center, Baltimore, Maryland, USA. Of 
glioma, twenty-seven primary tumour samples, corresponding to WHO grade I, II, III and IV 
were available for analysis. Tumour samples were collected from patients treated at the 
Hospital de Cruces, Barakaldo, Spain. The samples were snap frozen at surgery and stored at 
-80°C. RNA and proteins were extracted from the frozen tissues as detailed below. 
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Table 3. Primers used for RT-PCR analysis 
Gene Forward primers (5'-3') Reverse primers (5'-3') TafC) Product 
TFR GTCAATGTCCCAAACGTCACCAGA ATTTCGGGAATGCTGAGAAAACAGACAGA 
SIMO ACGAGGACGTGGAGGGCTG CGCACGGTATCGGTAGTTCT 
PTCH1* CTTCGGTCTGGAGCAGATTT CAGGACATTAGCACCTTCT 
GLI3* CAGCTCCACGACCACTGAA TCCATGGCAAACACCGTCC 
GLi1 TGTATGTAAGCTGCCTGGCT AGTATAGGCAGAGCTGATGC 
Cyciin D2 TACTTCAAGTGCGTGCAGAAGGAC TCGCACACTTCCAGTTGCGATCAT 
Plal^oglobin GTCACCAACTCCCTCTTCAA AAAGCAGGAGGAGAAGACTA 
60 
55 
55 
53 
59.2 
60 
58 
300bp 
580bp 
354bp 
324bp 
577bp 
497bp 
686bp 
* Primers used for both RT-PCR and qRT-PCR, Ta, annealing temperature; Product, base pairs of ttie amplified 
PCR product. 
Table 4.RT-PCR conditions 
dNTPs 
Buffer 10x 
IVIgCl2 
Primer F 
Primer R 
DMSO 
Taq polym 
cDNA 
SIVIO 
0.2mM 
1x 
2miVI 
5pmole 
5pmole 
5% 
1U 
125ng 
PTCH1 
0.2mM 
1x 
2mM 
5pmole 
5pmole 
5% 
1U 
125ng 
GUI 
0.2mM 
1x 
2mM 
lOpmole 
5pmole 
5% 
1U 
125ng 
Cyciin D2 
0.2mM 
1x 
2mM 
5pmole 
5pmole 
5% 
1U 
125ng 
PJal^ oglobin 
0.2mM 
1x 
2m M 
5pmole 
5pmole 
5% 
1U 
125ng 
GLI3 
0.2mM 
1x 
2mM 
5pmole 
5pmole 
4% 
1U 
125ng 
Taq polym(Taq Polymerase):Amplitaq Gold™ (Applied Biosystem,Foster City.CA.USA); 
Primer F:forward; Primer R;Reverse 
Materials & Methods 
Standard RT-PCR and quantitative RT-PCR 
RNA was extracted from fouteen cell lines including medulloblastoma and glioblastoma and 
forty one primary glioma tumour samples, using the Quick Prep Total RNA Extraction Kit 
(Amersham Biosciences, UK). Normal brain RNA (Stratagene, Cedar Creek, TX) and lung RNA 
(Chemicon International Inc., Temecula, CA), were used as normal controls of expression. In 
this expression study, 1|jg RNA was converted to cDNA by the Superscript II RNase H 
Reverse Transcriptase kit (Invitrogen Life Technologies, Carisbad, CA). The cDNAs were 
finally amplified by standard RT-PCR using the oligonucleotides of following genes SMO, 
PTCH1, GLI1, Cyclin D2 and GLI3 (Table 3). The conditions for PCR were standardized in the 
laboratory mentioned in Table 4. We also observed SMO, PTCH1, HHIP, SUFU, GLI1, BMI1, 
CyclinD2, Plakoglobin, PAX6, NKX2.2, SFRP1 and GLI3 genes expression levels in all twenty 
five cell lines and forty one primary tumour samples including medulloblastoma and astrocytic 
tumours by qRT-PCR and all reactions were normalized to the housekeeping gene GAPDH 
expression. The oligonucleotides were designed with the help of Primer 3 software; their list is 
mentioned in Table 6 . 
Quantitative RT-PCR (qRT-PCR) 
The expression of SMO, PTCH1, HHIP, SUFU, GLI1, BMI1, Cyclin D2, Plakoglobin, NKX2.2, 
PAX6, SFRP1 and GLI3 were assessed by quantitative real time PCR. The housekeeping gene 
glyceraldehyde dehydrogenase (GAPDH, 12q) exemplified an internal control of expression in 
all reactions. Primers for the SMO, PTCH1, HHIP, SUFU, GLI1, Bmi-1, Cyclin D2, Plakoglobin, 
NKX2.2, PAX6, SFRP1 and GLI3 genes were designed using the Primer3 software (Rozen and 
Skaletsky, 2000). Primer sequences are mentioned in Table 6. All PCRs were carried out in an 
IQ5 Multicolor Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). About 25 ng 
of cDNA was used in a total volume of 25 ml. The reaction mix contained 12.5 ml 2x IQTM 
SYBR Green Supermix (Bio-Rad, Hercules, CA, USA) and 12.5 pmol forward and reverse 
primers. An initial denaturation step at 94°C for 10 min was followed by 35-40 cycles of 
amplification alternating between 94°C for 30 s, the corresponding annealing temperature for 
each gene for 30 s, and 72°C for 30 s. 
After the amplification step, the melting curve analysis was done as follows: from 70°C to 90°C, 
30 s at every 0.5°C. For the relative quantification, an efficiency corrected quantification model 
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Table.5 Programs for RT-PCR 
SMO PTCH1 GLI1 Cyclin D2 Plakoglobin GLI3 
Denaturation 
Denaturation 
Annealing 
Extension 
Cycle 
number 
Extension 
95°C 10' 
94°cr 
60°C45" 
72°C 45" 
30 
72°C 10' 
4°C 
95°C 10' 
94°C 4' 
60°C 45" 
72°C1' 
30 
72°C 10' 
4°C 
95°C 10' 
94°C 4' 
eo'c r 
72°C45" 
35 
72°C 10' 
4°C 
95°C 10' 
94°C4' 
60°C 30' 
72X1 ' 
30 
72°C 10' 
4°C 
95°C 10' 
94°C 4' 
60°C 45' 
72°C45' 
32 
72°C 10' 
4°C 
95°C 10' 
94°C1' 
60°C 30' 
72°C V 
30 
72°C 10' 
4°C 
Table. 6 Primers used for qRT-PCR analysis. 
Gene Forward primers (5'-3') Reverse primers (5'-3'] Ta fC) Product 
GAPDH GAAGGTGAAGGTCGGAGTCAAC 
SMO AAGGCTGCACGAATGAGGT 
GLI1 CAGTGTGGGGACAGAAGGA 
Cyclin D2 GAAGGACATCCAACCCTACA 
Plakoglobin AGGCTCAAGAAAAGCACCAC 
SFRP1 CAAGCCCCAAGGCACAAC TTTTTCACTTCTTTTATTTTCATCCTC 
HHIP ATGGTGGGTTGTGGTTTCC AGTTGTGTTTGTGCTTTCTGCT 
NKX2.2 TCTACGACAGCAGGGACAAC CGGCTTGGAGAAAAGCACTG 
PAX6 ATGCCTCATAAAGGGGGAAG AGTTGTGTTTGTGCTTTCTGCT 
SUFU CCAGACCCCTTGGACTATGTT AGACTCCCCAGTTTCTCTCTTC 
Bmi-1 ATTGTTCGTTACCTGGAGACC GGCAGCATCAGCAGAAGG 
CAGAGTTAAAAGCAGCCCTGGT 
GGGTTCTGGCACTGGATG 
CGGGGAGAAGAAAAGAGTGG 
TCTTCTTCGCACTTCTGTTCC 
GTCCTCGCCTGACACACC 
: 
62 
57 
57.4 
58,5 
58 
59 
60 
60 
60 
60.2 
60 
70bp 
133bp 
132bp 
81 bp 
132bp 
120bp 
123bp 
221bp 
112bp 
201bp 
195bp 
Ta: annealing temperature; Product: base pairs of ttie amplified PCR product. 
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was applied (PfaffI MW, 2001). The derivative ratio of values describe the relative expression in 
case of the target gene relative to the GAPDH reference gene expression: 
(Etarget) QCP target {control - sample) 
Ratio = 
(Eref)DCP ref {control - sample) 
Expression Analysis at the Protein Level 
Protein Extraction and Quantification 
Proteins from cell lines were extracted using the RIPA buffer (0.5% sodium deoxycholate, 0.1% 
SDS, 1% NP40, PBS1x with protease inhibitor cocktail and PMSF). One ml of RIPA buffer was 
used for every 10 million cells. The cells with the RIPA buffer were incubated for 30 min, at 4°C 
to prevent protein degradation. The mixture was then centrifuged 20-30 min at 13.000 rpm, 
4°C, to pellet the rest of the membranes and the organelles. The supernatant was taken into a 
pre-cold, clean tube and the protein concentration was measured, using the BCA Protein Assay 
Kit (Pierce, Rockford, IL, USA), following manufacturers instructions. This assay is a detergent 
compatible formulation based in bicinchoninic acid (BCA) for the colorimetric detection and 
quantitation of total protein. This method combines the reduction of Cu^* to Cu*^ by protein in 
an alkaline medium with the highly sensitive colorimetric detection of the Cu-"^  by the BCA 
containing reagent. The purple-colored reaction product of this assay is formed by the chelation 
of two molecules of BCA with one cuprous ion. This complex exhibits a strong absorbance at 
562 nm that is nearly linear with increasing protein concentration over a broad working range 
(20-2000 mg/ml). 
Western Blot 
Lysates from cell lines and samples were resolved by SDS-PAGE (Sodium Dodecyl Sulfate 
Polyacrylamide Gel Electrophoresis) under reducing conditions. The 20-30 |jg of total proteins 
was mixed together with the Loading Buffer (Table 7). The mixture was heated at 95°C for 5 to 
10 min to allow the denaturation of the proteins. After the incubation, the proteins were 
immediately left on ice to prevent the renaturation, and they were loaded in the Polyacrylamide 
gel. Kaleidoscope pre-stained Standard (Bio-Rad, Hercules, CA, USA) was used as protein 
molecular weight marker. The electrophoresis was run for 1 h at 180 V (Table 7).The resolved 
proteins were electro-blotted onto a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). 
The transfer was done at 300 mA for 45 min (Table 7). The membrane was blocked with 5% 
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non-fat milk in TBST buffer, to prevent non-specific binding, The immobilized proteins were 
subjected to inmuno-reaction with the primary antibody (1% non-fat milk in TBST with the 
antibody at the corresponding dilution). 
Stacking Gel 
- 7% polyacrylamide 
-pH6.8 
Resolving Gel 
-15% polyacrylamide 
-pH8 
Proteins from the lysates are resolved in the polyacrylamide gel. The SDS binds to the 
denatured proteins and gives them the negative charge. Proteins migrate to the positive pole 
according to their size. Overnight at 4°C, followed by three washes of 5 min in TBST. HRP-
conjugated secondary antibody (1% non-fat milk in TBST with the antibody at the 
corresponding dilution) was added and incubated for 1-2 h at room temperature, followed by 
another 2 washes of 5 min in TBST and one wash of 5 min in TBS. The information about the 
antibodies used and their dilution is shown in Table 8. 
The binding of secondary antibody was detected by enhanced chemiluminescence (ECLTM 
Western Blotting Analysis System, Amersham Biosciences, Piscataway, NJ, USA) and 
autoradiography. Enhanced chemiluminescence is achieved by performing the oxidation of 
luminol by the HRP in the presence of chemical enhancers such a phenols. This has an effect 
of increasing the light output approximately 1000 fold and extending the time of light emission. 
The maximum light emission is at 428 nm which can be detected by a short exposure to a 
sensitive autoradiography film. 
Promoter Methylation Study 
Introduction 
DNA methylation plays a critical role in the development and differentiation of mammalian cells 
and its deregulation has been implicated in oncogenesis. Generalized hypomethylation and 
regional hypermethylation have been associated with human neoplasia (Ehrlich et al., 2002). 
Hypermethylation has the potential of inactivating genes, such as tumour suppressor genes. 
Precise mapping of DNA methylation patterns in CpG islands is essential in diverse biological 
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Table.7 Composition of the buffers used in western blot 
Loading Buffer 
Electrophoretic Buffer 
Electroblotting Buffer 
Striping Buffer 
Tris 2IVI pH 6.8 
Glycerol 50% 
SDS 10% 
R-mercaptoethanol 5% 
Bromoplienol blue 
Gly 25Mm 
Tris 2,5Mm 
SDS 0.1% 
Gly 192 mM 
Tris 25 mM 
Mettianol 5% 
Tris 0.38 gm pH 6.7 
SDS (10%) 10ml 
fi-mercaptoetiianol 350|jl 
H20 30ml 
Table.8 Antibodies and conditions used for western blot 
Primary antibody 
Anti-GLI1(goat 
polyclonal N-16) 
sc-6153 
Cyclin D2(Rabbit 
polyclonal (H-289) 
Anti-GLI3(goat 
polyclonal (N-19) 
sc-6155 
GAPDH,Santa Cruz 
Biotech nolgy(sc-
32233) 
Dilution 
1:400 
1:200 
1:400 
1:2000 
Secondary 
antibody 
Anti-goat IgG-
HRP,Santa Cruz 
Biotechnology(sc-
2020) 
Anti-rabbit IgG-HRP 
Santa Cruz 
Biotechnology 
Anti-goat IgG-
HRP.Santa Cruz 
Biotechnology(sc-
2020) 
Goat anti-mouse 
lgG-HRP,Santa Cruz 
Biotechnology(sc 
2005) 
Dilution 
1:5000 
1:5000 
1:5000 
1:5000 
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processes such us regulation of imprinted genes, X chromosome inactivation and inactivation 
of tumour suppressor genes (Herman et al., 1996).The MSP technique can asses the 
methylation status of a group of CpG sites within a CpG island. The treatment of the template 
with sodium bisulfite converts all unmethylated cytosines to uracils; but methylated cytosines 
are resistant to modification. Then, PCR amplification is performed with specific primers for the 
methylated versus the unmethylated sequence. This technique is very sensitive and requires 
0.1% of methylated alleles of a CpG island. It can be used with paraffin-embedded samples, 
and it requires small amounts of DNA. Cytosine can form adducts across the 5-6 bond with a 
number of oxidation reagents, including the bisulfite ion. Reaction is highly single-strand 
specific, so DNA should be incubated with 3M NaOH at 37°C for 10 min to obtain single-
stranded DNA. Herring sperm DNA can be used as a carrier. There are three processes in the 
DNA modification by the bisulfite reaction (Figure xv). (Clark etal., 1994). 
Sulphonation:lt takes place by addition of bisulfite to the 5-6 double bond of cytosine and 
formation of a sulfonated cytosine derivative (Cytosine-S03). This step is reversible. The 
reaction is controlled by pH, bisulfite concentration and temperature. Low pH favors forward 
reaction. 
Hydrolytic deamination: Cytosine-S03 is hydrolytically deaminated to give a uracil-bisulfite 
derivative (uracil-S03). This step is catalyzed by basic substances, such us sulfite, bisulfite and 
acetate anions. This reaction is irreversible and is favored by pH below 7.0. 
Alkali desulfonation: alkali treatment removes the bisulfite adducts to give uracil. Although 5-
methylcytosine can also react with the bisulfite, the reaction is too slow and the equilibrium is 
favored to the 5-methyl-cytosine rather than to the deaminated product. y^K^'^'. - "'*•'> 
DNA Extraction vv ) ^-^ 
Tumour samples ^ T ^ ^ ^ w ^ ^-^ 
DNA from tumour samples was purified using the Wizard®Genomic DNA^Mlc^MOaraKft 
(Promega Corporation, Madison, Wl, USA) according to manufacturers' instructions. The 
frozen tissues were pulverized in a pre-frozen metallic mortar. To digest the tissues, the 
samples were incubated overnight at 55°C with gentle shaking in 600 |jl of 0.5 M EDTA/Nuclei 
Lysis Solution and 17.5 |jl of 20 mg/ml Proteinase K. RNA contamination was avoided with an 
incubation with 3 pi of RNase Solution for 15-30 min at 37°C. Proteins were precipitated with 
200 |jl of Protein Precipitation Solution, chilled on ice for 5 min and eliminated by centrifugation 
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2 Sulphonation 
HSO3 +HN 
OH O SO^ 
Cytosine 
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Fig. XV. DNA modification by the bisulphite reaction 
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for 4 min at high speed. DNA was precipitated from the supernatant with 600 \j\ of isopropanol 
and washed with 600 pi of the room temperature ethanol 70%. Finally, the DNA was 
resuspended in 1 mM TE pH 8 solutions and stored at 4°C. 
Cell lines 
DNA from cell lines was purified using the Wizard® Genomic DNA Purification Kit (Promega 
Corporation, Madison, Wl, USA) according to manufacturer's instructions. The cells were 
trypsinized, harvested in 1.5 ml centrifuge tubes and washed with 200 |jl of PBS. They were 
resuspended in 600 \j\ of Nuclei Lysis Solution and RNA contamination was avoided with 
incubation with 3 |jl of RNase Solution 15-30 min at 37°C.Proteins were precipitated with 200 
|jl of Protein Precipitation Solution, chilled on the ice for 5 min and eliminated by centrifugation 
for 4 min at high speed. DNA was precipitated from the supernatant with 600 pi of isopropanol 
and washed with 600 pi of the room temperature ethanol 70%. Finally, the DNA was 
resuspended in 1 mM TE pH 8 solutions and stored at4°C. 
DNA Eisuinitj muuiriuduuii 
Methylation patterns in CpG islands of promoters of the Smoothened (SMO), PTCH1, HHIP, 
SUFU, Cyclin D2, and SFRP1 genes were analyzed by MSP. DNA samples were treated with 
bisulfite to convert all unmethylated cytosines to uracils, while the methylated cytosines remain 
unmodified. Bisulfite modification of purified genomic DNA was facilitated by the CpGenomeTM 
DNA Modification Kit (Chemicon®lnternational Inc, Temecula, CA, USA). Briefly, one pg of 
genomic DNA was denatured by NaOH at a final concentration of 420 mM for 10 min at 
37°Cand then incubated with sodium bisulfite for 16 h at 50°C. The modification was completed 
by 0.2 M NaOH treatment for 5 min at room temperature. Modified DNA was purified, eluted in 
ImM TE (pH8), and used immediately or stored at -80°C for upto six months. The blood 
genomic DNA and in vitro hypermethylated genomic DNA (GenomeTM Universal Methylated 
DNA, Chemicon® International Inc, Temecula, CA, USA) validated the successful bisulfite-
modification. Both were used as controls for the methylation status of DNA. 
Methylation Specific PCR (MSP) 
The promoter regions of the Cyclin D2 gene were analyzed by MSP. Two pair of primers was 
used for each gene, based on the difference in the sequence after the bisulfite modification with 
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a pair of primers annealing to the unmethylated sequence and a pair of primers annealing to 
the methylated sequence (Figure xvi). The primers for Cyclin D2 have been taken from the 
paper of Evron e^  a/., 2001. All primer sequences are detailed in Table 9. MSP was carried out 
in a T3 thermocycler (Biometra, Goettingen, Germany) using 60 ng of bisulfite modified DNA in 
a total volume of 25 pi. The reaction mix contained 2.5 pi 10x reaction buffer, 2-2.5 mM MgCI2, 
0.2 mM of each dNTP, 5-10 pmol forward and reverse primers, 5% DMSO and one unit of 
AmpliTaq GoldTM polymerase (Applied Biosystems, Foster City, CA, USA). Denaturation at 
94°C for 10 min initiated the reaction, followed by 36-38 cycles of amplification. A final 
extension at 72°C for 10 min completed the reaction. PCR products were visualized with 
ethidium bromide using a 2% agarose gel. PCR conditions and programs for every gene are 
detailed in Tables 10 and 11. 
Melting Curve Analysis Based MSP (MCA-MSP) and Melting Curve Analysis Based Real 
Time Methylation Assay (MCA-METH) 
In standard PCR and cloning procedures, information about m5C and other covalent base 
moaifications in tne genomic Di\iA is iosi. Therefore, PCR methods for deieciiiig and iiidppiny 
m5C in specific genes rely on treatment of genomic DNA with methylation-sensitive restriction 
endonucleases or sodium bisulphite before amplification. Bisulphite treatment of genomic DNA 
converts unmethylated cytosines to uracil while methylated cytosines remain unchanged, 
thereby resulting in nucleotide sequence differences, which can be used to discriminate 
between methylated and unmethylated DNA. A specific target sequence can subsequently be 
amplified with primers specific for bisulfite-converted DNA and examined for its m5C content. 
The gold standard among bisulfite methods is genomic sequencing that provides a positive 
display of m5C at specific CpG sites in virtually any stretch of DNA (Frommer, et al., 1992). 
More simple methods using bisulfite-converted DNA as template include methylation-specific 
PCR (MSP) (Herman, et al., 1996), methylation-sensitive single nucleotide primer extension 
(Gonzalgo and Jones 1997), procedures based on the use of restriction endonucleases (Sadri 
and Hornsby, 1996 and Xiong et al, 1997) and the combined bisulphite restriction analysis 
(COBRA) (Xiong, et al, 1997). The above methods entail a two step procedure, an initial PCR 
amplification and subsequent product analysis, usually by gel electrophoresis. 
Furthermore, with the exception of genomic sequencing, they are limited to the analysis of one 
or a few CpG sites in each setting. More recently, a quantitative real-time methylation assay, 
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which utilized the fluorescence-based TaqMan Technology, was developed (Edas, ef a/., 
2000). This technique, called MethyLight, could provide a sensitive and quantitative assay of 
methylated DNA. However, TaqMan technology requires the design of a fluorogenic probe and 
it is also relatively expensive. We describe and compare 2 in-tubes PCR assays for the 
detection of aberrant DNA methylation that use a thermal cycler integrated with a fluorometer 
and exploit differences in melting temperature (Tm) between methylated and unmethylated 
DNA after bisulphite treatment. These real-time PCR techniques use the SYBR Green dye, 
which binds to double-stranded DNA. The bisulfite modified DNA is amplified and then a 
melting curve of the PCR product is performed. After bisulfite treatment, the methylated 
sequence conserves the CG pairs, while these will have been converted to AT pairs in the 
unmethylated sequence, which reduces the melting temperature of the DNA fragment. Melting 
curve analyses will then detect the CG to AT conversions as peaks appearing at lower 
temperature for the unmethylated DNA than for the methylated DNA. The first assay we 
describe is the Melting Curve Analysis-Methylation Specific PCR (MCA-MSP), that uses MSP 
primers for the amplification of the DNA (e.g. 2 pairs of primers, one is specific for the 
unmethylated DNA and a second one is specific for the methylated DNA. The reactions are 
carried out in two separate tubes). The methylated DNA will only be amplified in the PCR 
reaction with the pair of primers specific for the methylated DNA, giving a peak in the melting 
temperature. The same thing will occur for the unmethylated DNA respective to the 
unmethylated primers, but giving a peak at a lower temperature in the melting curve. The 
second assay, the Melting Curve Analysis-Methylation assay (MCA-Meth), uses a single pair of 
primers that amplifies both the methylated and the unmethylated DNA, as the primer-target 
annealing sequences do not contain any CpG dinucleotides. The methylation status of the 
sample will be assigned according to the pattern of peaks in the melting curve (Figure xvii). 
Setting up the IVICA-MSP and IVICA-IVIeth assays 
Fourteen medulloblastoma tumours (samples p3, p4, p7, p10, p11, p13, p14, p17, p20, p21, 
p23, p29, p30 and p52) forty four primary glioma tumours (samples 3, 4, 5, 6, 7, 8, 9,10,11, 
12,13,14, 15,16, 17,18,19,20, 21, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 41, 
42, 44, 45, 47, 48, 49, 50, 51 and 52) and fourteen cell lines included 6 medulloblastoma cell 
lines:TE671, PFSK-1, Daoy, TE671c2, D283 and SK-PN-DW, and eight astrocytomas cell 
lines: U87MG, A172, LN405, SW1783, T98G, SW1088, CCF-STTG-1 and GOS-3 were used 
for the study. DNA extraction and sodium bisulfate modification were performed as described 
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Unmethyiated DNA 
Sodium bisulphite 
5'ACATTA.. .CGTCGCG..TTATA 
5'AUATTA...UGTUGUG..TTATA 
TTTAAT 
HATA 
3'TTTAAT...ACAACAC.. AATAT 
Methylated DNA 
Sodium bisuipiiite 
5'ACATTA...CGTCGCG..TTATA 
5'AUATTA...CGTCGCG..TTATA 
TTTAAT 
TTATA 
3'TTTAAT...GCAGCGC..AATAT 
PCR Melting curve 
MoHPaokChttt Data 200605-15 plEmMlfneat-'nuaitiat.opd 
Fig. xvii. MSP-Meth method show melting curve by Real Time 
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above. The promoter regions of PTCH1, Cyclin D2, HHIP, SUFU, and SFRP1 genes were 
selected for this study. The MCA-MSP method for PTCH1, MSP and MCA-Meth Method for 
Cyclin D2 and MCA-Meth method for HHIP, SUFU and SFRP1 of gene promoter methylation 
analysis in the samples and cell lines were done to compare the potential of these techniques 
to detect DNA methylation. 
The MSP primers and PCR conditions were the same as described above. MCA-MSP primers 
were the same as MSP primers. MCA-MSP techniques was carried out with 3-6 ng of bisulfite 
modified DNA in a total volume of 25 ml, containing 12.5 ml of 2 x IQTM SYBR Green 
Supermix (Bio-Rad) and 2.5 pmol of primers (either the primers for the methylated or the 
unmethylated sequence). The reaction mixtures were heated at 94°C for 10 min, followed by 45 
cycles of 30 s at 94°C, 30 s at the corresponding annealing temperatures, 30 s at 72°C, and 30 
s at 76-77°C. We modified the MSP protocol by addition of an extra incubation step at 76-77°C 
in each cycle, to overcome the primer dimer artifact, as described previously (Chan et al., 
2004), After the amplification step, the melting curve analysis was done as follows; from 70°C 
to 90°C, for 30 s every 0.5°C. Both the amplification and the melting curves were carried out in 
an IQ5 Multicolor Real-Time PCR Detection System (Bio-Rad).The MCA-Meth primers were 
designed using the Meth Primer software (LiLC.DR 2002) (Table 9). The reaction mixtures 
were heated at 94°C in a first PCR step for 10 min and then amplified for 45 cycles of 30 s at 
94°C, 30 s at the corresponding annealing temperature, and 30 s at 72°C. After the 
amplification step, the melting curve analysis was done as follows: from 70°C to 90°C, 30 s at 
every 0.5°C. Both the amplification step and the melting curve were carried out in an IQ5 
Multicolor Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA).Specific PCR 
conditions for each gene are detailed in Table 10. 
MCA-Meth with the tumour suppressor genes 
Cyclin D2, HHIP, SUFU, and SFRP1 were analyzed by MCA-Meth using 3-6 ng of bisulfite 
modified DNA in a total volume of 25 ml. The reaction contained 12.5 ml of 2x IQTM SYBR 
Green Supermix (Bio-Rad, Hercules, CA, USA) and 2.5 pmol of primers. Primers were 
designed with the use of Meth Primer (LiLC, D.R 2002). Similar to bisulfite sequencing primers, 
MCA-Meth primers were designed lacking CpG- dinucleotides to facilitate amplification of the 
methylation status of amplified target DNA (Figure xv bisulphite modification.). Primer 
sequences are detailed in Table 9. 
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Table.9 Primers for Melting study including MCA-Meth, MCA-MSP and MSP 
Gene Forward primers (5'-3') Reverse primers (5'-3') Ta('C) Product 
PTCH1-M TAGGGTTTGATTTTTCGGTAGC TACTCGAACTCGAACTCCGAT 
PTCH1-U GAAGGTGTAGGGTTTGATTTTTT CTACTAACGACTCACTACTCAAA 
CyclinD2-M TACGTGTTAGGGTCGATCG CGAAATATCTACGCTAAACG 
CyclinD2-U GTTATGTTATGTTTGTTGTATG TAAAATCCACCAACACAATCA 
HHIP GAATATATGTGGGGATTTGAAAGG AACTTAAAAACAAAAAAACATCCCA 
SFRP1 GTTTGGGAGGTTAAGGTAGGAGTAT ACAAACCCATAAAATTATAAAAAC 
SUFU TTTTATTTTATTTTTGTTGGTTGGT TAAAAAAACTTAAACTCTCCTCCTC 
60 
61 
55 
55 
56 
TTTTT 57 
57 
104 bp 
126 bp 
276 bp 
222 bp 
227 bp 
227bp 
174 bp 
PTCH1-M and PTCH1-U were used as methylation primers (M) and 
unmethylation primers (U) for MCA-MSP method. Ta, annealing temperature; Product, base pairs of ttie amplified 
product. 
Table.10. Methylation-PCR Conditions 
PTCH1 HHIP SUFU 
dNTPs 0.2mM 0.2mM 0.2mM 
Cyclin D2 
C.2mM 
SFRP1 
0.2mM 
Buffer 10x 
MgCl2 
Primer F 
Primer R 
DIVISO 
Taq polym 
DNA 
1x 
2.5mM 
lOpmole 
lOpmole 
5% 
1U 
60ng 
1x 
2.5mM 
lOpmole 
lOpmole 
5% 
1U 
60ng 
1x 
2.5mM 
lOpmole 
lOpmole 
5% 
1U 
60ng 
1x 
2.5mM 
lOpmole 
lOpmole 
5% 
1U 
60ng 
1x 
2.5mM 
lOpmole 
lOpmole 
2.5% 
1U 
60ng 
Materials & Methods 
The reactions mixtures were heated at 94°C in a first PCR step for 10 min and then amplified 
for 45 cycles of 30 s at 94°C, 30 s at the corresponding annealing temperature, and 30 s at 
72°C. After the amplification step, the melting curve analysis was done as follows: from 70°C to 
90°C, for 30 8 at every 0.5°C. Both the amplification step and the melting curves were carried 
out in an IQ5 Multicolor Real-Time PCR Detection System (Bio-Rad, Hercules, CA, 
USA).Specific PCR conditions and program for each gene are detailed in Table 10 and 11. 
5-Aza-2'-deoxycytidine (5-Aza-dC) and Trichostatin A (TSA) Treatment 
Unlike mutagenic events, epigenetic mutations can be reverted. Demethylation of aberrantly 
silenced genes can restore gene expression and function. This effect has been observed both 
by demethylation of specific genes (Herman, JG et ai, 1998) and by global genomic 
demethylation [282] (Soengas, M.S et ai, 2001). One of the most widely known methylation 
inhibitors is the cytosine nucleoside analogue 5-aza-dC (Figure xviii.A). This cytosine 
derivative becomes incorporated into nucleic acids and acts as a suicidal substrate. The 
enzyme initiates catalysis and a covalently bound DNMT-DNA intermediate is formed. Bound 
methyltransferases become depleted from the nucleus and subsequent DNA replication over 
several cell generations results in a passive demethylation of the genome. However, the DNA-
methyltransferase adducts are believed to be responsible for the highly toxic effect of these 
cytosine analogue to have on mammalian cells (Jackson-Grusby et ai, 1997). This feature is 
the main drawback for the use of 5-aza-Dc and greatly limits its potential as chemotherapeutic 
agent. 
Trichostatin A (Figure xviiiB) is an organic compound which selectively inhibits the mammalian 
histone deacetylase family of enzymes. TSA can be used to alter gene expression by 
interfering with the removal of acetyl groups from histone (histone deacetylase, HDAC) and 
therefore altering the ability of DNA transcription factors to access the DNA molecule inside 
chromatin. We used both 5Aza-2'-deoxycytidine and trichostatin A (TSA) so their they worked 
better syngergically for the expression of silenced gene (Cameron et ai, 1999) 
5-Aza-dC and TSA Treatment 
Setting up the 5-Aza-dC and TSA treatment 
T98G glioblastoma cell line was treated with 5-aza-Dc and TSA at a concentration of 5Mm and 
50nM, respectively during 48 h, 72 h and 96 h, with a change of media every 24 h. After the 
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A.5-aza-Dc 
B.TSA 
Fig.xviii. A-B.Structure of the 5Aza-Dc and TSA 
Materials & Methods 
treatment, cells were trypsinized, counted in a bright line hemocytometer (Sigma-Aldrich 
Corporation, St Louis, Ml, USA) using the Trypan blue solution (0, 4%) (Sigma-Aldrich 
Corporation, St Louis, Ml, USA) and collected in pellets. DNA extraction, DNA bisulfite 
modification, RNA extraction and retro-transcription were performed as described above. Cyclin 
D2 expression by RT-PCR was performed to validate the reexpression of the gene after the 5-
aza-Dc and TSA treatment. Cyclin D2 demethylation was checked by Real Time methylation 
assay. 
Treatment of the brain tumour cell lines 
All cell lines were treated with 5mM and 50nM of 5-Aza-dC and TSA respectively for 72 hours. 
During treatment the media was changed every day. RNA was extracted immediately after 
treatment using the Trizol® Reagent (Invitrogen, Carlsbad, CA, USA). The cells were lysed 
directly in the culture dish by adding 5 ml of Trizol Reagent and transferred into a centrifuge 
tube. Then, 1 ml of chloroform was added; the mixture was shaken vigorously, and incubated 
at room temperature for 5min. The mixture was centrifuged at 13000 rpm for 30 min at 4°C. 
The aqueous phase was carefully transferred into a clean, sterile DEPC-treated tube. Then, 2.5 
ml of isopropanol was added for RNA precipitation. The RNA pellet was obtained by 
centrifugation at 4°C for 25 min at 13000 rpm. After washing with 5 ml of 75% ethanol (in 
DEPC) the pellet was air dried and resuspended in 40 ml of DEPC-treated water. RNA 
concentration was measured in a NanoDrop® Spectrophotometer (PEQLAB-Biotechnologie, 
Eriangen, Germany) measuring absorbance at 260 nm. The purified RNA samples were stored 
in DEPC water at -80°C. RT PCRs were performed to check for treatment induced re-
expression of Cyclin D2 gene as described above. 
The intensity of the bands obtained was quantified in a Bio-Rad GS-800 Calibrated with 
Densitometer (Bio-Rad, Hercules, CA, USA). The data obtained for each cell line was 
normalized with the value corresponding to the GAPDH and the value obtained for the 
untreated cell lines was compared with the value obtained for the treated cell lines to know 
whether the expression of the genes analyzed was restored after the 5-aza-dC treatment. 
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Table.11. PCR Program for MCA-MSP and MCA-Meth 
Denaturation 
Denaturation 
Annealing 
Extension 
No.of Cycle 
PTCH1 
95X10' 
94°C 30" 
60°C45" 
70°C 30" 
45 
HHIP 
95°C 10' 
94°C 30" 
55°C45" 
70°C 30" 
45 
95°C 30" 
70°C 30" 
Melting curve 
70°C^90°C 
Each 0.5°C 
4°C 
SUFU 
BS'C 10' 
94°C 30" 
57°C 45" 
70°C 30" 
45 
Cyclin D2 
95°C 10' 
94°C 30" 
55°C 45" 
70°C 30" 
45 
SFRP1 
95°C 10' 
94°C 30" 
57°C 45" 
70°C 30" 
45 
Materials & Methods 
MTT Test 
Harvest suspension cells by centrifugation. Adherent cells should be released from their 
substrate by trypsinization or scraping. 
i 
Resuspend cells at 1 x lO^per ml. 
i 
Prepare serial dilutions of cells in culture medium from 
1 x106to1 X 103 cells per ml. 
i 
Plate out, in triplicate, 100 |jl of the dilutions into wells of a micro titer plate. 
i 
Include three control wells of medium alone to provide the blanks for absorbance readings. 
i 
Incubate the cells under conditions appropriate for the cell line for 6 to 48 hours (to recover 
from handling). The time required will vary by 12 hours to overnight be sufficient for most cell 
types. 
i 
Add 10 pi of MTT ((3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) Reagent to 
each well, including controls 
i 
Return plate to cell culture incubator for 2 to 4 hours. 
i 
Periodically view the cells under an inverted microscope for presences of intracellular 
punctuate purple precipitate. 
i 
When the purple precipitate is clearly visible under the microscope add 100 pi of Detergent 
Reagent to all wells, including controls. Swirl gently; do not shake. 
i 
Leave plate with cover in the dark for 2 to 4 hours or overnight at room temperature. 
i 
Remove plate cover and measure the absorbance in each well, including the blanks, at 570 nm 
in a micro titer plate reader, [Absorbance can be read with any filter in the wavelength range of 
550 - 600 nm. The reference wavelength should be higher than 650 nm. The blanks should 
give values close to zero (+/- 0.1).] 
i 
If the readings are low retum the plate to the dark for longer incubation. 
i 
Determine the average values from triplicate readings and subtract the average value for the 
blank. Plot absorbance against number of cells/ml. The number of cells to use in your assay 
should lie within the linear portion of the plot and yield an absorbance of 0.75 -1.25. 
Cell cycle Analysis 
After Cyclopamine drug treatment, cells were fixed in 70% ethanol, stained with propidium 
iodide, and analyzed on a BD FACS Cell Analysis system (BD Biosciences) according to the 
standard protocol provided by the manufacturer. Percentages of cells in G0-G1, S, or G2-M 
phase were determined using BD Diva soft ware version 3.0 (BD Biosciences). 
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Materials & Methods 
Apoptosis Analysis: 
In this case we checked the effect of Cyclopamine in two cell lines including medulloblastoma, 
and glioblastoma. For apoptosis analysis we used ANNEXIN V-FITC Apoptosis Detection Kit I. 
The following protocol was followed. 
Wash cells twice with cold PBS and then resuspend cells in 1X binding buffer (0.1M 
Hepes/NaoH (pH 7.4)1.4M NaCI, 25Mm CaCb at a concentration of 1 x 106 cells/ml. 
i 
Transfer 100 |jl of the solution (1 x 105 cells) to a 5 ml culture tube. 
i 
Add 5 |jl of Annexin V-FITC and 5 [i\ of Propidium Iodide (PI). 
i 
Gently vortex the cells and incubate for 15 min at RT (25°C) in the dark. 
i 
Add 400 |jl of 1X binding buffer to each tube. Analyze by flow cytometry within one hour. 
Statistical analysis 
Statistical analyses were done using Graph pad Prism4 (Graph Pad Software, San Diego, CA). 
Data graphed with error bars represent mean and SE from experiment done in triplicate unless 
otherwise noted. A two-side student's t test was used to determine the significance of any 
difference. 
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Cfiapter -1: ^suCts 
Chapter-I Results 
Transfection of GLI1 siRNA and Expression of GLI1, PTCH1, Cyclin D2, Plakoglobin, 
PAX6, NKX2.2 and Bmi-1 in tlie medulloblastoma and astrocytoma cell lines 
After GLI1 siRNA transfection, expressions of GLI1 and other downstream GLI1 target genes 
including PTCH1, Cyclin D2, Plakoglobin, PAX6, NKX2.2 and Bmi-1 expression were checked. 
Transfection efficiency: After 24hrs of GLI1 siRNA transfection, its efficiency was confirmed 
with the intensity of fluorescent dye fluorescein in the medulloblastoma cell line Daoy 
(Figure 1A-C) and astrocytoma cell line U87MG (Figure 1D-F). 
R.1.Expression of GLI1: After 72hrs of transfection with GLI1 siRNA, GLI1 expression was 
checked by RT-PCR and Real Time RT-PCR PCR. There was a significantly by low level of 
GLI1 transcript, showed by RT-PCR (Figure 2A). Assay Real Time RT-PCR showed 86% loss 
in the expression of GU1 in medulloblastoma cell line Daoy (Figure 3A), whereas in 
astrocytoma cell line U87MG expression decreased by 60% (Figure 3B) compared to universal 
negative siRNA (U neg siRNA) and untransfected cell lines respectively. This difference in 
expression between untransfected and transfected cell lines were highly significant (p<0.001). 
R.2.Expression of PTCH1: After 72hrs of transfection with GUI siRNA, we further checked 
the downstream target gene PTCH1 and found distinct low expression of PTCH1 in GLI1 
siRNA transfected cell lines compared to universal negative siRNA and untransfected cell line 
(Figure.2C) by RT-PCR. Real Time RT-PCR showed 50% loss in expression of PTCH1 
transcript in the medulloblastoma cell line Daoy (Figure 4A) and 35% loss in expression of 
PTCH1 in astrocytoma cell line U87MG (Figure 4B) compared to untransfected and universal 
negative cell lines. The difference in expression was highly significant between transfected and 
untransfected was highly significant (p<0.001). 
R.3.Expression of Cyclin D2: From the same GLI1 knockdown cell lines Daoy and U87MG 
cDNA, we checked another GLI1 downstream target gene Cyclin D2 in the medulloblastoma 
and astrocytoma cell lines and found 20% loss in expression of Cyclin D2 in medulloblastoma 
cell line Daoy (Figure 5A) and found 2.5 fold increased expression of Cyclin D2 in glioblastoma 
cell line U87MG (Figure 58) compared to universal negative siRNA transfected and 
untransfected cell lines respectively. This difference in expression between transfected and 
untransfected cell lines was highly significant (p<0.001). 
R.4.Expression of Plakoglobin: Then we further checked other downstream target gene of 
GLI1, Plakoglobin from the same GLI1 knockdown cDNA and found 25% loss in expression of 
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Transfection Study 
Daoy cell line 
Transfected with Gli1 siRNA 10x 
B 
Transfected with U Neg siRNA 
Untransfected Cell line 
Fig.1.Transfection of medulloblastoma cell line Daoy. Fig.A.Daoy cell line was 
transfecetd With StealthTM sIRNA GLII(lnvitrogen) lOOpmol concentartion, using 
LipofectamineTM 2000 and a transfering agent and fluorescein-labeled 
oligo(BLOCK-iTTM Fluorescent oligo) for identification of trasfectlon efficency 
Fig.B.Transfected with neg sIRNA Fig.C.Untransfected Cell line Daoy aftet 24hrs, 
Transfection Study 
U87MG cell line 
Transfected with Gli1 siRNA 10x 
Transfected with U Neg siRNA 10x 
Untransfected Cell line 10x 
Fig.1.Transfection of astrocytoma cell line U87MG. Fig. D. U87MG cell line 
was transfecetd With Stealth™ siRNA GLII(lnvitrogen) lOOpmol concentartion, 
using Lipofectamine™ 2000 and a transfering agent and fluorescein-labeled 
oligo(BLOCK-iT™ Fluorescent oligo) for identification of trasfection efficency.Fig. 
E.Transfected with neg siRNA Fig. F.Untransfected Cell line U87MG after 24hrs. 
Chapter-I Results 
Plakoglobin in the medulloblastoma cell line Daoy (Figure 6A) and two fold increased 
expression of Plakoglobin in astrocytoma cell line U87MG (Figure 6B) compared to 
untransfected and universal siRNA transfected cell lines. It was highly significant (p<0.001). 
R.S.Expressicn of PAX6: Thereafter we also checked expression of sonic hedgehog signaling 
mediated gene PAX6. This is considered as a putative downstream target gene of GLI1. After 
GUI knockdown PAX6 showed 38% loss of expression in the medulloblastoma cell line Daoy 
(Figure 7A) and two fold increased expression of PAX6 in the astrocytoma cell line U87MG 
(Figure 7B) compared to universal negative siRNA and untransfected cell lines respectively. 
The difference in expression between transfected and untransfected cell lines was highly 
significant (p<0.001). 
R.e.Expression of NKX2.2: Another putative downstream target gene of GLI1, NKX2.2 
expression was also checked from the same source of GLI1 knockdown cDNA and found 50% 
loss of NKX.2 expression in the medulloblastoma cell line Daoy (Figure 8A) however, 
astrocytoma cell line U87MG did not show any expressional changes compared to universal 
negative siRNA transfected and untransfected cell lines respectively. Highly significant 
(p<0.001). 
RJ.Expression of Bmi-1: Finally, we checked another putative downstream target gene of 
GLI1, Bmi-1 expression in these GLI1 knockdown cell lines and found 70% loss in expression 
of Bmi-1 in the medulloblastoma cell line Daoy (Figure 9A) and two fold increased expression 
of Bmi-1 in astrocytoma cell line U87MG (Figure 98) compared to universal negative siRNA 
transfected and untransfected cell lines respectively. It was highly significant (p<0.001). 
Transcript expression of GLU, PTCH1, Cyclin D2, Plakoglobin (y catenin), PAX6, NKX2.2, 
and Bmi-1 In six medulloblastoma and eight astrocytoma cell lines 
After the GLI1 knockdown in medulloblastoma cell line Daoy and astrocytoma cell line U87MG, 
we checked the expression of GLI1 downstream target genes including PTCH1, Cyclin D2, 
Plakoglobin, PAX6, NKX2.2, PAX6 and Bml-1 in these two cell lines and which helped to 
understand the gene regulatory mechanism by GUI. 
Then we furthered checked the gene expression pattern in six medulloblastoma and eight 
astrocytoma cell lines by RT-PCR and Real Time RT-PCR. Similarly, we also checked these 
gene expressions in 14 medulloblastoma and 27 glioma primary tumour samples. 
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RT-PCR 
Fig. 2A-D 
A. GU1 
IsiRNA 2siRNA si- untransfected 
C. PTCH1 
IsiRNA 2siRNA si- untransfected 
B. TFR 
IsiRNA 2siRNA si- untransfected 
D. TFR 
IsiRNA 2siRNA si- untransfected 
Fig. 2A.D. RT-PCR expression of GLI1 and PTCH1 after the GLI1 siRNAs 
transfection in Daoy Ceil iine: Fig. A showed GLI1 transcript expression after 72hrs 
of GLI1 siRNA transfection at lOOnM concentration/well. Fig. C.PTCH1 gene showed 
decresed in expression after 72hrs of GLI1 siRNA transfection in medulloblastoma cell 
line (Daoy).si- and untranfected stand for negative siRNA control and untransfected 
control respectively. Fig. B and D. TFR gene was taken as internal control of mRNA 
expression 
Chapter-I Results 
Transferin receptor (TFR) mRNA expression was taken as an internal control for the RNA 
expression in RT-PCR. As a control of expression, cDNA obtained from normal brain was used 
for this study. All data obtained from Real Time RT-PCR was normalized by Glyceraldehyde-3-
phosphate dehydrogenase gene (GAPDH, 12p13). 
R.8 GLI1 
Medulloblastoma cell lines 
RT-PCR: All six cell lines (TE671, PFSK-1, Daoy, TE671c2, D283 and SK-PN-DW) showed 
many fold expression of GLI1 transcript as compared to normal brain tissue (Figure 10A) 
Real Time RT-PCR: All six cell lines showed many fold expression of GLI1 transcript as 
compared to normal brain, (Figure 10B). 
Astrocytoma cell lines 
RT-PCR: All 8 cell lines showed high expression of GL11 transcript as compared to normal 
brain tissue (Figure 10C). 
Real Time RT-PCR: All 8 cell lines showed high fold expression and even reached up to 70 
fold in SW1088 cell lines compared to normal brain tissue. (Figure 10D). 
R.9 PTCH1 
IVIedulloblastoma cell lines 
RT-PCR: In 3/6 cell lines of medulloblastoma (TE671, PFSK-1 and Daoy), PTCH1 transcript 
expression was high and 3/6 cell lines medulloblastoma (TE671c2, D283 and SK-PN-DW) 
showed low expression compared to normal brain tissue (Figure 11 A). 
Real Time RT-PCR: Similarly, 3/6 cell lines of medulloblastoma (TE671, PFSK-1 and Daoy) 
showed high fold expression and 3/6 cell lines (TE671c2, D283 and SK-PN-DW) showed low 
expression of PTCH1 transcript as compared to normal brain tissue (Figure 11B). Comparative 
expression was statistically significant (p=0.04). 
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Fig. 3A-B 
Real Time RT-PCR 
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Fig. 3A-B. Real Time RT-PCR comparative expression of GLI1 transcript after 
GLU sIRNA transfection in medulloblastoma and astrocytoma cell lines: Fig. 
A.This fig showed the 86% lost in expression of GLI1 transcript after the 72 hrs 
treatment of GLI1 siRNA as compared to negative siRNA and untransfected control 
in medulloblastoma cell line Daoy Fig. B. This fig.showed 60% lost in GLI1 
tranascript after 72 hrs treatment of GLI1 siRNA as compared to negative siRNA and 
untransfected control in astrocytoma cell line U87MG. All data from Real Time RT-
PCR were normalized by GAPDH. 
Chapter-I Results 
Astrocytoma cell lines 
RT-PCR: In this 4/8 cell lines (U87MG, A172, LN405 and SW1783), we showed low or equal 
expression and remaining 4/8 cell lines {T98G, SW1088, CCF-STTG-1 and GOS-3) showed 
high expression of PTCH1 transcript compared to normal brain tissue (Figure 11C). 
Real Time RT-PCR: Similarly, 4/8 cell lines{U87IVlG, A172, LN405 and SW1783) showed low 
or equal expression and 4/8 cell lines showed 3-6 high-fold expression of PTCH1 transcript 
compared to normal brain.(Figure 11D). 
R.10 Cyclin D2 
Medulloblastoma cell lines 
RT-PCR: In 5/6 cell lines, Cyclin D2 expression was high and in the remaining one cell line SK-
PN-DW, showed low expression of Cyclin D2 as compared to normal brain tissue 
(Figure 12A). 
Real Time RT-PCR: Similarly, 5/6 cell lines showed many fold expression and only one cell 
line SK-PN-DW showed low expression of Cyclin D2 as compared to normal brain tissue. 
(Figure 12B). 
Astrocytoma cell lines 
RT-PCR: Only three cell lines (G1:U87MG, G3:LN405 and G6:SW1088) showed Cyclin D2 
transcript expression and remaining 5 cell lines(A172, SW1783, T98G, CCF-STTG-1 and GOS-
3) did not show any expression of Cyclin D2 transcript compared to normal brain tissue 
(Figure 12C). 
Real Time RT-PCR: Only four cell lines showed low expression of Cyclin D2 transcript and 
remaining four cell lines did not show the expression of Cyclin D2 transcript as compared to 
normal brain tissue. It was statistically highly significant (p<0.0001) (Figure 12D). 
R.11 Plakoglobin (y catenin) 
Medulloblastoma cell lines 
RT-PCR: All six medulloblastoma cell lines showed high expression of plakoglobin transcript as 
compared to normal brain tissue (Figure 13A). 
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Real Time RT-PCR 
Fig. 4A-B 
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Fig. 4A-B. Real Time RT-PCR comparative expression of PTCH1 transcripts 
after GLI1 knockdown in medulloblastoma and astrocytic cell lines: Fig. A. 
This fig showed 50% lowexpressionof PTCH1 transcript after the 72 hrs treatment 
of GLI1 siRNA as compared to negative siRNA and untransfected medulloblastoma 
cell line Daoy.Fig. B.This fig.showed 35% low expression of PTCH1 transcript after 
the 72hrs treatment of GLI1 siRNA as compared to negative siRNA and 
untransfected control astrocytoma cell line U87MG. 
Chapter-I Results 
Real Time RT-PCR: Similarly, all six cell lines showed high-fold expression of plakoglobin 
transcript as compared to normal brain tissue. (Figure 13B). 
Astrocytoma cell lines 
RT-PCR: In four cell lines (A172, SW1088, CCF-STTG-1 and GOS-3), we showed high 
expression of plakoglobin transcript and remaining four cell lines (U87MG, LN405, SW1783 
and T98G) showed low expression of plakoglobin transcript compared to normal brain tissue 
(Figure 13C). 
Real Time RT-PCR: In this case, five cell lines showed low and remaining three cell lines 
showed high-fold expression of plakoglobin transcript compared to normal brain tissue. It was 
highly significant (p<0.0001) (Figure 13D). 
R.12 PAX6 
Medulloblastoma cell lines 
Real Time RT-PCR: Most of the cell lines showed low expression of PAX6 except two cell lines 
TE671 and TE671c2 which showed high expression compared to normal brain tissue 
(p=0.06137) (Figure 14A). 
Astrocytoma cell lines 
Real Time RT-PCR: Most of the cell lines except two cell lines U87MG and A172 showed low 
expression of PAX6 compared to normal brain tissue. The difference was highly significant 
(p=0.007) (Figure 14B). 
R.13NKX2.2 
Medulloblastoma cell lines 
Real Time RT-PCR: Most of the cell lines except SK-PN-DW showed low expression (Daoy 
and TE671c2) and even no expression (TE671, PFSK-1 and D283) of NKX2.2 compared to 
normal brain tissue. It was significant (p=0.501) (Figure 15A). 
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Real Time RT-PCR 
Fig. 5A-B 
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Fig. 5A-B. Real Time RT-PCR comparative expression of Cyclin D2 
transcript after GLI1-Knockdown: Fig. A. This fig. showed the 20% lower 
expression of Cyclin D2 transcript after the 72 hrs treatment of GLI1 sIRNA as 
compared to negative siRNA and untransfected Control medulloblastoma Cell 
line Daoy Fig. BThis fig. showed 2 fold higher expression of Cyclin D2 transcript 
after the 72hrs treatment of GLI1 siRNA as compared to negative siRNA and 
untransfected control astrocytoma cell line, U87MG. 
Chapter-I Results 
Astrocytoma cell lines 
Real Time RT-PCR:' In glioblastoma, 6/8 cell lines, showed low expression and remaining two 
cell lines showed no expression of NKX2.2 transcript as compared to normal brain tissue. The 
difference was highly significant (p<0.0001) (Figure 15B). 
R.14Bmi-1 
Medulloblastoma cell lines 
Real Time RT-PCR: All six cell lines of medulloblastoma showed low fold expression of Bmi-1 
transcript as compared to normal brain tissue and this difference was highly significant 
(p<0.0001) (Figure 16A). 
Astrocytoma cell line 
Real Time RT-PCR: In astrocytoma, six cell lines showed low expression and remaining two 
cell lines (U87MG and A172) showed high expression of Bmi-1 compared to normal brain 
tissue. It was significant (p=0.0232) (Figure 16B). 
Western blotting: 
R.15 GLI1 and Cyclin D2 Protein expression by cell lines: 
The expression of GLI1 protein was checked in all eight cell lines of astrocytoma (LN405, 
SW1783, T98G, SW1088, CCF-STTG-1 and GOS-3) and found most of the cell lines showed 
GLI1 protein expression except two cell lines (U87MG and A172) did not show GLI1 protein 
expression (Figure 17A). 
Few cell lines showed faint band of Cyclin D2 protein expression except one cell line (SW1783) 
which did not show Cyclin D2 protein band (Figure 17B). 
R.16 Expression of GLI1, PTCH1, Cyclin D2, Plakoglobin, PAX6, NKX2.2 and Bmi-1 genes 
in primary tumour samples of medulloblastoma and glioma. 
GLI1 Expression 
IVIedulloblastoma: In medulloblastoma 7/11(64%) primary tumour samples showed high fold 
expression and reached up to 14 fold and remaining 4/11 primary tumour samples showed low 
expression as compared to normal brain tissue. It was highly significant (p=0.0107) 
(Figure 18A). 
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Fig. 6A-B 
Real Time RT-PCR 
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Fig. 6A-B. Reai Time RT-PCR comparative expression of Plakoglobin 
transcripts after GLi1 gene Knockdown in medulloblastoma and 
asctrocytoma cell lines: Fig. A.This fig. showed the 25% lower expression of 
Plakoglobin transcript after the 72 hrs treatment of GLI1 siRNA as compared to 
negative siRNA and untransfected control medulloblastoma cell line.Daoy.Fig. B. 
This fig. showed 3 fold higher expression of Plalcoglobin transcript after 72hrs 
treatment of GLI1 siRNA as compared to negative siRNA and untransfected 
control astrocytoma cell line U87MG. 
Chapter-I Results 
In glioma, 23/27(85%) primary samples showed 2-6 high fold GLI1 transcript expression and 
remaining 4/27 samples showed low expression as compared to normal brain tissue. Highly 
significant (p<0.0001) (Figure 18B). 
PTCH1 Expression 
In medulloblastoma samples, the expression of PTCH1 transcript was 2-5 high-fold in 3/7 
samples and remaining 4/7 samples showed low expression compared to normal brain tissue 
(Figure 18C). 
In primary glioma tumours most of the samples (21/27) showed either low or equal PTCH1 
transcript expression and remaining 6/27 samples reached up to 2 to 40 high-fold expression of 
PTCH1 transcript as compared to normal brain tissue. (Figure 18D). 
Cyclin D2 Expression 
In medulloblastoma, 12/14 samples showed high-fold expression and remaining 2/14 primary 
tumours showed low expression of Cyclin D2 transcript compared to normal brain tissue. 
Significant (p=0,0198) (Figure 19A). 
In glioma tumour, 14/27 samples showed low or no expression of Cyclin D2 transcript and the 
remaining 13/27 tumours showed high fold expression of Cyclin D2 transcript as compared to 
normal brain tissue. Statistically significant (p=0.0017) (Figure 19B). 
Plakoglobin: 
In medulloblastoma samples, 8/9 samples showed high fold expression of plakoglobin and 
remaining one sample showed low expression of plakoglobin transcript as compared to normal 
brain tissue. Significant (p=0.0097) (Figure 19C). 
In glioma tumour, 25/27 samples showed low expression of plakoglobin and remaining 2 
samples showed high-fold expression compared to normal brain tissue. Significant (p=0.0024) 
(Figure 19D). 
PAX6: 
In medulloblastoma 7/11 primary tumour samples showed high fold and remaining 4/11 
samples showed low expression of PAX6 transcript compared to normal brain tissue. 
Significant (p=0.0135) (Figure 20A). 
70 
Fig. 7A-B 
Real Time RT-PCR 
A. Daoy Cell line 
•a 
5 120 1 
c 
1 100 
M 
O 
6 80 
1 60 
a 
o 
1 20-
a 
o U 
DPAX6 
Glil siRNA U Neg siRNA Control 
B. U87MGCellline 
•a 
£ 600 n 
c 
•i 500 • 
o 
o. 400 
g 300 
K 
S 200-
0) 
> 
1 100-
a 
a 
E 0 -
o 
o 
aPAXB 
GUI SiRNA U Neg siRNA Control 
Fig. 7A-B. Real Time RT-PCR comparative expression of PAX6 transcripts 
after GLI1 Knockdown in medulloblastoma astrocytic cell lines: Fig. A. This 
fig. showed the 38% lower expression of PAX6 transcript after the 72 hrs 
treatment of GLI1 siRNA as compared to negative siRNA and untransfected 
Control medulloblastoma cell line Daoy.Flg. B. This fig. showed 2 fold increased 
expression of PAX6 transcript after 72hrs treatment of GLI1 siRNA as compared 
to negative siRNA and untransfected control astrocytic cell line U87MG. 
Chapter-I Results 
In glioma tumour, 24/27 samples showed low expression of PAX6 transcript and remaining 
3/27 samples showed high-fold expression of PAX6 compared to normal brain tissue 
(Figure 20B). 
NKX2.2 
In medulloblastoma, 3/8 samples showed low and remaining 5/8 did not show expression 
NKX2.2 transcript compared to normal brain tissue. Highly significant (p<0.0001) (Figure 20C). 
In glioma tumour, 20/27 samples showed either low or no expression of NKX2.2 transcript and 
remaining 7/27 samples showed high fold expression of NKX2.2 transcript as compared to 
normal brain tissue. (Figure 20D). 
Bmi-1 
Bmi1 transcript expression was not checked in medulloblastoma samples because of 
insufficient RNA quantity. 
Astrocytoma 
Most of the primary glioma tumours samples showed low expression of Bmi-1 transcript and 
remaining 4/27 samples showed high expression of Bmi-1 compared to normal brain tissue 
(Figure 20E). 
R.17 GLI1 and Cyclin D2 Protein expression by primary tumour samples of glioma: 
Most of the astrocytic tumour samples showed distinct protein expression of GUI, which were 
showed in Figure 21A (samples: 1-4 and 6), Figure 21B (samples: 7, 9, 11, 20-21) and 
Figure 21C (samples: 22-23, 26-29).The C+ was HeLa cell lysate taken as normal control for 
GUI protein expression. 
IVietliylation Results for PTCH1 and Cyclin D2 
Methylatlon Study: 
Besides understanding GLI1 regulation on PTCH1, Cyclin D2 was also chosen for 
understanding epigenetic regulation in these tumours. Moreover, PTCH1 showed overall low 
expression in medulloblastoma and glioblastoma cell lines tumours. However, Cyclin D2 
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Fig. f. "Real Time RT-PCR coiTTparative expression of NKX2.2 transcript 
after GLI1 knockdown in medulloblastoma and astrocytic cell lines: This 
fig. showed the 50% lower expression of NKX2.2 transcript after the 72 hrs 
treatment of GLI1 siRNA as compared to negative siRNA and untransfected 
Control in Daoy cell line. There was no expression of NKX2.2 transcript even 
after the 72hrs treatment of GLI1 siRNA as compared to negative siRNA and 
untransfected control U87MG cell line. 
Chapter-I Results 
expression was low in astrocytoma cell lines and tumour but not in medulloblastoma cell lines 
and tumours. 
Epigenetic regulation plays a very significant role in the progression of many cancers, because 
this phenomenon silences many tumour suppressor genes (TSGs) and causes the proliferative 
progression among cancer cells. In this section, we have determined the epigenetic regulation 
of these putative tumour suppressor genes (TSGs): PTCH1, Cyclin D2 in medulloblastoma, 
astrocytoma cell lines and primary tumour samples. 
R.18 PTCH1 Methylation: 
Medulloblastoma: In medulloblastoma 3/6 cell lines {TE671, PFSK-1 and D283), we showed 
partial hypermethylation and remaining three cell lines (Daoy, TE671c2 and SK-PN-DW) did 
not show any promoter hypermethylation by MCA-MSP. These partial methylated melting 
peaks showed amplification with methylated DNA specific primers (Figure 22A) but did not 
give amplification with unmethylated DNA specific primers (Figure 22B) (Table 12). 
In medulloblastoma only 2/14 samples (p7 and p11) showed partial promoter methylation 
(Figure 22G) (Table 14). 
These partial/hemi methylated cell lines and samples showed amplification with methylated 
specific primers (blue color peak) and their melting peak temperature was close to methylated 
DNA specific primers positive control, in vitro methylated DNA (IMD) (83° temp, green color 
peak) (Figure 22G) but unmethylated cell lines and samples did not show any amplification 
with methylated DNA specific primers (Figure 22C and 22E). However, both partial/hemi 
methylated and unmethylated cell lines and samples also showed amplification with 
unmethylated DNA specific primers and their melting peak temperature was close to normal 
blood, which was taken for positive control of unmethylated allele (78° temp ,red color peak) 
(Figure 22B and 22H). 
Astrocytoma: Only one cell line CGF-STTG-1 out of 8 astrocytoma cell lines showed 
partial/hemi methylation in the PTCH1 promoter region by MCA-Meth method. Melting peak 
temperature was close to positive control in vitro methylated DNA (IMD) (83° degree) 
(Figure 23C) (Table 13). 
In glioma samples, only 4/44 samples showed partial/hemi methylated peak with methylated 
DNA specific primers and remaining 40/44 samples did not show any amplification with these 
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Fig. 9A-B. Real time RT-PCR comparative expression of Bmi-1 transcripts after 
GLI1 knockdown in medulloblastoma and astrocytic cell lines: Fig. A. This fig 
showed the 70% low expression of Bmi-1 transcript after the 72 hrs treatment of GLI1 
siRNA as compared to negative siRNA and untransfected control medulloblastoma cell 
line Daoy. Fig. B. This fig showed 2 fold high expression of Bmi-1 transcript after the 
72hrs treatment of GUI siRNA compared negative siRNA and untransfected control 
astrocytoma cell line U87MG. 
Chapter-I Results 
primers, however all forty four glioma samples showed amplification with unmethylated DNA 
specific primers and their peak temperature was close to unmethylated specific primers melting 
peak for normal blood taken as positive control for unmethylated allele (red color peak, 79° 
temp) (Figure 23D) (Table 15). 
R.19 Cyclin D2 Promoter Methylation: 
With the help of methprimers software (http://www.urogene.orq/methprimer/index1.html) we 
found three putative CpG regions in the Cyclin D2 promoter region selected a CG rich region 
spanning -1624 to +6 bp (Gene Bank Accession No.447284).This sequence is 5' upstream of 
the Cyclin D2 transcriptional start site from the Cyclin D2 promoter region (Brooks et al., 1996). 
Then we designed the primers for these CpG rich regions and got primers for first and second 
CpG rich regions of Cyclin D2 promoter region. However, we were unable to get methylated 
primers for third CpG rich region of Cyclin D2 promoter region (Figure 24A-B). 
The first primer pairs amplified the first CpG rich region of Cyclin D2 promoter region spanning 
from -1550 to -1288 using MCA-Meth method. The second primer pairs of MSP-PCR amplified 
the region from -1616 to -1152, which is included both first and second CpG regions of Cyclin 
D2 promoter (Figure 24A-B). 
IVIedulloblastoma: Only 2 cell lines (PFSK-1 and SK-PN-DW) showed promoter methylation in 
the first CpG rich region of Cyclin D2 promoter by MCA-Meth method. In this case, their melting 
peak temperatures were close to positive control of methylated allele, in vitro methylated^ 
DNA(IMD) (green color peak, 81° temperature) (Figure 24D). Remaining 4 cell lines did not 
show methylation by this method and their melting peak temperatures were close to that of 
normal blood which was taken as positive control for unmethylated allele (Fig.24C).However 
with methylation specific PCR (MSP) 5 cell lines (PFSK-1, Daoy, TE671c2, D283 and SK-PN-
DW) showed promoter methylation in the second CpG rich region of Cyclin D2 promoter 
(Figure 24E) (Table 12). 
In medulloblastoma samples did not show methylation for all primary tumour samples in the 
first CpG rich promoter regions of Cyclin D2, using MCA-Meth method (Figure 24F and 24G), 
however with MSP 3/14 medulloblastoma samples showed hemi-methylation in the second 
CpG rich region of the Cyclin D2 promoter (Figure 24H) (Table 14). 
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Fig. 10 A-B. RT-PCR and Real Time RT-PCR comparative expression of GLI1 
transcripts in six medulloblastoma cell lines: (M1-TE671, M2-PFSK-1, M3-Daoy, 
M4-TE671C2, M5-D283, M6-SK-PN-DW). Fig. A. All six cell lines showed high 
expression compared to normal adult brain tissue. Transferin receptor (TFR) was 
taken for internal control of RNA. Fig. B. All six medulloblastoma cell lines showed 
high fold expression of GLI1 transcripted as compared to normal brain tissue. All 
data from Real Time RT-PCR were normalized by GAPDH 
Chapter-! Results 
Astrocytoma: In astrocytoma, three cell lines (U87MG, T98G and GOS-3), showed 
methylation in the first CpG rich promoter region of Cyclin D2, with IVICA-Meth method 
(Figure 25A-D) and remaining five cell lines did not show methylation in this region 
(Figure 25B-C). However with MSP, five cell lines (U87MG, SW1783, T98G, CCF-STTG-1 and 
GOS-3) showed partial methylation in the second CpG rich region of Cyclin D2 promoter 
(Figure 25E) (Table 13). 
In glioma, 10/44 primary tumour samples showed hypermethylation in the first CpG rich region 
of Cyclin D2 promoter region by MCA-Meth method (Figure 25G-I). In case of MSP 15/44 
glioma samples showed hypermethylation in the second CpG rich region of the Cyclin D2 
promoter (Figure 25J-N) (Table 15). 
R.20.Reversal in expression of Cyclin D2 and PTCH1 gene after the treatment of 5-aza-2'-
dexoyctidine and TSA treatement of cells 
On treating cell lines with demethylating agent 5'Aza-2-deoxycytidine and HDAC inhibitor 
Trichostatin A, we observed an onset of expression of Cyclin D2 transcript as observed by RT-
PCR and Real Time RT-PCR analysis in all five previously unexpressing cell lines (A172, 
SW1783, T98G,CCF-STTG-1 and GOS-3) (Figure 26A-B).This increase in expression value 
was statistically significant in all cell-lines (p<0.01) (Figure 260). However, this was not true in 
the case of A172, which initially did not show methylation/partial methylation at the two CpG 
sites (Figure 26A-B) in spite of no expression of Cyclin D2 transcript. 5'Aza-2'-dC and TSA 
treatment induced the expression of Cyclin D2 indicating that the 3 '^' CpG site which we were 
unable to analyze may play an important role in regulating Cyclin D2 expression in this cell-line. 
Reversal of Cyclin D2 promoter methylation melting curve after treatment with 
demethylating drug 5-aza-2'-dexoycytidine and histone deacetylating agent TSA 
We also compared the melting curve (MSP-Meth) of Cyclin D2 promoter region before and 
after demethylating agent and TSA treatment by Real Time MSP and found shifting in the melt 
curve from methylated region, which has temperature 81° degree to unmethylated melt curve, 
which gives temperature 78" degree. (Figure 27A and 278). 
74 
Astrocytoma cell Vines 
Fig. 10C-D 
C. RT-PCR 
Mr L B G1 G2 G3 04 05 06 07 08 NTC 
L B 01 02 03 04 Mr 05 06 07 08 NTC 
300 bo^l i 1 J I I l - i I l i ^ i ^ TFR 
D. Real Time RT«PCR 
Fig. 10 C-D. RT-PCR and Real Time RT-PCR expression of GUI transcript in 8 
astrocytic cell lines (G1-87MQ, G2-A172, G3-LN405, G4-SW1783, G5-T98G, 
G6-SW1088, G7-CCF-STTGG8-GOS-3). Fig. C. GLI1 expression was comparativly 
high in all eight cell lines as compared to normal adult brain tissue, Transferin 
receptor (TFR) was taken as internal control of RNA Fig. D. All eight astrocytoma cell 
lines showed high GLI1 expression compared to normal brain tissue (p=0.1411) 
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Fig. 11 A-B. RT-PCR and qRT-PCR comparative expression of PTCH1 transcript 
in 6 medulloblastoma cell lines (M1-TE671, M2-PFSK-1, M3-Daoy, M4-TE671c2, 
M5-D283 and M6-SK-PN-DW), Fig. A. Three cell lines M1, M2 and M3 showed high 
PTCH1 transcript expression as compared to normal adult brain (B), NTC stand for 
non-template control, Transferin receptor (TFR) taken as internal control of RNA. 
Fig. B, Three cell lines showed high fold expression as compared to normal brain 
tissue showed (p=0.0487) 
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Fig. 11 C-D. RT-PCR and Real Time RT-PCR comparative expression of PTCH1 
in astrocytoma tumor cell lines (G1-U87MG, G2-A172, G3-LN405, G4-SW1783, 
G5-T98G, G6-SW1088, G7-CCF-STTG-1 and GOS-3) Fig. C. Four cell lines (05, 
G6, G7 and G8) showed high expression of PTCH1 trancript as compared to nonnal 
adult brain. L, B and NTC stands for lung, brain and no-tennplate control respectively. 
Transferin receptor (TFR) expression consider as internal control. Fig. D. Only four 
cell lines showed high fold expression PTCH1 transcript compared to normal brain 
tissue. All data were normalized by GAPDH 
Medulloblastoma cell lines 
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Fig. 12 A-B RT-PCR and Real Time RT-PCR comparative expression of Cyclin 
D2 transcript expression in six medulloblastoma cell lines (M1-TE671, I\/I2-
PFSK-1, M3-Daoy, M4-TE671c2, M5-D283 and M6-SK-PN-DW. Fig. A. Most of the 
cell lines except (SK-PN-DW) showed high fold expression of Cyclin D2 compared to 
normal adult brainTransferin receptor (TFR) is taken as a internal control expression 
of RNA in all six cell lines. Fig. B. All six medulloblastoma cell lines showed high fold 
expression of cyclin D2 expression compared to normal brain tissue (p=0,0939). All 
data of Real Time RT-PCR were normalized by GAPDH . 
Fig. 12 C-D 
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Fig. 12 C-D. RT-PCR and Real Time RT-PCR of Cyclin D2 transcript 
expression in 8 astrocytoma cell Lines (G1-U87MG, G2-A172, G3-LN405, G4-
SW1783, G5-T98G, G6-SW1088, G7-CCF-STTG-1 and G8-Cos-3). Fig.C. All cell 
lines showed either low or no expression of Cyclin D2 as compared to normal adult 
brain tissue. L, B and NTC stand for Lung.brain and Non-template control 
respectively. Transferin receptor (TFR) consider as internal control. Fig. D. All cell 
lines either showed low or no expression of Cyclin D2 compared to normal brain 
tissue (p<0.0001). All data from Real Time RT-PCR were normalized by GAPDH 
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Fig. 13 A-B RT-PCR and Real Time RT-PCR comparative expression of 
Plakoglobin in 6 medulloblastoma cell lines. (M1-TE671, M2-PFSK-2, M3-Daoy, 
M4.TE671C2, IVI5-D283 and M6-SK-PN-DW). Fig. A. All six cell lines showed high 
expression of Plakoglobin as compared to normal adult brain tissue. L, B and NIC 
stands for lung, brain and non template control. Transferin receptor (TFR) taken as 
internal control. Fig. B. Similarly all six medulloblastoma cell lines showed high fold of 
Plakoglobin expression compared to normal brain tissue. All data from Real Time RT-
PCR were normalized by GAPDH 
Astrocytoma cell lines 
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Fig. 13 C-D. RT-PCR and Real Time RT-PCR comparative expression of 
Piakoglobin showed by 8 astrocytoma cell lines (G1-U87MG, G2-A172, 
G3-LN405, G4-SW1783, G5-T98G, G6-SW1088 GZ-CCF-STTG-I and G8-GOS-3). 
Fig. C. Four cell lines (G1, G3, G4 and G5) showed low expression of Piakoglobin 
compared to normal adult brain tissue. L, B and NTC stands for lung, brain and 
no-template control respectively. Transferin receptor (TFR) taken as internal control. 
Fig. D. Five cell lines showed low expression of Piakoglobin compared to normal 
brain tissue (p<0.0001). All data from Real Time RT-PCR were nomnalized by 
GAPDH 
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Fig. 14 A-B. Real Time RT-PCR comparative expression of PAX6 in 
medulloblastoma cell lines and astrocytoma cell lines. Fig. A. Most of the 
cell lines of medulloblastoma except (TE671 and TE671c2)showed low 
expression compared to normal brain tissue. Fig. B. Most of the cell lines of 
astrocytoma except (U87MG and LN405) showed low expression compared to 
normal brain tissue (p=0.0070). All expression results have been equilibrated 
with GAPDH 
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Fig. 15 A-B. Real Time RT-PCR comparative expression of NKX2.2 transcript in 
medulloblastoma and astrocytoma cell lines. Fig. A. Most of the cell lines of 
medulloblastoma except (SK-PN-DW) showed either no or low expression of NKX2.2. 
compared to normal brain tissue (p=0.0501). Fig. B. Most of astrocytic cell lines 
showed either low or no expression of NKX2.2 compared to normal brain tissue 
(p<0.0001) 
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Fig. 16 A-B. Real Time RT-PCR comparative expression of Bmi-1 in 
medulloblastoma and astrocytic cell lines. Fig.A. All 6 medulloblastoma cell lines 
showed low expression of Bmi compared to normal brain tissue (p<0.001). Fig. B. 
IVIost of the astrocytic cell lines except (U87MG and A172) showed low expression 
compared to normal brain tissue (p=0.0232) 
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Fig. 17A. Protein expression of GLI1 shown by astrocytoma cell lines. 
Fig. A. First two cell lines (G1:U87MG and G2:A172) not shown very distinct band 
but remaining Cell lines (G3:LN405, G4:SW1783, G5:T98G, G6:SW1088, G7:CCF-
STTG-1 and G8:GOS-3) showed distinct band of GLI1 
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Fig. 17 8. Protein expression of Cyclin D2 in eight astrocytoma cell lines. 
G1-U87IVIG, G2-A172, G3-LN405, G4.SW1783, G5-T98G, G6-SW1088, G7.CCF-
STTG-1 and G8-GOS-3. Fig. B. Most of the cell lines showed Cyclin D2 band 
except (G4 cell lines). The remaining cell lines also showed Cyclin D2 protein 
expression.Amounts of protein loaded for western blots have been same for Cyclin 
D2 and GAPDH expression 
Real Time RT-PCR of Glioma samples 
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Fig. 18 A-D. Real Time RT-PCR comparative expression of GLI1 and PTCH1 
transcripts in medulloblastoma and glioma samples. Fig.18A-B. Most of the primary 
tumours showed high fold GLI1 transcript expression but PTCH1 expression is low in 
most of the medulloblastoma (Fig. C) and glioma samples (Fig. D). 
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Fig. 19A-D. Real Time RT-PCR comparative expression of Cyclin D2 and 
Plakoglobin transcripts in medulloblastoma and glioma samples. Fig. A. Most of the 
medulloblastoma primary tumours showed either high fold or equal expression of Cyclin 
D2 compared to normal brain tissue. Fig. B. Among glioma samples 52% showed high 
fold and 48% showed low expression compared to normal brain tissue. Fig. C-D. Most of 
the medulloblastoma samples showed high fold and 77% of the glioma samples showed 
low expression of Plakoglobin compared to normal brain tissue. All expression results 
have been equilibrated with GAPDH 
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Fig. 20 A-E. Real Time RT-PCR comparative expression of PAX6,NKX2.2 and Bmi 
transcripts in medulloblastoma and glioma samples.Fig.AMost of the medulloblastoma 
primary tumours showed either high fold or equal expression of PAX6 compared to normal 
brain tissue (p=0.013).Fig.20B.Among glioma samples most of them showed low expression of 
PAX6 compared compared to normal brain tissue.Fig. 20 C.AII of the medulloblastoma 
samples showed either no or low expression of NKX2.2(p<0.001) and 70% of the glioma 
samples showed low expression of NKX2.2 compared to normal brain tissue (Fig. 20 D). 
Fig. 20 E.Few samples showed high fold expression of Bmi-1 compared to normal brain tissue. 
All expression results have been equilibrated with house keeping gene GAPDH 
Western blots 
Fig. 21 A-C 
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Fig. 21 A.Astrocytoma samples 1-6 showed Gli1 Protein Expression.C+ is HeLa Cell line 
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Fig. 21 B-C. GLI1 protein expressioned shown by glioma samples. Fig. B. 
Showed GLI1 protein expression in samples (7, 9 ,11, 20 and 21). Fig. C.GLI1 
protein expression shown by glioma samples (22, 23, 26-28). C+ : HeLa Cell 
lysate was considered as positive control. 
PTCH1 Promoter Methylation analysis by MCA-MSP in medulloblastoma cell lines 
TE671 cell line 
Fig.22A.D 
A. Methylated DNA Specific Primers B. Unmetliylated DNA Specific Primers 
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Fig. 22 A-D. Promoter Methylation analysis of PTCH1 gene by MCA-MSP method in 
medulloblastoma cell lines. Fig. A-C. In this case specific primers for methylated DNA 
amplified methylated/partial methylated cell line/sample (blue color peak,83° temp, TE671 
Cell line, no methylation in Daoy cell line). Here in vitro methylated DNA(IMD) was taken as 
positive control for methylated allele and its amplification temp (green color peak, 83° 
temp). Fig. B-D. In case of specific primers for unmethylated DNA amplified partial 
methylated/ unmethylated cell line/sample (blue color peak, 80° temp, TE671 and Daoy cell 
lines), nornial blood was taken as positive control for unmethylated allele (red color peak, 
80° temp), there was no amplification of IMD (green color) by unmethylated DNA specific 
primer. No template control did not give any amplification by both primers (black color) 
PTCH1 Promoter Methylation analysis by MCA-MSP in medulloblastoma samples 
p3 
Fig.22E-H 
E. Methylated DNA Specific Primers F. Unmethylated DNA Specific Primers 
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Fig. 22 E-H. Promoter Methylation analysis of PTCH1 gene by MCA-MSP method in 
medulloblastoma samples. Fig. E-G. In this case specific primers for methylated DNA 
amplified methylated/partial methylated cell line/sample (blue color peak, 83° temp 
showed by sample p7, no methylation In sample p3). Here ;'n Viro methylated DNA (IMD) 
was taken as positive control for methylated allele and Its amplification temp (green color 
peak, 83° temp). Fig. F-H. In case of specific primers for unmethylated DNA amplified 
partial methylated/ unmethylated cell line/sample (blue color peak, 80° temp showed by 
samples p3 and p7), nomnal blood was taken as positive control for unmethylated allele 
(red color peak,80° temp), there was no amplification of IMD (green color) by 
unmethylated DNA specific primer. No template control did not give any amplification by 
both primers (black color) 
PTCH1 Promoter Methylation study by Melting Curve Analysis 
MSP (MCA-MSP) in astrocytoma cell lines 
U87MG cell line 
Fig.23A-D 
A. Methylated DNA Specific Primers B. Unmethylated DNA Specific Primers 
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Fig. 23 A-D. Promoter Methylation analysis of PTCH1 gene by MCA-MSP method in 
astrocytoma cell lines. Fig. A-C. In this case specific primers for methylated DNA 
amplified methylated/partial methylated cell line/sample (blue color peak, 83° temp 
showed by cell line OOF, no methylation in U87MG Cell line). Here /n w'fro methylated 
DNA(IMD) was taken as positive control for methylated allele and its amplification temp 
(green color peak, 83° temp). Fig. B-D. In case of specific primers for unmethylated 
DNA amplified partial methylated/unmethylated cell line/sample (blue color peak, 80° 
temp showed by Cell lines U87MG and CCF), nonnal blood was taken as positive control 
for unmethylated allele (red color peak, 80° temp), there was no amplification of IMD 
(green color) by unmethylated DNA specific primer, No template control did not give any 
amplification by both primers (black color) 
Cyclin D2 promoter sequences 
Fig.24A 
-1624 
GAGCTCGACX:CACaCCATGCCCGCTGCACGTGCCAGCTTGCGCAGCACATCAGGGCGCTOGTCT 
CTCCCCTTCCTCCTGGAGTGA -1540 
A AT AC ACQ A A4 GGGCCCGGTGGGGGTGGGGGGTGA CGGGAGGAA GGA GGTG 
A A GAAA CGCCA CCA GA TCGTA TCTCCTGTAAA GA CA GCC-1450 
TTGA CTCAA GGA TGCGTTA GA GCA CGTGTCA GGGCCGA CCGTGCTGGCGGA C 
TTCA CCGCA GTCGGCTCCCA GGGA GAAA GCCTGGCA GA-1360 
GTGA GGCGCGAAA CCCGA GGGTCCCCGA GGA TGCGGGCGAA GGA CCCA GCG 
TGGA GGCCTCA TGCCTCCGGGGAAAGGAAGGGGTGGIGG-1270 
TGTTTGCGCAGGGGGAGCGAGGGGGAGCCGGACCTAATCCC7C4 CrCCCCCC 
CTCCCCCTCCCGGGCCA TTTCCTA CAAACCTGCA TCGG-IISO 
TGTGGCCA CGCTCA GCCCA GA CA CCTCGGGCGGCTTGTCA GCA GA TGCA GGG 
GCGAGGAAGCGGGTTTTTCCTGCGTGGCCGCTGGGCGG-1090 
GGGA A CCGCTGGGA GCCCTGCCCCCGGCCTGCGGCGGCCCTA GA CGCTGCA C 
CGCGTCGCCCCA CGGGCCCCGAA GA GCCCCCA GAAA CA-IOOO 
CGUCCZTTCTGCTCGAGGATCACATTCTATCCCTCCAGAGAAGCACCCCCCT 
TCCTTCCTAATACCCACCTCTCCCTCCCTCTTCTTCC-910 
TCTGCACACACTCTGCAGGGGGGGGCAGAAGGGACGTTGTTCTGGTCCCTTT 
AATCGGGGCTTTCGAAACAGCTTCGAAGTTATCAGGAA-820 
CACAGACTTCAGGGACATGACCTTTATCTCTGGGTATGCGAGGTTGCTATTTT 
CTAAAATCACCCCCTCCCTTATTTTTCACTTAAGGGA-730 
CCTATTTCTAAATTGTCTGAGGTCACCCCATCTTCAGATAATCTACCCTACATT 
CCTGGATCTTAAATACAAGGGCAGGAGGATTAGGAT-640 
CCGTTTTGAAGAAGCCAAAGTTGGAGGGTCGTATTTTGGCGTGCTACACCTA 
AGAATGAGTGAAATTAGAGGGCAGAAATAGGAGTCGG-550 
TAGTTTTTTGTGGGTTGCCTGTCCGGGGCCCCTGGCATGCAGGCTGGATGGAG 
GGAGAGGGGTGGGGGGTGGCGGGGGACCGCGTTTGAA-460 
GTTGGGTCGGGCCAGCTGCTGTTCTCCTTAATAACGAGAGGGGAAAAGGAGG 
GAGGGAGGGAGAGATTGAAAGGAGGAGGGGAGGACCGG-370 
GAGGGGAGGAAAGGGGAGGAGGAACCAGAGCGGGGAGGCGCGGGGAGAGG 
GAGGAGAGCTAACTGCCCAGCCAGCr7'C?CCrC4CCC;C7TC-2«0 
A GA GCGGA GAA GA GCGA GCA GGGGA GA GCG A GA CCA GTTTTAA GGGGA GG 
A CCGGTGCGA GTGA GGCA GCCCCGA GGCTCTGCTCGCCCA-190 
CCA CCCAA TCCTCGCCTCCCTTCTGCTCCA CCTTCTCTCTCTGCCCTCA CCTCT 
CCCCCGAAAA CCCCCTA TTTA GCC AAA GGAA GGKGG-100 
TCAGGGGAACGCTCTCCCCTCCCCTTCCAAAAAACAAAAACAGAAAAACCCT 
TTTCCAGGCCGGGG AAAGC AGG AGGGAGAGGGGCCGCC+10 
GGGCTGGCCATGGAG -i-
FirstCpG-1550 to-1288 (262 bp) 
Second CpG -1230 to -982 (248 bp) 
Third CpG -296 to -104 (192 bp) 32 bp consensus sequences. 
Fig. 24B 
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Fig. 24 A-B : Localization of CpG islands and GLI1 binding site in Cyclin D2 
promoter region 
Cyclin D2 Promoter Methylation study by Melting Curve 
Analysis-Meth (MCA-Meth) 
Fig.24C.E Medulloblastoma cell lines 
C. TE671 D. PFSK-1 
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Figures.24C-D. Cyclin D2 Promoter methylation study by MCA-IVIeth in 
medulloblastoma cell lines. Fig.C-D. In this case used single pair primers designed 
with no CpG in its sequence.These primers amplify both unmethylated and methylated 
sequences and melting peak temperature varies with the percentage of methylation in 
the given squenecs.blood used as positive control for unmethylated DNA region (red 
peak, 77° temp) (Fig.C and D), in vitro methylated DNA (IMD) used as positive control 
for methylated DNA region (green color peak, 80.5°temp) (Fig.C and D), umethylated 
DNA region in cell line/sample (blue color peak, 77.''temp, cell line TE671) (Fig.C) and 
methylated DNA region in cell line/sample (blue color peaks, SCS^temp ,Cell line 
PFSK-1) (Fig.D). No template control did not give any amplification by this primers 
(black color) 
Methylation Specific PCR 
E. Medulloblastoma Cell lines 
TE671 PFSK-1 Daoy TE671c2 D283 SK-PN-DW 
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Figure.24E. Cyclin D2 Promoter analysis of six medulloblastoma cell lines by MSP-
PCR. TE671(M), PFSK1 (M),Daoy (U/M), TE671c2 (U/M), D283 (U/M) and SK-PN-DW(M). 
U:Unmethylated; M:Methylated; U/M: Partial/Hemimethylated 
Cyclin D2 Promoter Methylation study by Melting Curve Analysis-Meth 
(MCA-Meth) in medulloblastoma samples 
24. F-H Medulloblastoma samples 
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Flg.24 F-G. Cyclin D2 Promoter methylation study by MCA-Meth in medulloblastoma 
primary samples. Fig.24F-G. In this case used single pair primers designed with no CpG 
in its sequence.These primers amplify both unmethylated and methylated sequences and 
melting peak temperature varies with the percentage of methylation in the given squenecs 
blood used as positive control for unmethylated DNA region (red peak, 77° temp) (Fig.F 
and G), /n y'iro methylated DNA (IMD) used as positive control for methylated DNA region 
(green color peak, Srtemp) (Fig.F and G),umethylated DNA region in cell line/sample 
(blue color peak, 77.''temp, Sample, p13) (Fig.F) and methylated DNA region in cell 
line/sample (blue color peaks, 80.5°temp, Sample p20) (Fig.G). No template control did 
not give any amplification by this primers(black color). 
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Fig. 24 H. Cyclin D2 Promoter analysis of medulloblastoma primary tumor samples 
by MSP-PCR. p3(U), p4(U/M), p10(U), p11 (U/M), p13(U/M), p14(U), p17(M) and 
p20(U/M). U:Unmethylated; M:Methylated; U/M: Partial/Hemimethylated 
Cyclin D2 Promoter Methylation study by Melting Curve Analysis-Meth (MCA-Meth) 
in astrocytoma cell lines 
Fig.25A.E 
A. U87MG 
Astrocytoma Cell lines 
B. A172 
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Fig. 25A-D. Cyclin D2 Promoter methylation study by IVICA-Meth in astrocytoma cell 
lines. Blood used as positive control for unmethylated DNA region (red peak, 77°temp) 
(Fig. A-D), /n Wfro methylated DNA (IMD) used as positive control for methylated DNA 
region (green color peak, 81°temp) (Fig. A-D),umethylated DNA region in cell 
line/sample (blue color peak, 77.°temp, Cell lines, A172 and CCF-STTG-1) (Fig. B-C) 
and methylated DNA region in cell line/sample (blue color peaks, 79° and Srtemp, Cell 
lines, U87MG and GOS-3) (Fig. A-D). No template control did not give any amplification 
by this primers (black color) 
U87 A172 
Methylation Specific PCR 
Astrocytoma cell lines 
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Fig. 25 E. Cyclin D2 Promoter analysis of eight astrocytoma cell lines by MSP-PCR. 
U87MG(U/M), A172(U), LN405 (U),SW1783(U/M), T98G(M), SW1088(U), CCF-STTG-
1(M) and GOS-3 (U/M). U:Unmethylated; M:Methylated; U/M:Partial/Hemimethylated 
-280bp 
-220bp 
Cyclin D2 Promoter Methylation study by Melting Curve Analysis-Meth 
(MCA-Meth) in glioma samples 
Glioma samples 
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14 
1, 
7 
I 
f ^It^ 
E iV' 
70 
MM PsA Chat. C|ic*i 02 Bit FmHi Q 
/ \ . 
1 V 
. , 
5 t 
\ 
\ 
'v_ 
, , , , 
0 
l l i c w J 
6 
1 AJ.Mfr I 
0 1 
i l pMkOiH t StinmsihandUflmethPifnotOTlZ-26 SnOSnpd 
H. 19 22 
7 
:iO(l 
0 
X/ 
, , , 
3 
Me«PB*Cha1 ;'inrne(hmdUnnettiPnnRGT12'X 2511 QS.opd 
/ 2 y 
4 
/ ; 
'' / 
6 
' 
A 
\\ \\ 
9 
\ \ \ 
\ 
\ 
' 
0 
|\ 
-^ . 
e « ; s $ 0 
^ T1 (^  
" 
^""TT' 
•^ Ik 
v// 
7 D 
/ ? ^ 
/ 
, 
^ 
HdPMkChM Sttiom()hvidUmi«iPiing(>SI12'2S.»11IEi«d 
^ 
^ 
1 1 • 
4 
/ 
>^ /A 
^ 
\ 1 
I / 
i/'l \ 
\ \ 
M 
fe 
""x 
\ 
\ 
\ 
0 
X 
^ G 
. . 1 
t 3 0 
Fig. 25F-I. Cyclin D2 Promoter methylation study by MCA-Meth in astrocytoma cell 
lines. Blood used as positive control for unmethylated DNA region (red peal<, 77°temp) 
(Fig. F-l), /n wfro methylated DNA (IIVID) used as positive control for methylated DNA 
region (green color peak.Srtemp) (Fig. F-I),umethylated DNA region in cell line/sample 
(blue color peak, 77."temp, glioma sample, 4) (Fig. F) and methylated DNA region in cell 
line/sample (blue color peaks,79° and 81° temp, glioma samples, 14, 19 and 22) 
(Fig. G-l). No template control did not give any amplification by this primers (black color). 
J. Methylation Specific PCR 
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Fig. 25 J. Cyclin D2 Promoter analysis of glioma samples by MSP-PCR. 3(U/M), 4(ND), 
5(U),6(U/M), 7(U), 8(U/M), 9(U) and 10(U/M). U:Unmethylated; M:Methylated; U/M: 
Partial/Hemimethylated; nd:Not determined. 
Cyclin D2 Promoter analysis of glioma samples by MSP-PCR 
Fig.25K-N 
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Fig. 25 K-N. Cyclin D2 Promoter analysis of glioma samples by MSP-PCR. Fig. 25 K. 
11(ND), 12(U), 13(M), 14(U), 15(U/M), 16(U/M), 17(ND) 18(U/M) and 20(U). Fig.L 
21(U/M), 22(U), 23(U), 24(U/M), 25(U), 26(U), 29(U), 30(U/M) and 31(U/M). Fig. M. 32(U), 
34(U), 35(U), 36(U), 41 (U), 43(U/M), 44(U), 45(U), 46(U) Fig. N.19(U), 27(U), 28(ND), 
47(U), 48(U/M), 49(U/M), 50(U) 51(U/M) and 52(U) U:Unmethylated; M:Methylated; U/M: 
Partial/Hemimethylated; nd:Not determined 
Table.12. Cyclin D2 and PTCH1 expression and Promoter methylation status in cell lines 
Cell lines 
TE671 
PFSK-1 
Daoy 
TE671c2 
D283 
SK-PN-DW 
Cyclin 
D2 
express! 
on 
++ 
++ 
++ 
++ 
++ 
+ 
Cyclin D2 
promoter 
Hypermeth 
ylation by 
MCA-Meth 
U 
M 
U 
U 
U 
U+M 
Cyclin D2 
Hypermethy 
lation by 
MSP 
M 
M 
U+M 
U+M 
U+M 
M 
Cyclin D2 
Hypermet 
hylation 
by both 
methods 
V 
V 
No Hyper 
Methylation 
in Cyclin D2 
Promoter 
PTCH1 
Expressio 
n in 
medullobi 
astoma 
cell lines 
++ 
++ 
++ 
+ 
+ 
+ 
PTCm promoter 
Hypermethylation 
by MCA-MSP 
method 
U 
U 
u 
u 
U+M 
U 
+: normal expression, ++: High expression, U: unmethylation U: IVI-hemi/partial methylation, M: 
complete methylation, V: Yes 
Table.lS.CycIin D2 and PTCHl expression and Promoter hypermethylation 
analysis in astrocytoma cell lines 
Astrocytoma 
Cell lines 
U87MG 
A172 
LN405 
SW1783 
T98G 
SW1088 
CCF-STTG-1 
GOS-3 
Cyclln D2 
express! 
on 
+ 
-
+ 
-
-
+ 
-
-
Cyclln D2 
Expression after 
5'aza+TSA 
+ 
+ 
+ 
+ 
++ 
+ 
+ 
++ 
Cyclln D2 
promoter 
hypermethylatio 
n analysis by 
MCA- MSP 
V 
< 
V 
V 
V 
Cyclln D2 
promoter 
hypermethylat 
ion 
Analysis by 
MCA-Meth 
V 
V 
V 
Cyclln D2 
Hypermethylat 
Ion by both 
techniques 
V 
V 
V 
No 
Hypermethylat 
Ion in Cyclln 
D2 promoter 
V 
V 
V 
PTCH1 
expressi 
on in 
glioma 
cell lines 
+/-
-
+ 
-
++ 
++ 
++ 
++ 
PTCH1 
promoter 
hypermethyl 
ation by 
MCA-MSP 
V 
-: No. expression +/-: Low expression +: Normal expression ++: High expression V: Yes 
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Table.15. Cyclin D2 and PTCH1 gene expression and promoter methylation analysis in astrocytic tumor 
samples 
Glioma 
sample Grade 
And Sample 
ID 
GBM(3) 
Alll(4) 
GBM(5) 
GBM(6) 
Alll(7) 
GBM(8) 
GBM(9) 
Alll(10) 
GBM(11) 
GBM(12) 
GBM(13) 
Alll(14) 
GBM(15) 
Alll(16j 
GBM(17) 
GBM(18) 
Alll(19) 
All(20) 
Alll(21) 
GBM(22) 
GBM(23) 
GBM(24) 
Al(25) 
GBM(26) 
GBM(27) 
GBM(28) 
GBM(29) 
GBM(30) 
GBM(31) 
GBM(32) 
Al(34) 
Alll(35) 
GBM(36) 
GBM(41) 
GBM(43) 
GBM(44) 
GBM(45) 
GBM(46) 
GBM(47) 
GBM(48) 
GBM(49) 
All(50) 
GBM(51) 
GBM(52) 
Expression of 
Cyclin D2 in 
Samples 
-
++ 
-
-
+ 
-
+ 
-
++ 
+ 
-
++ 
- M -
• 
• 
+ 
+ 
-
-
-
-
nd 
nd 
Nd 
nd 
nd 
+ 
nd 
nd 
nd 
nd 
nd 
nd 
+ 
nd 
nd 
nd 
nd 
nd 
nd 
++ 
-
++ 
Methylation by 
MSP in Cyclin 
D2 promoter 
V 
V 
V 
V 
V 
A/ 
V 
V 
V 
V 
V 
V 
V 
V 
V 
Methylation by 
Melting curve in 
Cyclin D2 
promoter 
^ 
V 
V 
V 
V 
V 
V 
V 
^ | • 
V 
Methylation by both 
techniques in Cyclin 
D2 promoter 
V 
V 
V 
V 
No 
hypermethylation 
in Cyclin D2 
promoter 
V 
V 
-1 
V 
V 
V 
V 
V 
V 
V 
V 
V 
V 
V 
V 
V 
V 
V 
V 
V 
V 
V 
V 
Expression 
ofPTCHI 
transcript In 
tumor 
samples 
-
+ 
V-
• • / -
^-
++ 
-
*i-
ty-
+ 
+ 
-
M-
^-
++ 
+ 
+ 
+ 
-
-
+ 
+ 
nd 
nd 
nd 
nd 
nd 
+ 
nd 
nd 
nd 
nd 
nd 
nd 
-
nd 
nd 
nd 
nd 
nd 
nd 
-
-
+ 
Methylation of 
PTCH1 promoter 
by MCA-Meth 
(Samples ID) 
V 
V 
V 
: no expression + = normal expression;++=higti expression; V:Yes nd : not determined 
Table. 15 Promoter methylation and expression correlation among primary glial tumors of Cyclin D2 and 
PTCH1 genes. In tills table we tiave mentioned tiiat 93% (13/14) of samples not sfiowed the Cyclin D2 expression 
showed methylation in the Cyclin D2 promoter region. In PTCH1 gene 67% (2/3) of the samples showed relation with 
no expression of PTCH1 transcript expression and promoter methylation. 
Reversal in expression of Cyclin D2 after thie treatment of 5Aza-2'-deoxycytosine 
and TSA in astrocytoma cell lines 
Fig.26A-C 
A. 
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Fig. 26 A-C. Reversal of Cyclin D2 expression after the treatment of demethylating 
agent and TSA estimated by RT-PCR and Real Time RT-PCR. Fig. A. Reversal of 
expression Cyclin D2 transcript after the treatment of demethylating agent and TSA by 
RT-PCR,Fig. B. Comparative increased fold in expression of Cyclin D2 after the 
treatment of demethylating agent 5Aza and TSA. Fig. C.Some of astrocytoma cell lines 
even show >300 fold increased in Cyclin D2 expression (p=0.0014) 
Comparative Cyclin D2 Promoter Methylation study by Melting Curve Anaiysis-iVletli 
(MCA-IVIeth) after the treatment of 5Aza and TSA in astrocytoma cell lines 
Astrocytic cell lines 
Fig.27A-B 
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Fig. 27 A-B. Comparaive Cyclin D2 Promoter methylation analysis by MCA-Meth 
after the treatment of 5Aza and TSA in astrocytoma cell lines: Here in vitro 
methylated DNA (IMD) was taken as positive control of methylated promoter region 
(green color peak:8r temp), normal blood was taken as positive control for 
unmethylated promoter region (red color peak:77.5° temp) methylated samples before 
the treatment of demethylating agent and TSA (blue color peak:80° temp) (Fig. A-B), 
and methylated samples after the treatment of demethylating agent and TSA (violet 
color peakJS.S" temp). Non- template control (black color line) did not give any 
amplification. 
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Chapter-I Discussion 
siRNA transfection, gene expression and methylation studies of GLI1, PTCH1, Cyclin D2, 
Plakoglobin, PAX6, NKX2.2 and Bmi-1 
D.I Expression of GLI1 transcript after transfection: After GLI1 siRNA transfection, there 
was distinct decrease in >60% in the expression of GLI1 transcript in the medulloblastoma and 
astrocytoma cell lines namely Daoy and U87MG respectively. This decreased expression of 
GLI1 compared to universal negative siRNA and untransfected cell-lines indicate the efficient 
knockdown of GLI1 mRNAbyGLM siRNA. 
We further checked downstream expressions of other target genes, which are regulated by 
GLI1 in these tumour cell lines. 
D.2 Expression of PTCH1 transcription after transfection: From the same source of GLI1 
knockdown cDNA, there was distinct loss in expression of PTCH1 transcript in both the tumour 
cell lines i.e., Daoy and U87MG respectively compared to negative siRNA and untransfected 
cell lines. This result further supports the belief that this PTCH1 is a downstream target of GLI1 
and in turn is upregulated by GLI1 (Zedan, W 2001). Thus we may say that sonic hedgehog not 
only plays a very important role in medulloblastoma tumour development, but it is also 
important in case of astrocytoma (Agren et ai, 2004; Wetmore e^  a/., 2005). 
D.3 Expression of Cyclin D2 transcription after transfection: 
It has been reported that GLI1 also regulates cell cycle genes and its immediate target is Cyclin 
D2.This Cyclin D2 gene has binding motif consensus sequence CACCACCA in the 5' promoter 
region for interaction with GLM.This interaction up-regulates Cyclin D2 expression in GLI1 
transfected epithelial cells, as Cyclin D2 regulates the G1/S phase of the cell cycle and 
upregulation of this gene by GLI1 further leads to continuation of cell cycle (Brooks et al., 1996; 
Yoon et ai, 2002). After attempting GUI knockdown, there was distinct decrease in 
expression of Cyclin D2 transcript in the medulloblastoma cell line Daoy; however astrocytic 
cell line, U87MG showed 2.5 fold high expression of Cyclin D2 transcript compared to universal 
negative siRNA treated and untransfected treated cell lines. This decrease in Cyclin D2 
expression in GLI1 knockdown medulloblastoma cell line indicates the GUI up-regulation of 
this gene in medulloblastoma and hence it was akin to previous report. However, increase in 
expression of Cyclin D2 in GUI knockdown astrocytoma cell lines reveals the possibility of 
totally reverse mechanism of regulation in astrocytoma. Moreover, it was also reported that 
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sonic hedgehog signaling showed regional differential gene expression pattern (Nakagawa, ef 
a/., 1996) and because of different origin of site of these tumours, it could be possible to see 
different patterns of regulation by GLI1 in its downstream target genes. 
D.4 Expression of Plakoglobin (y catenin) transcription after transfection: Plakoglobin, a 
cytoplasmic protein, binds with cadherins which (cadherin) furher links to cytoplasmic actin 
bundles. High expression of Plakoglobin showed reduced epidermal growth and caused 
apoptosis[289] (Charpentier et ai, 2000). GLI1 knocked down medulloblastoma cell line Daoy 
showed decrease in expression of plakoglobin transcript while GLI1 knocked down 
astrocytoma cell line U87MG showed 3-fold increased expression of plakoglobin transcript 
compared to universal negative siRNA (U neg siRNA) as well as untransfected cell lines. Here 
astrocytoma cell lines support the previous finding, which has showed that Plakoglobin is an 
immediate downstream target gene of GLI1 and has a consensus motif of GACCACCAA in the 
5' promoter region for the interaction with GLI1 protein. 
The GLI1 protein down-regulates Plakoglobin in GLI1 transfected epithelial cell. However, GLI1 
knockdown medulloblastoma ceil line, Daoy showed low expression of Plakoglobin which was 
in contrast to the astrocytoma cell line results or the previous report of GLI1 on Plakoglobin 
regulation in transformed epithelial cell line. The differential regulation of GLI1 on its 
downstream target genes further suggest that Shh signaling pathway varies from its origin of 
tissue and reveals its multifaceted character. 
D.5 Expression of PAX6 transcription after transfection: PAX6 is a homeobox domain gene 
and is included under transcriptional factor I (TF.I) during embryonic ventral patterning; this 
PAX6 is downregulated by Shh signaling, as it is a putative downstream target gene of GLI1. 
After knockdown of medulloblastoma Daoy cell line, its expression gets decreased and 
Knockdown of astrocytoma cell line U87MG shows 1.5 fold increases in its expression as 
compared to universal negative siRNA and untransfected cell lines. Increase in the expression 
of PAX6 in astrocytoma cell line is akin to previous report, which suggests downregulation by 
GUI ; however, downregulation in medulloblastoma opens a new understanding of sonic 
hedgehog differential regulation of gene expression at tissue level. 
D.6 Expression of NKX2.2 transcription after transfection: 
The NKX2.2 is a homeobox gene and is included among transcription factor II (TF.II). It is also 
putative immediate target gene of GLI1 factor and shows upregulation during early embryonic 
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ventral patterning (Fuccillo et al., 2006;Vokes et a/.,2007). After GLI1 knockdown in 
medulloblastoma cell line, Daoy PAX6 transcript expression was decreased compared to 
negative siRNA and untransfected cell lines. This decrease in the expression suggests that 
NKX2.2 is upregulated by GLI1 not only during early embryonic development but also in 
medulloblastoma progression. However, GLI1 knockdown astrocytoma did not show any 
changes in expression. 
D.7 Expression of Bmi-1 transcription after transfection: It was reported that this Bmi-1 
gene acts as an oncogene and coordinates the stem cells proliferative characteristic with sonic 
hedgehog signaling in medulloblastoma (Liu etai, 2006).The regulation of Bmi1 by GLI1 is not 
very clear. After GLI1 knockdown in medulloblastoma cell line Daoy, Bmi-1 expression was 
decreased, however its expression was 2-fold increased in GLI1 knockdown astrocytoma cell 
line U87MG, compared to universal negative siRNA and untransfected cell lines. Decreased 
expression of Bmi-1 after GUI knockdown in medulloblastoma revealed the possibility of 
upregulation of Bmi-1 by GUI. However, upregulation of Bmi-1 transcripts after GLI1 knockout 
in astrocytic cell line indicated that Bmi-1 could be negatively regulated by GLI1 in astrocytoma. 
Moreover few reports mention copy number alteration of polyco^.gertfe Bmi=1 4n„glioma 
tumour (Hayryef a/., 2008). 
Expression of GLI1, PTCH1, Cyclin D2, Plakoglobin, PAX^^NKX2.2 and Bmi-1 in s^' 
medulloblastoma and eight astrocytoma cell lines. 
D.8 GLI1 (glioma associated human homologue 1) 
GLI1 is located at 12q 13.3-14.1 locus of the chromosome. GLI1 is the main zinc finger motif 
transcriptional activator of Shh pathway. It was earlier showed to be highly amplified gene in 
malignant glioma (Kinzler et al., 1987). Its high expression is the indication of Shh activation. 
Most of the medulloblastoma (FigurelOA and Figure 108), and astrocytoma cell lines 
(FigurelOC and Figure 10D) showed high expression of GLI1 transcript as compared to 
normal brain tissue by RT-PCR and Real Time RT-PCR. Most of the astrocytoma cell lines 
except, U87MG and A172 also showed the expression of GLI1 at protein level (Figure 17A). 
This high expression of GUI supports not only development medulloblastoma but also the 
glioblastoma; this pathway activates and plays important role in the progression of these 
tumours. 
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D.9 PATCHED (PTCH1) 
PTCH1 has twelve transmembrane receptors of sonic hedgehog pathway and is located at 
9q22.3 position of the chromosome (Unden et al., 1996). It inhibits the activation of SMO in the 
absence of Shh activation. When Shh signaling is activated, the secreted Shh molecule binds 
to PTCH1 receptor and this binding change the conformation of PTCH, which consequently 
relieves the inhibition of SMO. The relieved SMO further activates downstream target genes 
GLI family of transcription factors. The locus of PTCH1 is considered as a putative tumour 
suppressor gene(TSGs) of Shh pathway, however, it is also up-regulated by this pathway 
transcription factor GLI1, besides other genes including WNT, BMP and IGF2 (Wetmore et al., 
2003).This high expression of PTCH1 further checks Shh expression and controls the sonic 
hedgehog signaling pathway activation. In our results, 50% of the cell-lines of medulloblastoma 
and astrocytoma showed many fold and 50% showed low expression of PTCH1 compared to 
normal brain tissue. Mixed pattern of PTCH1 expression among medulloblastoma and 
glioblastoma cell lines support on one side the upregulation of this gene by GLI1 and on the 
other its low expression further indicates its tumour suppressive nature in this pathway and 
might be further under regulation of an epigenetic mechanism. In earlier, one report, this 
PTCH1 gene was also regulated epigenetically and showed hypermethylation pattern (Uhmann 
et a/.,2005).We have also discussed the possibility of epigenetic regulation of PTCH1 gene in 
these tumours in epigenetic section. 
D.10CyclinD2 
Cyclin D2 is one of the D-type Cyclins and it plays a crucial role for the cell transition from 
G0/G1 to S phase, with the help of Cyclin dependent Kinase 4 (CDK4) and Cyclin dependent 
kinase 6(CDK6) leading to phosphorylation of retinoblastoma (Matsubayashi et a/.,2003; Tam 
et al., 1994). Despite the growth of proliferative function of Cyclin D2, it also shows growth 
inhibitory effects and blocks the cell Cycle progression, thereby promoting exit from cell cycle 
and maintaining the non-proliferative state of many normal human tissues like brain and breast 
(Meyyappan et al., 1998). It has also been reported in one study, that this Cyclin D2 gene 
promoter has consequences binding site CACCACCA for GUI protein interaction 
and subsequently Cyclin D2 is up-regulated by GUI in transformed epithelial cells 
(Yoonefa/.,2002). 
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In medulloblastoma, most of the cell lines except SK-PN-DW showed many fold expression 
compared to normal brain tissue. (Figure 12A and Figure 12B) (p=0.0939). However, in 
astrocytoma, all cell lines showed either low (U87MG, LN405, SW1783 and SW1088) or no 
expression (A172, T98G, CCF-STTG-1 and GOS-3) of Cyclin D2 compared to normal brain 
tissue and which was also highly significant (p<0.0001). This high expression of Cyclin D2 in 
medulloblastoma cell lines indicates the possibility of upregulation of Cyclin D2 by GLI1 and 
support the previous report[172](Yoon et al.,2002). However, Cyclin D2 low expression in 
astrocytoma cell lines and upregulation in expression after GLI1 knockdown in U87MG reveals 
that this Cyclin D2 might be downregulated by GLI1 rather than showing up-regulation in 
medulloblastoma. These differential expressions of genes by GLI1 support the multifaceted 
characteristic of sonic hedgehog signaling pathway. Moreover, we have also discussed the 
epigenetic regulation in Cyclin D2 expression in glioblastoma tumour. 
D.11 Plakoglobin (vcatenin) 
It is a cell-adhesion protein, having highly conserved 12 armadillo repeats. It is mapped to 
chromosome 17q21 locus and showed loss of hetrozygosity in breast and ovarian cancer and 
also behaves as a tumour suppressor gene (TSGs) (Moreno-Bueno et a/., 2003). Loss in 
expression of Plakoglobin is associated with tumour invasion and metastasis. High expression 
of Plakoglobin suppresses the tumourigenicity in various transformed cell lines (Simcha et ai, 
1996). Most of the medulloblastoma cell lines show many fold expression of Plakoglobin 
transcript compared to normal brain tissue (Figure 13A-B). Of astrocytic cell lines, 5/8(63%) 
showed low expression and 3/8(23%) showed high-fold expression (p<0.0001) (Figure13C-D). 
It has been reported that plakoglobin(Y catenin) gene also has consensus binding site similar 
to Cyclin D2 for GUI gene in the 5'promoter region and consequently it is down regulated by 
GUI in GUI transfected epithelial cell line (Yoon ef a/.,2002). However, in medulloblastoma, 
most of cell lines showed high-fold expression of Plakoglobin transcript compared to normal 
brain tissue and hence this high expression suggests the possibility of upregulation of 
Plakoglobin (y catenin) gene in medulloblastoma. Our GUI siRNA transfection study also 
supports this possibility (Yoon et ai, 2002). 
However, low expression of Plakoglobin transcript in most of the astrocytoma cell lines 
suggests that this gene is down-regulated by GUI. This was validated in a transfection study 
in which Plakoglobin showed increase in U87MG cell lines after GUI knockdown. 
79 
Chapter-I Discussion 
D.12 PAX6 
This gene was initially reported in mouse and is responsible for small eye development and 
later human homologue was identified by positional cloning of the gene responsible for aniridia 
(Callaerts et al., 1997). It is located in 11p13 locus of chromosome. It was considered as a TSG 
in glioblastoma cell lines (Zhou YH et al, 2005). It was also reported that this gene has marked 
involvement in the suppression of tumourigenicity specially of glioblastoma (Mayes, D.A 
2006).It has also been reported that this gene high expression suppress the invasiveness of 
glioblastoma cells (Zhou YH et al., 2005).This PAX6 gene is included among homeodomain 
transcription factor I (TF. I) and it shows gradient distribution during the neuronal development. 
This early embryonic distribution is regulated by Shh signaling. It has been reported that this 
PAX6 gene was repressed by Shh signaling pathway during embryonic development (Marc 
Fuccilloefa/., 2006). 
In the expression study, most of the medulloblastoma cell lines except TE671 and TE671c2 
showed low expression of PAX6 transcripts compared to normal brain tissue (Figure 14A). 
Similarly, most of the astrocytic cell lines except two cell line U87MG and LN405 showed very 
low expression of PAX6 compared to normal brain tissue(p<0.0070)(Figure 14B). Taken 
together most of the cell lines of medulloblastoma, and astrocytoma showed low expression of 
PAX6 gene expression, which supported the down regulation of PAX6 by Shh, signaling; 
however, this assumption was supported by astrocytoma cell line after GLI1 knockdown in 
U87MG but not by medulloblastoma cell line, Daoy. It was also reported that PAX6 also acts as 
TSG in these types of tumours. It would be possible that this PAX6 gene is under second level 
of regulation including epigenetic and other signaling pathway. 
D.13 NKX2.2 
It is a homeodomain transcriptional factor II (TF II). During embryogenesis, NKX2.2 is found 
responsible for the morphogenesis and differentiation. It is located at 20pter-q11.23 locus of the 
chromosome. NKX2.2 is expressed by undifferentiated ventral region of neural tube and 
controlled by Shh signaling (Briscoe et al., 2000). Its expression is distributed in gradient 
manner during neurogenesis and upregulated by Shh signaling. It shows co-expression with 
Shh in neuronal domain and regulated by this Shh signaling (Agius et al., 2004). 
In this expression study, most of the medulloblastoma cell lines showed low or no expression of 
NKX2.2 transcript compared to normal brain tissue(Fig.15A) (p<0.001).This low expression of 
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NKX2.2 indicated that this gene expression could be suppressed by GLI1 in medulloblastoma 
development, but our GLI1 siRNA transfection study showed low expression of NKX2.2 in 
Daoy cell line. Moreover, during embryonic development this gene is upregulated by sonic 
hedgehog-GLH signaling pathway. Taking together, we may conclude this NKX2.2 is under 
multiple genetic and epigenetic regulations in case of these tumours. 
Similarly, In astrocytomas, most of cell lines showed low or no expression of NKX2.2 
transcripts as compared to normal adult brain tissue(Figure 15B) (p<0.001).This low 
expression of NKX2.2 could reveal the downregulation of this gene by sonic hedgehog-GLH 
signaling pathway in these tumours. It has also been reported that this gene shows expression 
in low grade of glioma, pliocytic astrocytoma but not in high-grade glioma (Collin et al, 2007). 
D.14 Bmi-1 (Polycomb gene) 
It was reported that this gene shows involvement in the regulation of stem cells which are 
renewable and the proliferation with sonic hedgehog signaling pathway, assists this. It is 
located at 10p11.23 locus of the chromosome. It acts through p21 dependent mechanism for 
the neuronal stem cell (NSC) regulation (Fasano et al., 2007). It also acts as one of the stem 
cell marker and shows high expression in the primary melanoma cell lines and melanoma 
metastases (Mihic-Probst et al., 2007). 
However, it has been reported that Bmi-1 shows low expression in most of the tissues but high 
expression in the brain, spinal cord, kidney, lung and gonads (Van der Lugt et al., 1994; Koch 
et al., 2008). It is also considered as an oncogene and plays significant role in the 
development of adult stem cells. Bmi-1 high expression had been seen in many tumours 
including human neuroblastoma cell lines and primary brain tumours (Cui et al., 2007, Hemmati 
et al., 2003; Leung et al., 2004). High expression of Bmi-1 in medulloblastoma is linked to Shh 
activation in medulloblastoma (Leung etal., 2004). 
Our results demonstrate the expression of Bmi-1 in medulloblastoma cell lines but their 
expression was low compared to normal brain tissue (Figure16A) (p<0.0001).However, it was 
reported that normal brain tissue showed high expression of Bmi-1, paradoxically we could say 
Bmi1 is upregulated by GLI1 in medulloblastoma. This assumption is further confirmed by GLI1 
knockdown study discussed previously in medulloblastoma cell line, which showed 
downregulation of Bmi-1 gene after GLI1 knockdown in medulloblastoma cell line. 
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In astrocytoma two cell lines out of eight showed high fold of Bmi-1 transcript expression 
compared to normal brain tissue and remaining six cell lines showed low expression of Bmi-1 
compared to normal brain tissue (Figure 16B) (p=0.0232). 
High expression of Bmi-1 has been reported in the human neuronal cell lines and primary 
tumours (Cui et al., 2007) and also in different cancer including colorectal cancer (Kim et ai, 
2004), lung cancer (Breuer ef a/., 2005), hepatocellular carcinoma (Wang ef al., 2008), prostate 
cancer (Glinsky ef al., 2005) and Neuroblastoma (Cui ef al., 2006).It could be that possible this 
Bmil gene is upregulated in astrocytoma due to sonic hedgehog pathway activation but GUI 
knockdown result was not supporting upregulation, rather supporting the possibility of down-
regulation of Bmi-1 byGLH. 
Moreover, it needs more extensive studies to understand Bmil gene regulation by GUI , but we 
could not deny the synergic role of Shh signaling and Bmi-1 in the development of astrocytoma. 
D.15 it was further shown that expression of these genes had been checlced in 
medulloblastoma and glioma tumour samples. 
Most of the medulloblastoma and glioblastoma tumour samples showed many fold expression 
of GUI (Figure 18A-B) (p<0.001).The expression of GUI protein was also high in most of the 
glioma tumour samples. This high expression of GUI in samples also suggests the activation 
of Shh signaling in these tumours. 
The PTCH1 showed mixed pattern of expression in these medulloblastoma and glioma 
samples (Figure 18C-D), as similar to the tumours cell lines and it is further suggested that 
there are two levels of PTCH1 control in these tumours, one is by GUI and another one under 
epigenetic control which is discussed in epigenetic regulation section of this chapter. 
After PTCH1, we also determined the regulation of other downstream target gene Cyclin D2.lt 
showed high expression in medulloblastoma and mixed expression in glioma samples. Taken 
together, it could be possible that Cyclin D2 gene is upregulated by GUI in medulloblastoma 
but downregulated in glioma; however, low expression of Cyclin D2 is also contributed by 
epigenetic regulation, which has been discussed later. 
Another downstream target gene, namely Plakoglobin shows high expression in 
medulloblastoma samples (Figure 19C) and low expression in glioma primary tumour samples 
(Figure 19D) compared to normal brain tissue and further suggests the possibility of 
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upregulation and downregulation by GLI1 in medulloblastoma and glioma respectively. This 
presumption was also supported by our GUI knockdown experiments in these tumours cell 
lines. 
Putative GLI1 downstream target gene PAX6 expression was, also checked in these tumours 
and found high fold expression in most of the medulloblastoma samples compared to normal 
brain tissue (Figure 20A) (p=0.013).This high level of PAX6 support the cell lines expression 
and GLI1 knockdown results and further it can be proposed that PAX6 upregulation taken place 
in medulloblastoma. However, in glioma most of the samples showed low expression of PAX6 
and it could be due to downregulation by GLI1. The GLI1 knockdown experiment also supports 
this assumption of PAX6 regulation by GLI1. 
Another gene NKX2.2 which is upregulated by GLI1 in embryonic development shows overall 
low expression in medulloblastoma and glioma tumours; however GLI1 knockdown 
experiments showed that its upregulation by GUI in medulloblastoma. This low expression of 
tumour samples and low expression after GUI siRNA transfection revealed the possibility of 
other signaling pathway involvement in the regulation of PAX6 in medulloblastoma. 
Bmi-1: Most of the glioma samples show either equal or low expression of Bmi-1 in glioma 
samples. (Figure 20E). This expression result was similar to cell lines.GLH knockdown 
experiment also confirmed by the possibility of down-regulation of Bmi1 by GUI. 
Epigenetic Regulation of PTCH1 and Cyclin D2 in medulloblastoma, glioma cell lines and 
primary tumour samples. 
D.16 PTCH1 gene methylation in medulloblastoma and glioblastoma 
The PTCH1 Is a twelve transmembrane protein receptor of sonic hedgehog pathway and 
before the activation of Shh signaling, it inhibits another seven transmembrane receptor (7T) 
SMO. The mechanism of SMO inhibition is still not very much clear, however, it was suggested 
that some kind of conformational changes do occur. This PTCH1 acts as a tumour suppressor 
gene of this pathway. In this study, promoter methylation status of PTGH1 gene has been 
determined in major brain tumours medulloblastoma and glioblastoma cell lines and primary 
tumour samples. 
PTCH1 methylation had been reported in breast cancer cell line MCF-7 and primary samples, 
and this methylation were correlated with low expression of PTCH1 transcript (Wolf et al., 
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2007). PTCH is also well known tumour suppressor gene and showed epigenetic regulation in 
many human malignancies (Berman etal., 2002; Toyota etal., 2001). 
It was found that three medulloblastoma cell lines TE671, PFSK-1 and D283, and 2/14 
medulloblastoma samples, showed partial/hemi methylation in the promoter region of PTCH1 
gene. This promoter hypermethylation was also correlated with low PTCH1 transcript 
expression in D283 cell lines and samples (p3 and p11) of medulloblastoma. Recently it was 
reported that proximal promoter of PTCH1 gene (variant exon 1B) showed methylation in some 
cases of medulloblastoma (Pritchard and Olson 2008). 
All of these studies support the possibility of methylation in PTCH1 promoter region and it 
could be one of the reasons for silencing of this gene in many cell tumours including 
medulloblastoma. 
In glioblastoma, only one cell line and 3/44(7%) glioma samples showed partial/hemi 
methylation in the promoter region of PTCH1 gene. However, their methylation showed 
correlation with low transcript expression in glioma cell lines and samples. 
This PTCH1 methylation in few cell lines and samples of all these major brain tumours 
comprise medulloblastoma, and glioblastoma further support the previous investigation which 
had postulated two way of sonic hedgehog pathway activation i.e. one is ligand depenedent 
and the other one ligand independent in which PTCH1 shows inactivation (Jeong and 
McMahon, 2005). 
D.17 Cyclin D2 Promoter Methylation in medulloblastoma and glioblastoma 
Cyclin D2 promotes the DNA replication in Cell-cycle phase and enforces cell cycle to enter the 
S-phase which is assisted by cyclin dependent kinase 4 and cyclin depenent Kinase 6, leading 
to phosphorylation of retinoblastoma. It also shows alternative function to help cell exit from cell 
cycle and maintain nonproliferative state (Meyyappan et al., 1998).It is a member of the D-type 
Cyclins, implicated in cell-cycle regulation, differentiation and malignant transformation. 
Many cases of Cyclin D2 promoter methylation had been reported in pancreatic cancer 
(Matsubayashi etal., 2003), breast cancer (Evron etal., 2001; Sharma etal, 2007) and Human 
epithelial Ovarian Cancer (Sakuma, et al., 2007). 
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These studies establish that the promoter hypermethylation of Cyclin D2 gene plays a major 
role in brain tumours of medulloblastoma and glioblastoma tumours cell lines and primary 
tumour samples. 
It was found to have three putative CpG rich regions in the promoter region of the Cyclin D2 
gene (Figure 24A-B) and the regions w/ere analyzed with two different techniques, viz one was 
MCA-Meth and another one standard MSP. MCA-Meth primers amplified first putative CpG rich 
region of this gene promoter and analysis was done by melting curve. MSP primers amplified 
both first and second putative CpG rich regions. Unfortunately, we did not get primers for the 
third putative CpG rich region (-296 to -104) because methprimers did not generate any 
primers for this CpG sequences (Figure 24A-B). 
Only one medulloblastoma cell line SK-PN-DW gives hemi/partial methylated peak by MSP-
Meth method but MSP showed promoter hypermethylation in the five cell lines of 
medulloblastoma. MSP-Meth method did not show any methylation melting peak in all 14 
medulloblastoma primary samples however 3/14 medulloblastoma primary samples showed 
promoter hypermethylation by MSP method. This MSP-Meth hypermethylation correlated with 
the low expression of Cyclin D2 in cell lines SK-PN-DW. Nevertheless, MSP methylation in five 
cell lines including SK-PN-DW did not fully support the methylation caused silencing of Cyclin 
D2 gene expression in medulloblastoma cell line. Similarly, MSP results in primary 
medulloblastoma did not support the silencing of Cyclin D2 expression in respective primary 
samples. It would be possible that hypermethylation in the first putative CpG region (-1550 to -
1288) influences the expression of Cyclin D2 but not second putative CpG rich region (-1230 to 
-982) of this gene in medulloblastoma tumour and cell lines (Figure 24A-B). 
In astrocytoma, three cell lines (U87MG, T98G and GOS-3) showed promoter hypermethylation 
in Cyclin D2 gene with MSP-Meth and five cell lines of astrocytoma (U87MG, SW1783, T98G, 
CCF-STTG-1 and GOS-3) showed hypermethylation with MSP primers. In glioma, only 10/44 
samples showed hemi/partial methylation with MSP-Meth and 15/44 glioma samples showed 
hypermethylation in Cyclin 02 promoter region with MSP method. This methylation in cell lines 
and primary samples correlates with low or no expression of Cyclin D2. 
Both promoter methylation analysis methods showed common methylation with three 
astrocytoma cell lines U87MG, T98G and GOS-3 and four primary tumour samples (3, 13,18 
and 24). Two cell lines SW1783 and CCF-STTG-1 and few samples (6, 8, 10, 15, 16 and 21) 
showed methylation with MSP but not with MSP-Meth. Such differential methylation pattern 
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indicated the accumulative effect of CpG rich regions for methylation in the promoter region of 
Cyclin D2 gene and caused silencing in the expression. 
D.18 Reversal of expression of Cyclin D2 and PTCH1 expression after the treatment of 
demethylating agent 5-aza-2'-deoxycytidine (5Aza) and HDAC inhibitor Trichostatin A 
(TSA) 
In cell lines A172, SW1783, T98G, CCF-STTG-1 and GOS-3 some showed low or no 
expression of Cyclin D2 and Cell lines U87MG, A172 and SW1783 showed low or no 
expression of PTCH1. 5-aza-2'-deoxycytosine and TSA showed increase in expression of 
these silence cell lines showing additional control at an epigenetic level (Figure 26A-26C) 
(p=0.0014). 
Promoter methylation of two CpG rich sites of Cyclin D2 in cell lines associated with low 
expression. In some situation, these two sites showed hypermethylation and there was by 
5-aza-2'-dC and TSA showing role of epigenetic control. 
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Expression of other sonic hedgehog genes including Smoothened{SMO), HHIP, SUFU, 
GLI3 and SFRP1 in six medulloblastoma and eight astrocytoma cell lines by RT-PCR and 
Real Time RT-PCR 
R. 20 (SMO) 
Medulloblastoma cell lines 
RT-PCR: All six cell lines (TE671, PFSK-1, Daoy, TE671c2, D283 and SK-PN-DW) showed 
high expression of SMO transcript as compared to normal brain tissue (Figure 28A). 
Real Time RT-PCR: Similarly, all of the six cell lines of medulloblastoma showed high fold 
expression of SMO transcript compared to normal brain tissue and this differences was highly 
significant(p=0.0009)(Figure28B). 
Astrocytoma cell lines 
RT-PCR: In seven cell lines of astrocytoma SMO transcript expression was high and one cell 
line U87MG did not show the expression of SMO transcript compared to normal brain tissue 
(Figure 28C). 
Real Time RT-PCR: Similarly, except one cell line (U87MG) all remaining seven cell lines 
showed high fold expression of SMO transcript, compared to normal brain tissue. (Figure 28D). 
R.21 HHIP 
Medulloblastoma cell line 
Real Time RT- PCR: All 6 cell lines showed low expression of HHIP transcript as compared to 
normal brain tissue and it was highly significant (p<0.0001) (Figure 29A). 
Astrocytoma 
Real Time RT-PCR: All 8 glioblastoma cell lines showed low expression of HHIP transcript as 
compared to normal brain tissue and the difference was highly significant (p<0.0001) 
(Figure 29B). 
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Fig. 28 A-B. RT-PCR and Real Time RT-PCR comparative expression of 
Smoothened (SMO) transcript in six medulloblastoma cell lines (M1-TE671, M2-
PFSK-I, M3-Daoy, M4.TE671c2, M5-D283 and MB-SK-PN-DW) Fig.A. All six 
medulloblastoma cell lines showed high expression of SMO transcript compared to normal 
brain tissue. L and B stand for lung and brain as normal control. Transferin Receptor 
(TFR) was taken for intemal control of RNA expression in RT-PCR. Fig. B. All six 
medulloblastoma cell lines showed high fold expression of SMO compared to normal brain 
tissue (p=0.009). All data from Real Time RT-PCR were normalized by GAPDH 
Chapter-ll Results 
R.22 SUFU 
Medulloblastoma 
Real Time RT-PCR: In this 2/6 cell lines TE671 and TE671c2, we showed 2-4 high-fold 
expression and remaining 4/6 cell lines showed either equal (SK-PN-DW) or low (PFSK-1, 
Daoy and D283) expression of SUFU transcript as compared to normal brain tissue 
(Figure 30A). 
Astrocytoma 
Real Time RT-PCR: All 8 cell lines showed low expression of SUFU transcript as compared to 
normal brain. It was highly significant (p=0.0009) (Figure SOB). 
R.23 SFRP1 
Medulloblastoma 
Real Time RT-PCR: cell line SK-PN-DW showed high-fold expression, Daoy cell line showed 
equal expression, three cell lines PFSK-1, TE671c2 and D283 showed low expression and one 
cell line TE671 showed no expression of SFRP1 compared to normal brain tissue. It was not 
significant (Figure 31A). 
Astrocytoma 
Real Time RT-PCR: One cell line(SW1783) showed high-fold, 5 cell lines showed low 
(U87MG, A172, T98G, CCF-STTG-1 and GOS-3) and remaining 2 cell lines did not show 
expression of SFRP1 transcript compared to normal brain tissue.(Figure 31B). 
R.24 GLI3 
Medulloblastoma 
RT-PCR: All 6 cell lines showed high expression of GLI3 transcript as compared to normal 
brain tissue (Figure 32A). 
Real Time RT-PCR: Similarly, all six cell lines also showed high-fold expression of GLI3 as 
compared to normal brain tissue.(Figure 32B). 
Astrocytoma 
RT-PCR: All eight cell lines showed high fold expression of GLI3 transcript as compared to 
normal brain tissue (Figure 32C). 
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Fig.28 C-D. RT-PCR and Real Time RT-PCR comparative expression expression 
of SMO transcript in 8 astrocytic cell lines: (G1-U87MG, G2-A172, G3-LN405, 
G4.SW1783, G5-T98G, G6-SW1088G7-CCF.STTG-1 and G8-GOS-3) Fig.28C. Most 
of the cell lines except, U87MG showed high expression of SMO as compared to 
normal brain tissue. L and B stand for lung and brain, taken as a normal control. 
Transferin receptor (TFR) was taken for internal control of RNA expression in RT-PCR. 
Fig.28D. Most of the cell lines except U87MG, showed high fold expression of SMO 
compared to normal brain tissue (p=0.0586). All data from Real Time RT-PCR were 
normalized by GAPDH 
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Real Time RT-PCR: In astrocytic cell lines, all eight cell lines showed high fold expression of 
GLI3 compared to normal control brain tissue (Figure 32D) significant (p=0.0247). 
R.25 Protein Expression of GLI3: 
Western blot: Most of the cell lines except A172 cell line showed protein expression of GLI3 
(Figure 33A). Most of the astrocytic samples also showed GLI3 protein expression 
(Figure 33B). 
R.26 Expression of other sonic hedgehog genes including SMO, HHIP, SUFU, GLI3 and 
SFRP1 in fourteen medulloblastoma and twenty seven glioma primary tumour samples. 
Most of the medulloblastoma samples and glioma samples showed high expression of SMO 
transcript compared to normal brain tissue (p=00.53) (p=0.013). (Figure 34A-B) 
All medulloblastoma and glioma primary tumours samples showed either no expression or low 
expression of HHIP transcript. Highly significant (p<0.0001) (Figure 34C-D). 
SUFU expression was not checked in medulloblastoma samples because of insufficient RNA 
quantity. In astrocytic tumours, 25/27 of the samples showed low expression, only 2/27 
samples showed high-fold expression as compared to normal brain tissue. It was not significant 
(Figure 35A). 
In medulloblastoma 2/11 samples showed high-fold of expression, 5/11 samples showed low 
expression and remaining 4/11 samples showed no expression of SFRP1 transcript compared 
to normal brain tissue (Figure 35C). 
In astrocytic tumour samples, 2/27 primary tumours showed high-fold expression and 
remaining 25/27 primary samples showed low expression of SFRP1 transcript as compared to 
normal brain tissue. (Figure 35D). 
GLI3 transcript expression was not checked in medulloblastoma samples because of 
insufficient RNA quantity. 
In astrocytic tumour, 6/27 samples showed high-fold expression of GLI3 transcript and 
remaining 21/27 samples showed more or less equal expression compared normal brain tissue 
(Figure 35B). 
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Fig. 29 A-B: Real Time RT-PCR comparative expression of HHIP transcript in six 
medulloblastoma and eight astrocytoma cell lines. Fig. A-B. All 6 cell lines of 
medulloblastoma and 8 astrocytoma cell lines showed low expression of HHIP 
compared to normal brain tissue (p<0.0001). All data were normalized by GAPDH. 
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Promoter hypermethylation analysis: 
Methylation Results: 
Epigenetic regulation plays a very significant role in the progression of many cancers, because 
this phenomenon silences many tumour suppressor genes (TSGs).ln this section we have 
checked the epigenetic regulation of these putative tumour suppressor genes (TSGs): HHIP, 
SUFUandSFRPL 
R.27 HHIP1 Promoter Methylation: 
In this case, methylation analysis was done by MSP-Meth method. For this we used single pair 
primers designed with no CpG in its sequences. These primers amplify both unmethylated and 
methylated sequences. In this case In vitro methylated DNA (IMD) melting peak (green color) 
was considered as positive control for methylated DNA and normal blood (red color peak) as a 
positive control for unmethylated DNA region and both controls have given different melting 
temperature, 81° and 77.5° respectively. Cell lines and samples were given melting peak (blue 
color) temperature which varies with the CpG methylation in the promoter region. 
Medulloblastoma: In this case, two cell lines TE671 and TE671c2 showed methylated peak 
and methylated melting temperature(80.5° degree) and remaining four cell lines PFSK-
1,Daoy,D283 and SK-PN-DW showed hemi/partial methylated peak and hemi/partial melting 
temperature range(79.5°-80° degree) (Figure 36A-B) (Table 16). 
In medulloblastoma samples, only 2/14 samples showed hemi/partial methylation peak and 
melting temperature (78.5° degree) (Figure 36C-D) (Table 16). 
Astrocytoma: In this case, two cell lines (CCF-STTG-1 and GOS-3), showed complete 
promoter methylation and their melting temperature was at 8r .O degree, four cell lines 
(U87MG, A172, LN405 and T98G) showed hemi/partial promoter methylation and their melting 
temperature was at 79.5° degree. One cell line (SW1088) did not show promoter methylation 
which gave melting temperature was at 77.5° degree (Figure 37A-D). 
In glioma, more than 75% (32/44) of the primary tumour samples showed methylation in the 
promoter region of HHIP (15/44 samples showed complete promoter methylation; 17/44 
samples showed hemi/partial methylation) and remaining 25% of the samples did not show 
methylation in the promoter region (Figure 37E-H) (Table 17). 
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Fig. 30 A-B. Real Time RT-PCR expression of SUFU in six medulloblastoma and 
eight astrocytoma cell lines. Fig.A. Most of the medulloblastoma cell lines except 
(TE671 and TE671c2) showed low expression of SUFU transcript as compared to 
normal brain tissue. Fig. B. All 8 astrocytoma cell lines showed low expression of 
SUFU transcript as compared to normal brain tissue (p=0.009). All data were 
normalized by GAPDH 
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R.28 SUFU Promoter Methylation: 
In this case, we also used MSP-Meth method for SUFU promoter methylation analysis. Positive 
control for complete methylated region was In vitro (IMD) showed green peak being given 
melting temperature was at 83° and positive control for unmethylated DNA region showed red 
peak, being given melting temperature was at 80° degree. 
Medulloblastoma: In this case all of the 6 cell lines and 14 samples showed unmethylated 
melting peak (blue color) being given melting temperature at 80° degree 
(Figure 38A-B)(Table.16) 
Glioblastoma: In this case all 8 cell lines showed unmethylated melting peak (blue color) and 
their melting temperature was at 80° degree (Figure 38A-B) (Table 17). 
In glioma 2/44 primary tumour samples showed hemi/partial methylated peak (blue color) being 
given melting temperature in the range of 81 °-83° degree. 
R.29 SFRP1 Promoter Methylation: 
This methylation study was also done with MSP-Meth method. The IMD was taken as a 
positive control for the methylated promoter region, which gave melting temperature of 82° 
degree. Normal blood DNA was taken as positive control for unmethylated promoter region 
which gave melting temperature of 77.5° degree. 
Medulloblastoma: only TE671 cell line showed hemi/partial methylation in the promoter region 
of the SFRP1 promoter region, the remaining cell lines did not show any methylation. In 
medulloblastoma samples, 5/14 samples showed partial/hemi methylated in the promoter 
region of SFRP1 gene. The melting temperature of methylated cell line and samples is 78.5 
degree (Figure 39A-C) (Table 16). 
Glioblastoma: In glioblastoma, 5/8 cell lines (A172, T98G, SW1088, CCF-STTG-1 and GOS-
3) showed partial/hemi methylation in the promoter region of SFRP1 gene. In glioma, 14/44 
samples showed hemi/partial methylation in the promoter region of SFRP1 gene. It showed 
melting peak temperature at 78.5 degree (Figure 39A-C) (Table 17). 
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Fig. 31 A-B. Real Time RT-PCR comparative expression of SFRP1 transcript in 
six medulloblastoma and eight astrocytoma cell lines. Fig. A. Most of the cell 
lines except (SK-PN-DW) showed low/no expression of SFRP1 transcript as 
compared to normal brain tissue (p=0.0831). Fig. B. Except one cell line (SW1783) 
all remaining cell lines showed either low no expression of SFRP1 transcript 
compared to nonnal brain tissue. All Data were normalized by GAPDH 
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Fig. 32 A-B RT-PCR and Real Time RT-PCR comparative expression of GLI3 
transcript in six medullobiastoma cell lines (M1-TE671,M2-PFSK-1,M3-Daoy,M4-
TE671c2,M5-Daoy and M6-SK-PN-DW). Fig. A. All six cell lines of medullobiastoma 
showed high expression of GLI3 as compared to normal brain tissue. L,B and NTC 
stands for lung, brain and no-template control respectively.Transferin receptor(TFR) was 
taken for intemal control of RNA expression in RT-PCR. Fig. B. All six medullobiastoma 
cell lines showed high fold expression of GLI3 compared to normal adult brain tissue. All 
Real Time RT-PCR data were normalized by GAPDH 
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Fig. 32 C"D. RT-PCR and Real Time RT-PCR of GLI3 transcript In eight astrocytoma 
cell lines(G1-U87MG, G2.A172, G3-LN405, G4-SW1783, G5-T98G, G6-SW1088,G7-
CCF-STTG-1, G8-GOS-3. Fig.C.AII 8 astrocytoma cell lines showed high expression of 
GLI3 compared to normal brain tissue.L,B, and NTC stands for lung.brain and no-
template control respectively. Transferin receptor (TFR) was taken for internal control of 
RNA expression in RT-PCR. Fig. D. All eight cell lines of astrocytoma showed high fold of 
GLI3 transcript expression as compared to normal brain (p=0.0247). All data from Real 
Time RT-PCR were normalized by GAPDH 
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Fig. 33 A-B. Protein expression of Gli3 showed by astocytoma cell lines and glioma 
samples.Fig.A.Westem blotting showed Gli3 protein expression in all eight astrocytoma 
cell lines(G1-G8). Among 8 cell lines 2 glioma cell lines (G2-A172,G3-LN405) did not 
show very distinct band of Gli3 protein.Fig. B. In glioma samples(1-4 and 6), all samples 
showed good expression of Gli3 protein. C+ was HeLa cell lysate of GLI3 protein taken 
for normal control. GAPDH protein was taken as loading control 
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Fig. 34 A-D.Real Time RT-PCR comparative expression of SMO, and HHIP genes In 
14 medulloblastoma and 27 glioma samples. Fig. A-B.Most of the primary tumour 
samples of medulloblastoma and astrocytoma showed high fold expression SMO 
compared to normal brain tissue. Fig. C.Most of the medulloblastoma samples showed 
either low or no expression of HHIP transcript compared to normal brain tissue 
(p<0.001).Fig. D.AII glioma samples showed low expression of HHIP transcript 
compared to normal brain tissue (p<0,001). 
Real Time RT-PCR expression of SUFU, GLI3 and SFRP1 
in medulloblastoma and glioma samplesO 
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Fig. 35 A-D. Real Time RT-PCR comparative expression of SUFU,GLI3 and SFRP1 
in 27 glioma samples and 11 medulloblastoma samples.Fig.35A.Most of the glioma 
primary tumour samples stiowed low expression of SUFU transcript as compared to 
normal brain tissue.Fig.38B.Among glioma primary tumors /27)26% of the samples 
showed high and remaining 76% of the samples showed more or less equal 
expression of GLI3 transcript compared to normal brain tissue. Fig. C.Among 
medulloblastoma,79%(10/14) samples showed low expression and remaining 
21%(4/14) samples showed high fold expression of SFRP1 compared to normal brain 
tissue. Fig. D. Among glioma, 24/27 of the samples showed low expression of SFRP1 
compared to nomnal brain tissue. All data were nomialized by GAPDH. 
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Fig. 36 A-B. HHIP Promoter hypermethylation study by MCA-Meth in 
medulloblastoma cell lines. This case used single pair primers designed with no CpG 
in its sequences and melting peal< temperature varies with the percentage of methylation 
in the given squenecs.Normal blood used as a positive control for unmethylated DNA 
region(red peakJS" temp) using bisulphite primers in medulloblastoma cell lines(TE671 
and Daoy) (Fig. A-B), /n wfro methylated DNA (IMD) used as positive control for 
methylated DNA region( green color peak, 80.5°tem) (Fig. A-B) Fig. A-
B.IVIedulloblastoma cell lines TE671 and Daoy showed complete promoter methylation 
and partial promoter methylation peaks respectively (blue color peak, 80.5° and 80° 
temps) No-template did not give any amplification by this primer (black color). 
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Fig. 36 C-D.HIHIP Promoter methylation study by MCA-Meth in medulloblastoma 
samples (p7 and p29). Fig. C-D. Unmethylated region in p7 sample (blue color 
peak.ZS" temp) (Fig. C) and hemi/partial methylated region in p29 sample (blue color 
peak.SO" temp) (Fig. D).No-template control did not give any amplification by this 
primers(black color). 
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Fig. 37 A-B.HHIP Promoter hypermethylatlon study by MCA-Meth in astrocytoma 
cell lines (U87MG and SW1088). Normal blood used as positive control for unmethylated 
DNA region (red peak,78° temp) (Fig. A and B), in Vitro methylated DNA (IMD) used as 
positive control for methylated DNA region (green color peak.Srtemp) (Fig. A and 
B),partial methylated DNA region showed in U87I\/1G cell line (blue color peak,80.° temp) 
(Fig. A) and unmethylated DNA region showed in SW1088 cell line (blue color peak,78° 
temp) (Fig. B).No template control did not give any amplification by this primers(black 
color). 
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Fig. 37 C-D. HHIP Promoter hypermethylation study by MCA-Meth in astrocytoma 
cell lines (CCF-STTG-1 and GOS-3). Normal blood used as positive control for 
unmethylated DNA region(red peak./S" temp) (Fig. C and D), /n wfro methylated DNA 
(IMD) used as positive control for methylated region (green color peak.Srtemp) (Fig. C 
and D), methylated region showed by CCF-STTG-1 cell line (blue color peak.SO.S" temp) 
(Fig. C) and methylated region showed by GOS-3 cell line (blue color peak,8r temp) (Fig. 
D). No-template control did not give any amplification by this primers(black color). 
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Fig. 37 E-F.HHIP Promoter hypermethylation study by MCA-Meth in glioma 
tumour samples no.(5 and15). Normal blood used as positive control for 
unmethylated DNA region(red peak,78° temp) (Fig. E and F), in vitro methylated DNA 
(IMD) used as positive control for methylated DNA region (green color peak,8rtemp) 
(Fig. E and F), unmethylated promoter region in samples no.5 (blue color peak,78° 
temp) (Fig. E) and hemimethylated methylated region in sample no. 15 (blue color 
peaks,78° and 80.5° temp) (Fig. F).No-template control did not give any amplification 
by this primers(black color). 
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Fig. 37. G-H. HHIP Promoter hypermethylation study by MCA-Meth in glioma 
samples(24 and 31).Normal blood used as positive control for unmethylated promoter 
region (red peak,78° temp) (Fig. G and H), in vitro methylated DNA(IMD) used as 
positive control for methylated promoter region(green color peak,81°temp) (Fig. G and 
H), partial methylated promoter region showed by samples no.24( blue color peak,80.° 
temp) (Fig. G) and methylated promoter region showed by samples no.31( blue color 
peak.Sr temp) (Fig. H). No-template control did not not give any amplification by this 
primers(black color). 
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Fig. 38 A-B. SUFU Promoter methylation study by IVISP-Meth. Fig. 38 A-B. In this 
case used single pair primers designed with no CpG in its sequence.These primers 
amplify both unmethylated and methylated sequenecs and melting peak temperature 
varies with the percentage of methylation in the given squenecs. blood used as positive 
control for unmethylated DNA region (red peak,80° temp) (Fig. A and B), in vitro 
methylated DNA(IMD) used as positive control for methylated DNA region (green color 
peak.BS^temp) (Fig. A and B),umethylated DNA region in cell line/sample( blue color 
peak.SO." temp) (Fig. A) and hemimethylated/partial methylated DNA region in cell 
line/sample( blue color peaks,80° and 84° temp)(Fig. B). No template control did not 
give any amplification by this primers(black color). 
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Fig. 39 A-B. SFRP1 Promoter hypermethylation study by IVISP-Meth. Normal blood 
used as positive control for unmethylated promoter region (red peak.TS" temp) {Fig.A 
and B), in vitro methylated (IMD) used as positive control for methylated promoter 
region (green color peak.Srtemp) (Fig. A and B), hemimethylated/partial methylated 
region in samples GT-22 and GT-23 blue color peak.SO" temp) (Fig. A and B). No-
template control did not give any amplification by this primers (black color). 
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Fig. 39C. SFRP1 Promoter hypermethylation study by MSP-Meth Method. 
Normal blood used as positive control for unmethylated promoter region(red 
peak.yS" temp) (Fig.C), in vitro Methylated DNA (IMD) used as positive control 
for methylated promoter region (green color peak,8rtemp) 
(Fig. C), unmethylated region showed by sample no.(33) (blue color peak,78° 
temp) (Fig. C) and no-template control did not give any amplification by this 
primers. 
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Chapter-ll Discussion 
Expression of SMO, HHIP, SUFU, GLI3 and SFRP1 in medulloblastoma and astrocytoma 
ceil iines. 
D.19 Smoothened (SiViO) 
It is a seven transmembrane receptor of sonic hedgehog pathway and this gene is located at 
7q32.3 locus of the chromosome. It is responsible for the downstream activation of Shh 
pathway and is considered as an oncogene of this pathway. Upregulation of Smoothened gene 
indicates the sonic hedgehog signal activation and leads to cancer development (Xie et al., 
1998).Through this study, the expression of this gene was determined in medulloblastoma cell 
lines and it was that found that all 6 medulloblastoma cell lines TE671, PFSK-1, Daoy, 
TE671c2, D283 and SK-PN-DW showed high expression of SMO transcript while this high 
expression level was significant (p=0.0009) compared to normal brain tissue (Figure 28A and 
Figure 28B). Even some cell lines (TE671 and TE671c2) reached up to >80 fold high 
expression of SMO transcript compared to normal brain tissue. 
In astrocytic cell lines, most of the cell lines except one cell line U87MG showed high fold SMO 
transcript expression. In LN405 cell line, the expression reached > 80 fold high compared to 
normal brain tissue (p=0.0586) (Figure 28C and Figure 28D). 
It was determined that most of the cell lines of medulloblastoma and astrocytoma showed high 
level expression of SMO mRNA except one cell line of astrocytoma U87MG compared to 
normal brain tissue. These comparative expressions between cells lines and normal brain 
tissue were highly statistically significant. This high expression of SMO itself is the indication of 
an oncogenic activity of SMO and sonic hedgehog pathway activation. In medulloblastoma, 
sonic hedgehog pathway is well studied but this sonic hedgehog pathway activation is not very 
much explored in these astrocytomas, in this study, we checked the role and activation of Shh 
signal activation in the astrocytoma. This high expression of SMO in astrocytoma cell lines 
could suggest the possibility of sonic hedgehog pathway activation in astrocytoma. In case of 
astrocytoma, one cell line U87MG, showed very low expression of SMO and this low 
expression was due to epigenetic regulation discussed in other chapter. 
D.20 HHIP1 (Hedgehog interacting protein 1) 
It acts as an antagonist of Shh pathway, the upregulation of Shh pathway leads to 
downregulation in the HHIP1 expression. In this study, overall low expression of HHIP 
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transcript in medulloblastoma and astrocytoma cell lines was compared with normal brain 
tissue. It was highly significant (p<0.0001) (Figure 29A-29B).The low expression of HHIP1 in 
these tumours cell lines indicate the possibility of sonic hedgehog pathway activation, because 
high expression of HHIP inhibits the Shh pathway in similar way as PTCH inhibition (Chuang 
and McMahon 1999a; Rowitch et al., 1999b). It was also reported that HHIP showed epigenetic 
regulation in many cancers including Pancreatic cancer cell lines (Martin et al., 2005). It also 
further establishes the possibility of epigenetic regulation of this HHIP gene in 
medulloblastoma, astrocytic cell lines and primary tumour samples. 
D.21 SUFU (Suppressor of Fused) 
This gene acts as one of the tumour suppressor genes (TSGs) of sonic hedgehog pathway and 
blocks the nuclear accumulation of GLI1 and GLI2 (Barnfield et al., 2005) by felicitating 
phosphorylation in them. It is located at 10q24 locus of the chromosome and shows loss of 
hetrozygosity (LOH) in many tumours including prostate cancer, breast cancer, 
medulloblastoma and lung cancer (Latini et al., 2001; Leube et al., 2002). Here in this study, it 
was found to show overall low expression of SUFU in medulloblastoma (Figure 30A) and 
astrocytoma cell lines (p=0.0090) (Figure 308). High SUFU expression showed negative effect 
on Shh signaling by inhibiting GLI1 and GLI2 transcriptional activation. Most of the tumours cell 
lines and samples had low expression of SUFU. This low expression indicated there could be 
possibility of inactivated SUFU in medulloblastoma and astrocytoma cell lines. This did not 
inhibit the transcriptional activator GLI1 and consequently GLI1 gets accumulated in the 
nucleus without any hindrance and gets activated other downstream target genes of this 
pathway. 
D.22 SFRP1 (Secreted frizzled-related proteini) 
This protein is an antagonist of canonical pathway of WNT. It is considered as a TSG and 
shows frequent loss of hetrozygosity (LOH) in the region 8p12-p11.1 of human hepatocellular 
carcinoma (HHC) (Finch etal., 1997). 
This WNT pathway is also responsible for many cellular processes, organ development and 
malignant transformation (Uren et al, 2006). The SFRP1 gene showed low expression in 
breast cancer (Ugolini et al, 2001), ovarian cancer (Takada ef a/., 2004) and many more. 
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Recent cancers studies had revealed the interrelation in SHH and WNT pathway, with the 
nexus of phosphorylation status of GSK-3(Serine-threonine kinase) (Kalderon et al., 2002). 
In another finding, it was reported that GLI1 also binds with the promoter region of SFRP1 and 
down regulates its expression (Katoh and Katoh, 2005). Thus, the study of transcript 
expression of SFRP1 was checked in major brain tumours comprising medulloblastoma and 
astrocytoma cell lines. 
In medulloblastoma, most of the cell line except SK-PN-DW showed high expression of SFRP1 
transcript compared to nornial brain tissue (p=0.0831) (Figure 31 A). 
In astrocytic cell lines, most of the cell lines except SW1783 showed either no expression or 
very low expression compared to normal brain tissue (Figure 31B). The results obtained show 
that most of the cell lines of medulloblastoma and astrocytoma show low expression of SFRP1 
transcript as compared to normal brain. This low expression indicates that SFRP1 is acting as 
a tumour suppressor gene and down regulates the activation of Shh signaling in 
medulloblastoma and astrocytoma. However, our results are contrary to previous reports which 
had explained the process of upregulation of SFRP1 in medulloblastoma development 
(Lee efa/., 2003). 
D.23 GLI3 
The Drosophila Shh pathway is mediated by downstream transcriptional molecule cubitus 
interruptus (Ci) having both activator and repression domain and their functions are according 
to the signal activation. The homologue of Vertebrate Ci has three GLI1, GLI2 and GLI3 
transcriptional factors. Thus GLI1 and GLI2 are activators, and GLI3 has both activator and 
repressor domain. 
It has been reported that GLI3 has two forms, one is full length (190kDa) and acts as 
activator(GLI3A) of Shh and another one Is truncated and acts as a repressor(GLI3R) (89kDa) 
of Shh (Dai, et a/., 1999). This activator showed high expression due to activation of Shh 
signaling and increases the expression of GLI1 by binding at 5'promoter region of GLI1. In the 
absence of Shh signaling, the processing of GLI3 into shortened form acts as a transcriptional 
repressor in cultured cells and limb explants culture (Wang ef al., 2000). 
In this study, it was determined that all six medulloblastoma cell lines showed high expression 
of GLI3 transcript as compared to normal adult brain tissue (p=0.0554) (Figure 32A-B). All 
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eight astrocytoma cell lines also showed high fold expression of GLI3 transcripts compared to 
normal brain tissue (Figure 32C-D). Astrocytic cell lines also showed full length expression of 
GLI3 protein (190kD) (Figure 33A). 
High expression of GLI3 in medulloblastoma and glioblastoma cell lines support the expression 
of full length GLI3 transcript which acts as an activator for sonic hedgehog pathway. 
D.24 Expression of SIVIO, HHIP, SUFU, SFRP1 and GLI3 by medulloblastoma and glioma 
primary tumours: 
Similar to medulloblastoma and astrocytoma cell lines, tumour samples of medulloblastoma 
(Figure 34A) (p=0.0053) and glioma (Figure 34B) (p=0.013) showed many fold expression 
compared to normal brain tissue. This high expression further extends the possibility of sonic 
hedgehog activation in astrocytoma including medulloblastoma. 
Most of the medulloblastoma (Figure 34C) (p<0.001) and glioma (Figure 34D) (p<0.001) 
primary tumours showed either low or no expression of HHIP compared to normal brain tissue. 
This low expression correspondence to cell lines expression of HHIP in these respective 
tumours. Low expression of HHIP showed the activation of Shh signaling in these tumours. 
Most of the glioma samples showed low expression of SUFU compared to normal brain tissue 
(Figure 35A) and this low expression is akin to astrocytoma cell lines. Low expression of SUFU 
indicates non-functional inhibition on GLI gene which further activates sonic hedgehog 
signaling in glioma tumours. Due to insufficient RNA quantity of medulloblastoma samples, 
SUFU expression was not check. 
SFRP1 transcript expression (except 1-2 samples) was either very low or nil in most of the 
samples of medulloblastoma (Figure 35C) and glioma primary tumour samples (Figure 35D) 
compared to normal brain tissue. Low expression itself indicates suppressed inhibitory effect in 
sonic hedgehog pathway; this result was very much similar to cell lines of these tumours. 
In GLI3, 7/27(26%) of the glioma samples showed high-fold and remaining 20/27 samples 
showed equal expression compared to normal brain tissue (Figure 35B). This high expression 
revealed the expression of full length GLI3 activator and it is assisting sonic hedgehog 
activation. Most of the glioma samples also showed GLI3 full length protein (190Kd) expression 
(Figure 33B). 
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Promoter Methylation Analysis 
In this study, some genes of the pathway including HHIPP, SUFU and SFRP1 were selected 
and their promoter methylation status was determined besides its correlation with expression in 
medulloblastoma cell lines and tumour samples. 
The HHIP, SUFU and SFRP1 are considered as tumour suppressor genes (TSGs), however 
recently HHIP and SFRP1 have been reported for promoter hypermethylation in some tumours. 
D.25 HHIP Promoter Methylation In medulloblastoma and astrocytoma cell lines and 
primary tumour samples: 
The Human hedgehog interacting protein (HHIP) is a negative regulator of hedgehog signaling. 
It encodes a glycoprotein which binds to all 3 human hedgehog proteins with a similar affinity to 
the membrane receptor protein PTCH1 (Kayed, et al., 2004, Chuang et al., 2003). HHIP 
expression is under influence of ectopic expression of Shh and is lost in mutant Shh expression 
(Chung et al., 1999).This indicate that HHIP is transcriptional target of Shh and acts as key 
molecules for negative regulatory feedback. It is also regulated epigenetically and was reported 
to show promoter methylation in pancreatic neoplasm (Martin ef a/., 2005) and gastrointestinal 
cancer (Taniguchi etai, 2007). 
In this study, HHIP promoter hypermethylation has been checked in major brain tumours 
comprising medulloblastoma and astrocytoma cell lines and primary tumour samples. It was 
found that both medulloblastoma and astrocytoma tumours cell lines and primary samples 
showed methylation and their methylation correlated with low or no expression of HHIP 
Moreover, HHIP acts as a negative regulator of Shh signaling and its methylation in these 
tumours, besides other tumours, suggested the possibility of two kinds of regulatory 
mechanisms controlling the expression of HHIP. Henceforth, HHIP is under two levels of 
regulation; one is epigenetic and another one is influenced by Shh signaling activation. 
D.26 SUFU Promoter Methylation in medulloblastoma and astrocytoma: 
The candidate SUFU is a newly identified tumour suppressor gene which is predisposed in 
individual to develop medulloblastoma tumour (Taylor ef al., 2002).Hence it is critical for 
embryonic development and tumour suppression. It is indispensable during development, one 
allelic mutation of SUFU +/- p53-/- in mice develop tumours including medulloblastoma and 
rhabdomyosarcoma which show aberrant Shh signaling (Lee ef al., 2007). 
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In the present study, we checked the promoter hypermethylation of SUFU gene in 
medulloblastoma and astrocytoma cell lines and samples. It was found that only 2/44 glioma 
samples showed partial/hemi methylation in the promoter region of SUFU. This gene did not 
show any methylation in the 6 medulloblastoma, 8 astrocytoma cell lines, 14 medulloblastoma 
and remaining 42 glioma primary tumours samples. Moreover, there was no report which has 
mentioned SUFU promoter methylation in any tumour so far. Henceforth, SUFU may not be 
under epigenetic control in these major brain tumours. 
D.27 SFRP1 Promoter Methylation in medulloblastoma and astrocytoma: 
The SFRP1 encodes a Wnt/fJ-catenin signaling antagonist and showed frequent promoter 
methylation in many tumours.SFRPI is also one of the target molecules of Shh signaling and is 
repressed by Shh activation (Ingram etai, 2002).This SFRP1 showed promoter methylation in 
hepatocellular carcinoma (Shih et al., 2006;Huang et al., 2007). It was also reported that this 
gene did not show methylation of the promoter region in medulloblastoma, however, it was 
show found promoter methylation supratentorial primitive neuronectodermal tumours (SPNETs) 
(Chang et al., 2005).The gene SFRP1 also showed methylation in the colorectal cancer 
(Suzuki efa/.,2002). 
In this study, we determined the methylation of SFRP1 in medulloblastoma and glioblastoma 
cell lines and primary tumour samples. In medulloblastoma, one cell line TE671 and 5/14(36%) 
samples showed partial/hemi methylation in the promoter region of SFRP1. However, this 
medulloblastoma methylation result is contrary to previous investigation, which showed no 
methylation in the promoter region of SFRP1 gene in medulloblastoma (Chang et al., 2005). 
Moreover, this hypermethylation results were in correspondence to no expression of SFRP1 
transcripts in respective cell line and primary tumour samples. 
In glioblastoma, 5/8 cell lines (A172, T98G, SW1088, CCF-STTG-1 and GOS-3) and 14/44 of 
glioma samples (Figure 39A-C) showed partial/hemi methylation in the promoter region of 
SFRP1 gene; however this methylation was supported by low or no expression of SFRP1 
transcript. 
Moreover, it was reported that GUI binds to the promoter region of the SFRP1 gene and 
down-regulates its activity [316](Katoh and Katoh 2006). From this result, it is found that 
SFRP1 shows promoter hypermethylation in both brain tumours medulloblastoma and 
astrocytoma, and this methylation is correlated with low expression of SFRP1 in these tumours. 
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Taken together, it has revealed two levels of controls which regulates SFRP1 expression gene, 
one is regulated by sonic hedgehog signaling and the other is under epigenetic regulation. 
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Chapter-Ill Results 
R.30 MTT Test 
Medulloblastoma: For this test the Daoy cell line of medulloblastoma was taken and the 50nM 
concentration of Cyclopamine was used. After 24hrs of treatment, proliferative nature of cell 
lines (pink color: DAOY T) decreases compared to control untreated cell line (blue color: DAOY 
C). It was expressed as low absorbance in treated cell line. The difference was statistically 
significant (p=0.0212) (Figure 40A). 
Astrocytoma: For this test, the GOS-3 cell line of astrocytoma was taken and the 50nM 
concentration of cyclopamine was used. After 12hrs of treatment the proliferative nature of cell 
lines (pink color: GOS-3 T) decreases compared to control untreated cell line (blue color: GOS-
30).It was shown by the low absorbance in treated cell line. Again the difference was 
statistically significant (p=0.04398) (Figure 40B). 
R.31 Cell Cycle Analysis 
Medulloblastoma: For cell cycle analysis, the Daoy cell line of medulloblastoma was taken 
and treated with 50nm concentration of Cyclopamine for 48 hrs. After the treatment, the cell 
line showed increase in G0-G1 phase of cell cycle and decrease in the percentage in S phase 
and G2/M phase of the cell cycle (Grey Shed) compared to normal control untreated cell line. 
This decrease in S phase and G2/M phase of Cell cycle indicated the anti-proliferative effect of 
Cyclopamine on the cell-line. This inhibitory effect of cyclopamine in Daoy cell line proliferation 
supports the Shh activation (Figure 41A). 
Astrocytoma: For this analysis, U87MG astrocytic cell line was taken and then treated with 
50nm concentration of Cyclopamine for 24 hrs, specific inhibitor of sonic hedgehog, this cell 
line(Grey shed) showed the differences in the different phases of cell cycle compared to the 
untreated cell line(White shed). This indicated anti-proliferative effect of cyclopamine on 
U87MG cell line (Grey Shed) (Figure 41B). 
R.32 Apoptosis Assay 
Medulloblastoma: For apoptosis assay, we used Annexin V which is a marker for apoptotic 
cells. We used 50nM concentration of Cyclopamine and after 24 hrs of treatment, this cell 
showed 3-fold high apoptosis cell death compared to untreated Daoy cell line (Figure 42A, 
428 and 42C). The difference was highly significant (p<0.0001). 
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after the treatment of cyclopamin 
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Fig. 40 A-B. MTT assay of medulloblastoma (Daoy) and astrocytoma cell line (GOS-3) 
after the treatment of Cyclopamine. Fig.A. Daoy cell line showed progressive cytotoxic 
effect of cyclopamine, showed decreasing in cell proliferation after 24hr of treatment 
and furter decrased in proliferation measured by low absorbance (pink colour) 
compared to normal untreated cell line used as control (in blue colour)(p=0.0212). Fig. 
B.Similarly the progessive toxic effect of cyclopamine showed by GOS-3 cell line 
however decreasing cell proliferation started after 12hr of cyclopamine treatment and 
further decreasing in cell proliferation (pinl( color) compared to nomal untreated cell 
line(blue color)(p=0.0439) 
Chapter-Ill Results 
Astrocytoma: For apoptosis assay, we used Annexin V which Is a marker for apoptotic cells, 
we used 50nM concentration of Cyclopamine in U87MG astrocytic cell line, after 24hrs of 
treatment, this cell showed 2 fold high apoptotic cell death compared to normal control and 
untreated U87MG cell line (Figures 43A, 43B and 43C).lt was also statistically significant 
(p=0.003). 
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Fig. 41 A-B. Comparative cell cycle analysis of medulloblastoma (Daoy) and 
astrocytoma cell line (U87MG) after the treatment of cyclopamine,a specific 
inhibitor of sonic hedgehog pathway. After tratement this cell line showed increasing 
percenatge of G0-G1 phase of cell cycle however decreasing the percentage in S and 
G2/M phase of the cell cycle.This decreasing in S phase and G2/M phase of cell cycle 
indicated antiproliferative effect of cyclopamine in these cell lines.This inhibitory effect of 
Cyclopmaine in Daoy (Fig. A) and U87MG cell line (Fig. B) proliferation support the Shh 
activation in the respective tumour. 
Apoptosis analysis in medulloblastoma cell line after the treatment of 
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Fig. 42 A-C. Apotosis analysis in medulloblastoma cell line(Daoy) control. Fig. A 
Medulloblastoma cell line before the treatment of cyclopamine and under this very low 
percentage of cells showed apoptosls.Fig. B.After the cyclopamine treatment the 
numbers apoptosis cells has been increased 3 fold compared to untreated, this is the 
indicated the cyclopamin inhibitory effect on Shh pathway activation.Fig. C.Comparative 
no. of cells before and after the treatment of cyclopamine treatment comapred to alive 
and dead cells. 
Apoptosis analysis in astrocytoma cell line after the 
treatment of Cyclopamine 
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Fig. 43 A-C. Apotosis analysis in astrocytoma cell line (U87MG) control. Fig. A. 
Astrocytoma cell line before the treatment of Cyclopamine and under this very low 
percentage of cells showed apoptosis.Fig. B.After the cyclopamine treatment the 
numbers of apoptosis cells has been increased to 2 fold compared to untreated cells, this 
is an indicated the cyclopamin inhibitory effect on Shh pathway activation.Fig. C. 
comparative no. of cells before and after the treatment of cyclopamine treatment 
compared to alive and dead cells showed statistically significant value (p=0.003). 
chapter - III: (Discussion 
Chapter-Ill Discussion 
D.28MTTTest 
This test could check the cell viability and proliferation with applied external factors or inhibitor 
molecule. In this test, yellow tetrazolium MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyl 
tetrazollum bromide) is reduced by metabolically active cells in part by the action of 
dehydrogenase enzymes to generate reducing equivalents such as NADH and NADPH. The 
product of this reducing reaction formazan can be solubilized and quantified by 
spectrophotometeric means. 
In this study, MTT test had done in one cell line of each tumour including medulloblastoma 
(Daoy) and astrocytoma (GOS-3) cell lines. 
It found that reduction in cell proliferation in both Daoy and U87MG cell lines after the treatment 
of Cyclopamine, the specific inhibitor of this pathway, when compared to normal control cell 
lines. The difference was statistically significant in both medulloblastoma (Figure 40A) 
(p=0.021) and astrocytoma (Figure 40B) (p=0.043). This inhibition of proliferation by 
cyclopamine in these two cell lines further support the activation of Shh signaling in these two 
major brain tumours including medulloblastoma and astrocytoma. 
D.29 Cell cycle analysis 
In this analysis, live cell DNA was analyzed in different phases of the cell cycle and its 
percentages in different phases of Cell-cycle act as an indicator of nature of growth in cells, to 
monitor apoptosis, to study tumour behavior of cells and suppressor gene mechanism. In this 
study, we checked the Cyclopamine effects on phases of the cell cycle compared to normal 
control. It was found that this cyclopamine showed increase in G0/G1 phase and decrease in S 
and G2/M phase compared to normal control of both tumour including medulloblastoma and 
astrocytoma cell lines, Daoy and U87MG respectively. (Figure 41A and 41B). This low S and 
G2/M phases was indicated the anti-proliferative effect of cyclopamine on these cell lines 
because Cyclopamine is specific inhibitor of Shh signaling pathway. Shh pathway activation is 
blocked in these cell lines after the treatment of Cyclopamine because it specifically binds to 
SMO receptor which further stops the activation of Shh signal in the downstream region. This 
further leads to no DNA synthesis in S phase and division of the cell in M phase and finally anti-
proliferation of these tumour cell lines. 
101 
Chapter-Ill Discussion 
D.30 Apoptosis Assay 
For this analysis, Annexin V-FITC Apoptosis detection kit I (BD Biosciences) was used. 
Apoptosis is the normal physiological process which occurs in developing embryo for 
maintaining homeostatic balance of tissues. 
During apoptosis process, membrane phospholipids, viz phosphatidyl serine (PS) is 
translocated from the inner to the outer leaflet of the plasma membrane and this leads to 
exposed PS to external environment. 
Annexin V is a 35-36 KDa Ca^ -^  dependent phospholipids binding protein that has a high affinity 
to PS, and therefore it binds to cells having exposed PS. This annexin is conjugated to 
flourochromes such as FITC and this modification retains its high affinity for PS, it is thus used 
as sensitive probe for flow cytometric analysis of cells that are undergoing apoptosis. 
In this analysis, we used two cell-lines including Daoy and U87MG of tumours medulloblastoma 
astrocytoma respectively. For this analysis, 50nM concentration of cyclopamine was taken and 
to check the effects of cyclopamine treatment on both cell lines after 48hrs of treatment. It 
showed significant transition from normal cells to apoptotic cells compared to normal control. 
However, Daoy cell lines showed three-fold apoptosis (Figure 42A-C) whereas U87MG 
showed two-fold high apoptosis compared to normal control (Figure 43A-C). This apoptosis 
assay further confirmed the inhibition of Shh signaling by Cyclopamine in these tumours. 
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Conclusions 
C.1 Our results demonstrated two levels of control-transcriptional and epigenetic, over the final 
downstream genes, which included PTCH1 and Cyclin D2 of the sonic hedgehog pathway 
in these brain tumours namely, medulloblastoma and astrocytoma. 
C.2 The differences in the transcriptional regulation by GLI1 on these genes including Cyclin 
D2, Plakoglobin, PAX6, NKX2.2 and Bmi-1 indicate their embryological differences which 
in part might be explain the differential expression and regulation by Shh in these 
tumours. 
C.3 Our study cleariy shows not only medulloblastoma but also astrocytoma is proliferative in 
nature in due course of Shh signaling activation and this Shh activation may contribute to 
stem cell origin of astrocytoma tumour besides medulloblastoma. 
C.4 Signaling pathway of sonic hedgehog shows heterogeneity between medulloblastoma and 
glioblastoma tumours even at molecular level. 
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Abstract. Wc investigated a role for Hedgehog signalling in 
glioblastoma, neuroblastoma and medulloblastoma by studying 
the transcription ol PTCH, SMO, GUI and GU3 in a total of 
25 cell lines by standard RT-PCR and qRT-PCR, before and 
after 5-a7.a-2'-deoxycytidine and trichostatin A (TSA) treat-
ments. Also 25 glioblastoma samples were tested by qRT-PCR. 
We also performed real-time methylated specific PCR (qMSP) 
of the SMO promoter region in DNA from 80 tumor sainples 
(40 glioblastomas and 40 neuroblastomas) and from the 25 cell 
lines. We detected SMO promoter methylation in more than 
half of the cell lines and tumor samples. PTCH expression in 
cell lines was lower than in normal controls, just the opposite 
to GUI. SMO and GU3 expression were high and fully corre-
lated in glioblastoma and medulloblastoma, although partially 
in neuroblastoma. Our results support the existence of 
Hedgehog signalling in glioblastoma and medulloblastoma, 
and to a lesser extent, in neuroblastoma. 
Introduction 
Genes of the Bmi-1, Notch, Wnt and Sonic Hedgehog (Shh) 
pathways are crucial for development and may also be involved 
in stem cell regeneration. The Shh pathway regulates the 
embryonic development of both invertebrates and vertebrates, 
and contributes to the formation of different organs and tissues, 
including the neural tube. Shh is a secreted protein relea.sed 
from Purkinje cells, being responsible for the patterning, 
polarity and development of the cerebellum. It binds to target 
cells presenting the twelve transmembrane receptor Patched 
(Ptch), prompting cell growth and proliferation. Shh deregu-
Correspondence to: Dr Javier S. Ca.stresana, Unidad de Biologi'a 
de Tumores Cerebrales, Universidad de Navarra, Irunlarrea 1.31008 
Pamplona. Spain 
E-mail: jscastresana@unav.es 
Ahhreviations: DMEM, Dulbecco's modified Eagle's medium; 
MSP, mediylation specific PCR; PCR, polymerase chain reaction; 
PNET. primitive neuroectodermal tumor; qMSP, real-time 
methylation specific PCR; qRT-PCR, quantitauve (real-time) reverse 
transcribed-PCR; RT-PCR, reverse transcribed-PCR; Shh, Sonic 
Hedgehog; TFR, transferrin receptor: TSA, trichostatin A 
Key words: PTCH, SMO, GLIl, GLI3, methylation 
lated expression leads to developmental abnormalities and 
tumor formation as m the case of pancreatic. colorectal, breast 
and prostate cancer, basal cell carcinoma and brain tumors, 
including medullobla.stoma (1). The first evidence for Shh roles 
in tumorigenesis came from a patient suffering froin Gorlin's 
Syndrome, a kind of familial predisposition to medullo-
blastoma, rhabdomyosarcoma and basal cell carcinoma (2). 
In the absence of Shh, Ptch inhibits the seven transmem-
brane receptor Smoothened (Smo) (3). Shh-Ptch binding 
relieves Smo, that further activates the downstream target Glil, 
and Patch itself (4.5). The GU gene family was first identified 
in glioblastoma (6). GUI, GU2 and GU3 share five highly 
conserved tandem C2H2 zinc finger domains and a histidine-
cysteine linker sequence in between the zinc fingers. In 
humans. GUI has two isoforms, GU2 has three alternatively 
spliced exons, and GUS has only one isoform. Glil acts as an 
activator, Gli2 as an activator or as a repressor depending upon 
its catalytic activity, and Gli3 as a repressor (7-11). 
It has recently been reported that functional Smo is required 
for GU3 expression in colorectal carcinoma cell lines and 
that SMO methylation leads to silence of GU3 expression 
independently of the Shh pathway (12). In order to prove this 
in malignant brain tumors, we selected 25 cell lines (6 of 
medulloblastoma, 8 of glioblastoma, and 11 of neuro-
blastoma) and 80 tumor samples (40 glioblastomas and 40 
neuroblastomas) to check for PTCH, GUI, SMO and GU3 
expression, together with SMO methylation. The expression 
was checked by standard RT-PCR and qRT-PCR and 
compared with normal adult brain RNA as a positive control. 
After treating the cell lines with 5-aza-2'-deoxycytidine and 
TSA (trichostatin A), mRNA expression was newly checked. 
We also checked SMO promoter methylation by real-time 
melting curve (qMSP) analysis in both tumor samples and 
cell lines. 
Materials and methods 
Cell lines and tumor samples. Twenty-five cell lines (6 from 
medulloblastoma, 8 from glioblastoma and 11 from neuro-
blastoma), together with 80 tumor samples (40 glioblastomas 
and 40 neuroblastomas) were analyzed in this study. For a 
complete list of the cell lines, see Table III. Medulloblastoma 
and glioblastoma cells were maintained in RPMI-1640 medium 
(Gibco/Invitrogen) supplemented with 10% fetal calf serum, 
1 % penicillin and 0.1 % amphocin. For medulloblastoma cells, 
4% non-essential amino acids were added. Neuroblastoma cell 
lines were maintained in DMEM medium (Gibco/Invitrogen) 
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Table I. Primers used for RT-PCR and MSP analyses. 
Gene Forward primers (5'-3') Reverse primers (5'-3') T" CC) bp 
GAPDH (s) 
GLI! (s) 
SMO (s) 
TFR(s) 
PTCHl (s,q) 
GLI3 (s,q) 
GLIl (q) 
SMO (q) 
SMO-M 
SMO-U 
GAAGGTGAAGGTCGGAGTCAAC 
TGTATGTAAGCTCCCTGGCT 
ACGAGGACGTGGAGGGCTG 
GTCAATGTCCCAAACGTCACCAGA 
CTTCGCTCTGGAGCAGATTT 
CAGCTCCACGACCACTGAA 
CAGTGTGGGGACAGAAGGA 
AAGGCTGCACGAATGAGGT 
TTTTTTTATTTTTTCGTTTTTTCGT 
TTTTTTATTmTTGTTTTTTTGT 
CAGAGTTAAAAGCAGCCCTGGT 
AGTATAGGCAGAGCTGATGC 
CGCACGGTATCGGTAGTTCT 
ATTTCGGGAATGCTGAGAAAACAGACAGA 
CAGGACATTAGCACCTTCT 
TCCATGGCAAACACCGTCC 
CGGGGAGAAGAAAAGAGTGG 
GGGTTCTGGCACTGGATG 
CCGACTCCTTTATTACTCTAACTCG 
AACTCCTTTATTACTCTAACTCACT 
62 
59.2 
55 
60 
55 
53 
57.4 
57 
51 
51 
70 
577 
580 
300 
354 
324 
132 
133 
125 
122 
Primers used for standard RT-PCR (s), qRT-PCR (q) or both (s,q). SMO~M and SMO-U were used as mcthylation primers (M) and 
unmethylation primers (U) for qiMSP. T", annealing temperature; bp, ba.se pairs of tiic amplified produet. 
Table II. All techniques applied to explore PTCH, SMO. GUI and GLI3 in each group of cell lines and in the tumor samples 
PTCH SMO GLll GLI3 
MB cell lines 
(6) 
NB cell lines 
(11) 
GB cell lines 
(8) 
RT-PCR', qRT-PCR" RT-PCR\ qRT-PCR^ 
qMSP 
RT-PCR', qRT-PCR' RT-PCR=. qRT-PCR" 
qMSP 
RT-PCR•. qRT-PCR' RT-PCR\ qRT-PCR^ 
qMSP 
RT-PCR, qRT-PCR 
RT-PCR. qRT-PCR 
RT-PCR, qRT-PCR 
RT-PCR', qRT-PCR' 
RT-PCR'. qRT-PCR' 
RT-PCR% qRT-PCR' 
GB samples (40) qRT-PCR (25 samples) qRT-PCR (25 samples) qRT-PCR (25 samples) qRT-PCR (25 samplt-;) 
qMSP (40 samples) 
NB samples (40) nd qMSP (40 samples) nd nd 
^Techniques performed before and after 5-aza-2'-deoxycytidine and TSA; nd, not determined; MB, medulioblastoma; NB, neuroblastoma; 
GB. glioblastoma. 
supplemented with 10% fetal calf serum, 5% non-essential 
amino acids, 1% penicillin and 0.1% amphocin. 
Standard and quantitative RT-PCR. RNA was extracted from 
all ceil line pellets, using the Quick Prep total-RNA extraction 
Kit (Amersham Biosciences, UK). Normal adult brain RNA 
(Stratagene, Cedar Creek, TX) and lung RNA (Chemicon 
International Inc., Temecula, CA), were used as positive 
controls of expression. RNA was converted to cDNA by the 
Superscript II RNase H Reverse Transcriptase kit (Invitrogen 
Life Technologies, Carlsbad, CA). The cDNAs were finally 
amplified by standard PCR by using the oligonucleotides in 
Table I. We also checked these gene expression levels in all 
the 25 cell lines and 25 glioblastoma samples by qRT-PCR. 
A complete list of techniques applied to explore PTCH, 
SMO, GUI and GL/i iri each group of cell lines and in the 
tumor samples is given in table II. 
5-aza-2'-deoxycytidine and TSA treatments of cells. Treatments 
of cells in culture were started when the confluence was 
about 30% (2.6x10' cells/ml). Five micrograms of 5-aza-2'-
deoxycytidine (Sigma-Aldrich) was used for 72 h, and 100 ng/ 
ml TSA (Sigma-Aldrich) was applied for the next 24 h. Cell 
media were changed every 24 h. RNA extraction was 
performed before and after t reatments with 5-aza-2'-
deoxycytidine and TSA, in order to perform cDNA synthesis, 
RT-PCR and qRT-PCR of PTCH, SMO and GU3 and to 
compare their expression levels in the two conditions. 
Bisulphite modification, amplification and melting curve 
analysis. We selected the SMO promoter region for MSP 
analysis (13) from a CG rich region spanning -753 to -303 bp 
5' upstream of the SMO transcriptional start site. Bisulfite 
modification of genomic DNA extracted from the 25 cell lines 
and 80, tumor saiTiples was applied by using the CpGenome 
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Figure 2 Comparative RNA expresbion ol SMO and GL/i determined by standard (A) and quantitative (B-E) RT-PCR M, medulloblastoma, N, neuroblastoma 
G. glioblastoma, L, lung RNA, Br, normal adult brain RNA, NTC, non-template control. Mr, 1 Kb Plus DNA ladder (Invitrogen Lite Technologies) 
(qMSP) in an iQ 5 multicolor real-time PCR detection system 
(Bio-Rad). SYBER Green superniix (Bio-Rad) was used as 
PCR reagent. Each sample was tested m triplicate. Universal 
methylated DNA (Chcmicon International) was included as a 
positive control, blood DNA as a negative control, and water 
(B Braun Medical S.A., Barcelona) as a non-template control. 
The results were analyzed with the help of the melting curves 
produced by the methylated and unmethylated primers 
Results 
PTCH, GUI, SMO and GL13 expression All 6 medullo-
filastoma cell lines, 7 of 8 glioblastoma cell lines (except for 
U87MG), and 4 of 11 neuroblastoma cell lines (SK-N-MC, 
MC-IXC, SK-N-DZ and IMR-32) expressed both SMO and 
GU3 genes (Figs. 1 and 2, Table III). The rest of the neuro-
blastoma cell lines (7 of 11) expressed only SMO The glio-
blastoma cell line U87MG only expressed GLI3. Most of the 
medulloblastoma, glioblastoma and neuroblastoma cell lines 
showed lower expression of PTCH than normal adult brain 
RNA controls (Fig. 1) After 5-azd-2'-deoxycytidine and TSA 
treatments PTCH exptession was increased (Fig. 3, Table III) 
All 25 cell lines a.ia 25 glioma samples expressed GLIi at 
substantial quantity in comparison to normal controls (Fig. 1). 
SMO promoter methylatwn. Four medulloblastoma cell lines 
(PFSK-1, TE671c2, D283 and SK-PN-DW) presented an 
inci-ease in exptessidn of the SMO gene after 5-aza-2 -
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Table III. PTCH, SMO and GLI3 expression in meduUoblastoma, glioblastoma and neuroblastoma cell lines, before and after 
5'-aza-deoxycytidme and TSA treatments. 
MB cell lines 
TE671 
PFSK-I 
DAOY 
TE67fc2 
D283 
SK-PN-DW 
GB i-ell lines 
U87MG 
A172 
LN4()5 
SWi783 
T98G 
SW1088 
CCF-STTG 
GOS-3 
NB cell lines 
SK-N-Fl 
SK-N-Be(2) 
SK-N-MC 
KELLY 
MC-IXC 
SH-SY-5Y 
MHH-MB-11 
SK-N-DZ 
IMR-32 
SIMA 
Be(2)C 
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MB, meduUoblastoma, GB, ghobUbloma, NB, neuroblastoma, -, not expressed, -(-/-, not cle<ir level of expression, + to ++-\-+, different levels 
ot expression 
deoxycytidine and TSA treatments (Fig. 3). Also, the glio-
blastoma cell line U87MG and two neuioblastoma cell lines 
[SK-N-FJ and Be(2)cJ presented re-expression of the gene 
after the treatments (Fig. 3). The melting curves supported a 
partial/ hemimethylation status at the SMO promoter (Fig. 4) 
In order to corroborate this result in tumor samples. 40 
glioblastomas and 40 neuroblastomas were studied by qMSP 
and melting curve analysis (Fjig.,4).,pf these;,|2;4 gl^ pblas,tQrnas 
(60%), ^ (^ lj6 neu):9blastpn^as,,(4p ;^)| j)i^p;ile^ yieth^ l^ licjp^ .yfj 
parfial/hef]y;iJ9fl^ ylati.9n,,pf the^N^ geng,pron;iQ^€r region j^y 
1 ' ''i iit.r,-) \u( I , ),i CI ' 
D i s c u s s i o n •j^ni>c,'i,o'j 111 Mr ii'ip u ; I ,J"^!) 
•i l U V l^o.liilr t ! v.l ,^ \'\\vir^ ',^ )H-^ \^<) cyOV^ 
I^\^t|jis.study,,w(e ,^(^e^ed tbei/ole^qf-the S>h|>pafbw9y t^i^ lh^ 
a^.?lopmefi;,pf i)y^>igihiy tt^aligpap^^^jr^ia^tuip^rs i^lif^f. 
blastoma and meduUoblastoma) and in neuroblastoma, a 
malignant extracrajpia^ tui?P|9r|Of,thg,j)er){pheral, nervous ,system. 
In fact we incorpor^^d me^ullpbl^sCoipa as appntrql, as it^  
participation in(^ he,:51^h pathway is well known (14-16). 
These three turners iCCfirespond to the most malignant pheno-
types ot tumors of^  the nervous system in adults (glioblas-
toma) and ch^r^,j(piedulloblastoma and neuroblastoma). 
The,t,lir§e,,ljiunpr^ ij)^ :esent different genetic profiles. From the 
histopa^olggi£^^p|ipt^',o|:,jjiew, ther.e i?,a,cO|i:in^tion,betw9eip 
meduUoblastoma and neuroblastoma in the sense that both o^ 
them belong to the so-called small round cell tumors. N e^dull^ oj 
blastomas are considered to be primitive neuroectodermal 
tj^ fp^ ^^  j(f IJ^SP djf^ YfJlpp^ d in, the vC r^eb l^^ urp F^^l^ei;ipor?^ 
ce;|taunJy^ps^o£[SHgrafent9r}aj|]^NpJ,^« di^ ^gno^pji as,braip 
nef^ poplaj^ ^ma^ -iYjlipg they,pr,es^pt.r?e)ir9bl^fi9 dijfferentiationi 
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Figure 4Ji')l^OiprDmoterjtiettJylal.ion itatus'ia cell fines (A) and tumorsaijipJcs (B) detarmined by qRT-PCR.MelUnjg curves cprrespond «o iinmethylated (C), 
partial/h^pirnelhyljited (D.)^ ,.and comp^tely raelh>jlated-<E|> § M 0 projnptei; in Il]ree,different cfJl lin^s. ^Mejting curves refer to blood DNA as a negative 
qontro) (rpd)^upivfjrsal rnethylatet) DNA (Chemicon International) as a positive control (green), DNA titmor sample (blue), and non-template control (black). 
For inlerpfetation, we'referred to partikl/hemirnethylaii'on'wheii the raeltitig temperature oi'lhe saiiiple was 6'.,^'-f'6 liighir than the rneltitig temperature of the 
litSrmal contrbl, while a higher'diffeehbe would corresport'd to complete ihethylation. MB, medulloblastoma; GBM, glioblastoma; NB, neuroblastoma; ' 
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In this sense, in studies.on medulloblastoma, neuroblastoma 
and supratentorial PNET it is worthwhile to define specific 
genetic markers, that allow a, more accurate diagnosis and a 
more specific treatment of these relatively similar lessions. 
Embryologically speaking, glioblastoma and medullo-
blastoma derive from the neuroepithelium, while neuro- : 
blastema from the neural crest, as other tumors that appear 
outside of the nervous system (melanoma, thyroid medullary 
carcinoma, small cell lung cancer, malignant schwannoma, 
among others). 
The Shh pathway is an evolutionarily conserved develop-
mental cassette, leading different tasks in the developing 
organism, such as the development of the neural tube, cranio-
facial structures, limb, lung, and others, to ensure proper 
positional or polarity information within part of the developing 
embryo. The activation of the Shh pathway is conducted 
through Shh, which triggers a derepression of the negative 
modulation of the pathway executed by Ptch on Smo. The 
net effect of Shh binding to the cell surface complex is an 
activation of the pathway by downstream activators such as 
GUI. 
Wc have checked the expression of some of the major Shh 
pathway genes [PTCH, SMO, GUI and GLI3) in medullo-
blastoma. neuroblastoma and glioblastoma cell lines, together 
with glioblastoma and neuroblastoma samples. Methylation 
studies were applied on SMO as well. 
All medulloblastoma cell lines (except DAOY) and all 
glioblastoma cell lines (except GOS-3) shov>cd higher levels 
of expression of GIJI than in normal adult brain RNA 
expression. However, only .3 of the 11 neuroblastoma cell lines 
(SK-N-MC, MC-IXC and SH-SY-.5Y) showed higher 
expression of GUI than in normal adult brain RNA. This high 
expression level of GUI supports the Shh pathway activation 
(17) in glioblastoma and medulloblastoma, and, less frequently, 
in neuroblastoma. On the contrary, 2 medulloblastoma cell 
lines (DAOY, SK-PN-DW), 7 out of 8 cell lines of glio-
blastoma (all except SW1088), half of the glioblastoma 
samples (12 of 25) and 4 neuroblastoma cell lines [SK-N-MC, 
KELLY, MC-IXC and Be(2)Cl showed lower PTCH 
expression than in normal adult brain RNA. 
We detected SMO promoter methylation in 4 medullo-
blastoma cell lines (PFSK-1. TE671e2, D283 and SK-PN-
DW), 4 glioblastoma cell lines (U87MG, A172, LN405 and 
SW1088), and 6 neuroblastoma cell lines [SK-N-FI, SK-N-
MC, MHH-NB-11, SK-N-DZ, SIMA and Be(2)c]. The partial/ 
hemimethylation observed was also supported by the melting 
curves obtained from glioblastoma and neuroblastoma tumor 
samples. 
Expression of GLI3 in all medulloblastoma and glio-
blastoma cell lines and in almost all glioblastoma samples 
(except two samples) was higher than in normal adult brain 
RNA. However, similar results were obtained in only 4 out of 
11 neuroblastoma cell lines (SK-N-MC, MC-IXC, SK-N-DZ 
and IMR-32). 
We have demonstrates that the Shh pathway is activate(f| 
in medulloblastoma, glioblastoma and neuroblastoma. 
Prfeviousiy-; the activation <>f this rpaitfeW-a^^iiiniedwlloblastoiin*:' 
wa^'jkhd'wn (^4); bW, it is Mtya-MiyuMl iWteod wfrfethe!f '' 
activation 0bhq,Slihipatlwa)fi.,.',;:^ ' -.'.C • ..x^,v'J, .iV;- ;;i/ M :i,;i 
It was reported that high expression of PTCH implies the 
Shh pathway iictivation in tumors ofvthe digestives tr.act<17). In 
our study PTCH expression was lower than in'normal controls, 
but PrC/^'xa-'-expression after t r ea tments 'wi^5-aza-2 ' -
deox'^ycytidine and TSA supports its promoter methylation, as 
• demonstrated for breast cancer (20). 
In this' study, we paid special attention to the relationship 
between the expresion of SMO and GLI3, as they act 
together, oncC the Shh pathway has been initiated, to make 
the expression of GUI possible. Qncc this is initiated, a 
cascade of genes taking part in apoptosis control and regulation 
of growdi will be activated. Smo behaves as aii oncogene, as 
its activation by Shir promotes Glil activation. On the 
contrary. Gli3 exerts a dual possibility; as an activator 
(similarly to Glil and GIi2), or as a repressor (21) that brakes 
the activating function of Smo on Glil . .-
We demonstrated that SMO acts as an activator of the Shh 
pathway in medulloblastoma, glioblastoma and neuroblas-
toma, as we detected a good level of expresion of SMO in most 
cell lines and tumor samples studied. We also demonstrated 
the methylation of SMO promoter in cell lines and tumors, 
and the fact that expression of SMO increases after 5-aza-2'-
deoxycytidine and TSA treatments in cell lines. Nevertheless 
it seems methylation is not pl-aying a significant role in 
silencing this gene. 
Medulloblastoma and glioblastoma cell lines showed a 
very noticcble correjation, between SMO upAtGUS RT-PCR 
expression, with the exception of the U87MG glioblastoma 
cell line, which did'nbt shb\V a clear expression level ot SMO, 
although after treating ttie cell'line with 5-aza-2'-deoxycytidine 
and TSA, re-expresion of SMO was observed. These results 
were confirmed by qRT-PCR analysis before and after treat-
ments with demethylating agents, and by qMSP that revealed 
melting curves compatible with partial/hemimethylation of 
SMO in the U87MG cell line. 
Contrary to medulloblastoma and glio^astoma, neuroblas-
toma cell lines did not show a clear correlation between SMO 
and GU3 expression. Seven of 11 (64%)'cell lines presented 
SMO expression but did.iKit expresSc^L/5iTwo of these 7 cell 
lines did not even express GU3 after treatme^s with 5-aza-2'-
deoxycytidine and TSA, while the other 5i did. The rest of the 
cell lines (4 of 1 l,_3|(^)_,gtowed_W^ artd GU3 expression. 
qMSP also supported SAfO promofes'partial/hemimethylation 
in neuroblastoma cell lines and tumor samples. 
After the analysis of SMO and GU3 expression we 
concluded that SMO gene expression seems to be required 
for GU3 expression in medulloblastoma and glioblastoma, as 
shown by the clear correlation of expression of both genes in 
these types of brain tumors, and that Gli3 is acting as an 
activator of the Shh pathway in these tumors. On the 
contrary, neuroblastomas present different results, as the 
correlation between SMO and GU3 expression is seen in 
only 4 of 11 cell lines.;In these cases, we would equally suggest 
Gli3 as an activator of Shh. But the other 7 cell lines present a 
different scenario: 5 of them 're-express GLI3 after the 
treatments with 5-aza-2'-deoxycytidine and TSA, which even 
^WggestsijiBls :c6m]Mertttd for/TCWyittiat GL/5. might?be sub-: 
'jitiSt^a'l6[iifrbiihi6if'i^&iy\i^^^ its 
owil'expfessi6n;'mdep^ Mili. T*He fact tliat' ih thfi" 
.a,tlj?r..2,,fie}l,J,ipic;^,flo,e^pifp^sipi) .is:fpr(>diLiced„even..after the 
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treatments with 5-aza-2'-deoxycytidine and TSA indicates a 
non-activator but a repressor function for Gli3 in at least a 
subset of neuroblastomas. Also a gradient-like expression of 
other genes, SMO included e.g., might be needed for GLIS 
expression, in an Shh-dependent or - independan t 'mana^ , . ! ' 'i 
The fact that a clear activation of the Shh pathway has 
b e e n d e m o n s t r a t e d by ou r s t u d y in g l io -b las toma and 
medulloblastoma, but not clearly enough in neuroblastoma, 
suggests different embiyological ethiology of these tumors, as 
they arc n e u r o e p i t h e l i a l in or ig in , whi le n e u r o b l a s t o m a 
derives from the neural crest. This embryological difference 
might irt'part explain the differences in the involvement of 
the l^nh'^deinonstrated in oui^ ktudy ifdr these three malignant 
tumors of the nervous Sytcm. Further' studfes afe required to 
evaluate our hypothese 
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Sonic Hedgehog Epigenetics: GUI and Cyclin D2 in Brain Tumors 
Mehdi H. Shahi,' Subrata Sinha/ Mohammad Afzal,^ Javier S. Castresana.' University of Navaira,' 
Pamplona, Spain, All India Institute of Medical Sciences,^ New Delhi, India, Aligarh Muslim 
University,^ Aligarh, India. 
It is well determined that the Sonic Hedgehog (Shh) pathway plays a key role in the progression of 
several cancers like medulloblastoma and colorectal carcinoma among others. The Glil gene is the 
main transcriptional activator of this pathway, acting as a positive downstream effector on several 
genes, like Cyclin D2. Despite the putative function of Cyclin D2 as a cell cycle proliferation 
activator, it has also been shown to present a growth inhibitory effect linked to cell senescence. Even 
Cyclin D2 promoter has been demonstrated to be methylated in breast cancer. 
In our study we checked the regulation of Cyclin D2 by Glil in three major brain tumors: 
medulloblastoma, glioblastoma and neuroblastoma. We tested the RNA expression of twenty-five cell 
lines (six from medulloblastoma, eight from glioblastoma and eleven from neuroblastoma), before 
and after 5-Aza-2-deoxycytidine treatment by RT-PCR. Then we did Real Time Methylated Specific 
PCR (qMSP) of eighty tumor samples (forty glioblastomas and forty neuroblastomas) and the twenty-
five cell lines. 
Our RT-PCR results clearly indicate the lack of expression of the Cyclin D2 gene in fi\e glioblastoma 
cell lines (A172, SW1783, T98G, CCFSTTG-1 and GOS-3) and nine neuroblastoma cell lines (SK-
N-FI, SK-N-Be(2), Kelly, SH-SH-5Y, MHH-NB-11, SK-N-DZ, IMR-32, SIMA and Be(2)C), 
together with the re-expression of the gene after the treatment with 5-Aza-2 '-deoxycytidine. All 
medulloblastoma cell lines showed normal expression for Cyclin D2 gene. 
Our qMSP melting curves also support our results, as nine out of forty glioblastoma samples (23%) 
and seventeen out of forty neuroblastomas (43%) showed promoter methylation of Cylin D2. 
We might conclude that 1) methylation seems to be significant for the silencing of Cyclin D2 
expression in glioblastoma and neuroblastoma, and 2) the Gli 1 downstream upregulated target Cyclir 
D2 is activated only in medulloblastoma and not in glioblastoma or neuroblastoma. 
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